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ABSTRACT 
Adverse drug reactions (ADRs) are becoming an increasing burden for both the 
healthcare system and the pharmaceutical industry. Indeed, up to 6.5% of all hospital 
admissions are attributed to ADRs. Drug hypersensitivity reactions (DHRs) are of 
particular interest to us – ADRs with an immune aetiology - especially T cell mediated 
delayed type reactions. They are idiosyncratic in nature, and as such are not predictable 
based on the pharmacology of the drug. Genetic studies have elucidated associations 
between specific HLA alleles and DHR, but in most cases a reaction is not observed 
in the patient. In vivo drug challenge tests have been used to diagnose and predict the 
likelihood of an DHR, but are not always appropriate due to their invasive nature and 
inaccurate predictive capabilities. What is desperately needed in order to advance the 
field and prevent DHR are accurate, repeatable, and reliable in vitro tests for both the 
diagnosis and prediction of these reactions.  
Whilst dendritic cell T cell co-culture systems enable us to determine the ability of a 
compound to prime and activate naïve T cells, there are some problems that must be 
addressed. Existing assays do not take into account the precursor frequency of naïve 
T cells for a specific drug. Thus, naïve T cell priming to certain drugs cannot be 
detected, as there not enough T cells to reach the precursor frequency required for 
activation. The assay is also too complicated, with cells being cultured and moved 
between plates multiple times for each assay. Additionally, only one donor at a time 
can be analysed. For this reason, within this thesis I have generated two new assays; 
the T cell multi-well assay (T-MWA), and the T cell multi-donor assay (T-MDA). 
Post-dendritic cell generation, the T-MDA and T-MWA take place in a single 96-well 
plate, miniaturising and streamlining the assay. The T-MDA allows for the 
comparison of up to 16 donors in a single assay, with positive responses being able to 
be examined in further detail by the T-MWA. In each assay nitroso sulfamethoxazole 
(SMX-NO) led to positive priming in all donors (either SI>1.5 or p<0.05 in Mann-
Whitney statistical test), whilst the -lactam antibiotic piperacillin led to positive 
priming in only one donor in each assay. Bandrowski's base (BB), an oxidation 
product of the contact allergen p-phenylenediamine led to positive priming in 4 out of 
8 donors. The T-MWA allows for the analysis of 40 wells per drug treatment (opposed 
to 3), which accounts for the T cell precursor frequency associated to a drug reaction. 
The T-MWA was used to establish naïve T cell priming against SMX-NO, BB, 
piperacillin, and sulfamethoxazole (SMX). The greatest level of priming in terms of 
both statistical significance and the strength of response was observed to SMX-NO 
and BB as these regularly had good or strong responses (SI>2) and dot plots of all 
wells had p<0.05. Priming was still achieved to piperacillin and SMX, albeit with 
fewer responsive wells responding, with weaker levels of proliferation. This enables 
SMX-NO to be used as a positive control, and something by which in the future 
researchers can compare the immunogenicity of other drugs.  
Despite the success of the T-MDA and T-MWA, it was important to understand 
whether the assay recreates accurate immune regulation, and whether this would 
change dependent on the test drug and have a bearing on the observed results. T 
regulatory cells (Tregs) as well as programmed death-1 (PD-1) and cytotoxic T 
lymphocyte-associated protein-4 (CTLA-4) all have immunosuppressive actions on 
the immune system and can determine whether or not T cell activation occurs. Tregs 
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were generated during the course of priming in 3 out of 3 donors to both SMX-NO 
(Tregs <1% of CD4+ goes to mean of 3% of CD4+ cells) and piperacillin (Tregs <1% 
of CD4+ goes to mean of 2.5% of CD4+ cells); whilst PD-1 and CTLA-4 expression 
overall increased in all donors. Upon blockade of PD-1 and CTLA-4 in the T-MWA, 
the strength of the response increased, but negative priming was not reversed upon 
blockade of the co-inhibitory pathways due to increased background proliferation 
(P>0.05).  
The lymphocyte transformation test (LTT) is the current gold standard of in vitro 
diagnostic assays, but its applicability domain is limited in vulnerable paediatric 
patient cohorts who often suffer DHR due to their extended exposure to multiple 
drugs. Out of 13 patient samples tested for drug specific PBMC proliferative 
responses: 8 of them resulted in negative results (p>0.05), despite the patient 
presenting with suspected DHR from clinical observation. Four resulted in a single 
potential culprit drug being positive in LTT, whilst 1 flagged multiple potential culprit 
drugs. This makes determining the correct drug to withdraw extremely difficult in 
cases of multiple drug treatment. Additionally, the LTT takes 6 days to complete, 
which is too long for a diagnostic assay. miRNA are known to regulate a range of 
biological processes and regulate expression of up to 50% of genes. They are also 
known to play a regulatory role in the immune system and may determine whether or 
not activation occurs. miR 9, 18, 21, and 155 are known to be upregulated upon 
immune activation. We used a miR upregulation assay whereby upregulation of these 
known miR could be quantified and correlated with T cell activation in 3 days instead 
of 6. miR 9, 18, 21, and 155 were differentially upregulated in antigen specific T cell 
clones and patient PBMC all of which were positive by LTT or ELISpot, proving the 
concept that miR upregulation could be used in the future to determine T cell 
activation more rapidly than the LTT.  
These studies were successful in bringing about improvements to in vitro assays such 
as the naïve T cell priming assay and LTT. However, further studies into the immune 
regulatory pathways involved at the cellular and transcriptional level will be the key 
to improving and therefore moving towards truly dependable predictive and diagnostic 
in vitro assays for DHR.  
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Due to rapid increase in novel drugs being developed for a plethora of illnesses, the 
issue of adverse drug reactions (ADR) to these drugs are becoming more and more 
common 1. These reactions are a bigger problem than most realise; with some reactions 
resulting in high morbidity illnesses, and in extreme cases, mortalities. In fact, adverse 
drug reactions have been associated with 6.5% of all hospital admissions, and over 
100,000 admissions to hospital are due to drug exposure 2. This problem is increasing 
in severity for both the patients, and the hospitals that deal with an increasing number 
of patients taking up hospital beds due to ADR. Indeed, it was estimated that the 
increase in additional hospital bed days directly due to ADRs could be placed up wards 
of 2000 at any single point in time. More shockingly, the equivalent of ten, eight 
hundred bed hospitals could be filled when combining the above data with total bed 
days for in-patients due to an ADR 3.  
Drug hypersensitivity reactions (DHR) are ADRs with an immunological aetiology. It 
is abundantly clear that it is necessary to find ways to determine why these ADRs, in 
order that we can prevent them where possible, and effectively treat them in a time 
efficient manner as soon as possible in other instances. Some of the current methods 
of diagnosis of drug hypersensitivity reactions (DHR) such as intradermal, skin prick 
and patch tests 4 are both inconvenient for the patient due to their invasive nature, and 
not altogether useful due to the potential for false positives stemming from low 
sensitivity of the tests, or cross-reactivity of certain antibiotics, which can again lead 
to false results. It is evident that better testing for ADR and DHR must be established, 
and that a less invasive method would be better for both patients and clinicians.  
The use of in vitro testing is something that is increasing in popularity for its non-
invasive nature which can be carried out in a more convenient and less time-
consuming environment for the patient. The development of diagnostic tests such as 
4 
the lymphocyte transformation test (LTT) has gained popularity, particularly in 
research; but the development of a working, predictive in vitro assay remains the end-
goal. It would be remiss to discuss the various forms of in vitro assays for diagnosis 
and prediction of DHR, without further outlining what adverse drug reactions and drug 
hypersensitivity reactions are, and how they cause the need for the development of 
these assays. 
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 ADVERSE DRUG REACTIONS 
1.1.1 DEFINITION 
The definition of an ADR was first established in 1972 by the World Health 
Organisation, which stated that an ADR could be defined as ‘a response to a drug 
which is both noxious and unintended, and which occurs at doses normally used in 
man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of 
physiological function’ (WHO, 1972). This classification was well-accepted and 
understood for almost 30 years. However, a new definition was put forward in 2000 
by Edwards and Aronson which stated, ‘an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of medicinal product, which 
predicts hazard from the future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product’ 5. This 
updated definition of ADRs has since become the more accepted phrasing, since it 
takes into account any wording inaccuracies from the original definition; such as the 
inclusion of the word ‘noxious’. It was determined that the use of the word noxious 
may mislead people into the belief that all ADRs are severely harmful, in spite of the 
fact that some ADRs remain merely inconvenient, but not deeply harmful. 
1.1.2 CLASSIFICATION 
The classification of ADRs - much like the definition of them - was a progression from 
an original idea, which was later expanded upon by the discontent of Edwards and 
Aronson. Type A reactions are the most commonly observed drug reaction, due to 
their nature as an on-target reaction which is often dose-dependent. This type of 
reaction is predictable from the known pharmacology of the drug. Type A reactions 
occur usually as a consequence of drug overdose, drug-drug interactions if the patient 
is prescribed more than one drug, or as a result of compromised metabolism. Type B 
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reactions on the other hand, are often termed as idiosyncratic, dose-independent and 
bizarre due to the inability to predict them from the known pharmacology of a drug. 
Type B reactions are considered more dangerous as they are not predictable and often 
do not stop upon cessation of treatment, as they routinely activate the patients’ immune 
system which links them in with DHR. It could be argued that much like the definition 
of an ADR, the classification of them have become outdated also.  
With the relatively recent discoveries of HLA-linked drug reactions such as HLA-B 
57:01 in abacavir 6–8, any new classification system must take into account these 
important discoveries. In 2000, Edwards and Aronson added four more classifications 
to the original idea of Type A and B reactions. These were dose and time related Type 
C (chronic), time related Type D (delayed), Type E end of use of the drug, and type F 
which is related to therapeutic failure of the drug 5. Aronson added a further 
classification of ADRs known as DoTS, which related to the dose, timing and 
susceptibility factors, which tied in with reactions that were idiosyncratic in nature but 
were seen as dose-dependent 9.  
1.1.3 IMPORTANCE  
It is clear that the elucidation of the mechanisms of ADRs must be a key goal in current 
scientific research, in order that they become preventable, or at least more quickly and 
efficiently treatable. As previously stated, ADRs cause great damage each year via a 
plethora of avenues. They first and foremost, cause great problems for the patient on 
the drugs; whether the symptoms are either inconvenient or life-threatening. ADRs 
have been implemented in over 100,000 deaths per annum, solely in the United States 
10 and elsewhere been classified as one of the most common factors associated to the 
death of patients 11. Once again, these statistics clearly outline the potential danger of 
ADRs, and the severe effect they may have on countless individuals. Mortality due to 
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ADRs are not the sole concern; as ADRs often result in high morbidity illnesses that 
leave patients needing hospital stays, or at the very least, visits. The financial strain on 
the National Health Service (NHS) attributed to ADRs remains an important concern 
as up to 10% of impatient costs can be linked to drug reactions 3.  
 DRUG HYPERSENSITIVITY REACTIONS 
DHR can also be described as drug allergy and are linked to Type B ADRs. Like Type 
B ADRs, DHRs are unpredictable and idiosyncratic in nature; with reactions occurring 
at normal doses of the prescribed drug. The defining factor that distinguishes a DHR 
from an ADR is the triggering of the host's immune response. Therefore, a DHR can 
be defined more concisely as an adverse drug reaction that has an immune based 
aetiology to normal doses of safe therapeutic agents.  
One of the main causes of cases of DHR lies in response to the beta lactam classes of 
antibiotics 12, with drug-drug interactions playing a role in additional incidences of 
hypersensitivity. Indeed, patients who are exposed regularly to multiple drug therapies 
are increasingly likely to suffer from multiple drug DHRs which are becoming an 
increasing clinical concern 13 due to their unpredictable nature as different multiple 
DHR can occur with each different drug regimen. 
More than 95% of all DHRs are skin related reactions 14, with most of the reactions 
being classified as less severe; falling into the inconvenient but not necessarily 
dangerous category. It is believed that cutaneous DHRs are the more likely outcome 
due to the extensive network of blood vessels, which allow for T cells to quickly reach 
the site of action and cause some of the delayed type reactions observed. The less 
severe reactions observed are generally urticaria (hives) and other milder skin rashes 
which cause itching and mild discomfort. Stevens-Johnson syndrome and toxic 
epidermal necrolysis are two of the more severe cutaneous DHRs which are related to 
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skin detachment, leaving the patient open to infection. These reactions have a 
relatively high mortality rate; with high morbidity for those who are lucky enough to 
survive these reactions. 
The time of onset of a DHR can help in some ways to classify the reaction, with 
reactions with an onset of less than one hour being qualified as immediate reactions 
mediated primarily by IgG antibodies and mast cells. Whereas delayed-type DHRs are 
reactions with an onset later than one hour after drug administration; but can last up 
to a month as they are T cell mediated which requires time for T cell priming and the 
initiation of an immune response 15.  
1.2.1 CLASSIFICATION  
The classification of DHR is somewhat separate to ADR classification; although there 
are links. The initial classification of DHR were created based on the time of onset of 
the reaction, as well as the perceived mediators of the reaction by Gell and Coombes 
in 1963. Instead of using an alphabetised classification system, Gell and Coombes 
decided that DHR would be categorised as Type I-IV. 
Type I are immediate reactions, such as asthma or hay fever as well as anaphylaxis. 
They are mediated through the antigen cross-linking of immune cell receptors such as 
mast cells and bound IgE. Degranulation occurs and subsequent release of histamines 
and cytokines cause allergic responses.  
Type II reactions are semi-delayed cytotoxic reactions involving natural killer T cells, 
neutrophils, eosinophils, macrophages as well as complement pathway activation 
through FC receptor activation of these immune cells downstream of IgG and IgM 
release from triggered B lymphocytes.  
9 
Type III reactions are also IgG, IgM linked semi-delayed reactions propagated 
through soluble antigen-antibody complexes in the blood. This causes complement 
pathway activation and the recruitment of macrophages and neutrophils. Lupus is one 
example of a type III reaction.  
Type IV reactions are the major subset of DHRs of interest, especially in the 
development of in vitro T cell-based assays. They are delayed in onset and require 
antigen presenting cell-T cell interaction as a prerequisite. The classic model is one of 
an APC such as a dendritic cell presenting an antigen to T cells which become 
activated releasing inflammatory cytokines which cause the observable clinical 
response. DHRs such as Steven-Johnsons syndrome and toxic epidermal necrolysis 
can be categorized as a type IV response. Due to wide-spanning categorisation of DHR 
Type IV reactions, it was decided that it would be better to further categorise type IV 
reactions into 4 further subsets a, b, c and d, based on the immune cell type and 
cytokines involved in the reaction. Type IVa reactions involve macrophages and T cell 
IFN-γ release, IVb involve the release of interleukins (IL-) 4, 5 and 13 from T cells 
with eosinophil activation. IVc reactions are cytotoxic reactions mediated mainly by 
cluster of differentiation (CD) 4 and 8 cytotoxic T cells (CD4/CD8). Whilst IVd 
reactions involve neutrophils with the upregulation of GM-CSF and IL-8 release from 
T cells.  
1.2.2 DIAGNOSIS  
1.2.2.1  IN VIVO  
One of the main ways in which DHRs is diagnosed is through the use of in vivo tests 
such as a skin prick, patch and intradermal tests. All of these tests have their limitations 
and issues associated with them, one of the main issues being the compliance of the 
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patient as they are invasive procedures that can lead to some discomfort; including 
some side effects. However, these skin-based tests were developed in response to 
immediate cutaneous reactions to β-lactam antibiotics such as amoxicillin 16,17. 
Immediate IgE mediated drug eruptions can quickly be diagnosed by cutaneous tests 
like the prick/intradermal tests in less than one hour 18. More recently in vivo tests have 
been used to diagnose reactions with a delayed onset. Tests when positive may take 
up to a few days to develop 19. Of all the cutaneous hypersensitivity reaction in vivo 
tests, the most popular are the skin prick, skin patch and intradermal tests.  
The Skin prick test involves placing a small amount of allergen onto the forearm of 
the patient, and then carefully scratching the outer layer of the skin in order to allow 
entry of the potential allergen. It has traditionally been used to test for immediate 
allergic reactions such as contact urticaria, asthma, and food allergy 20.  
The Patch test is one in which the clinician attaches a patch containing the allergen to 
either the arm or the back, this is usually a skin allergen resulting in an immediate 
reaction 21. This patch stays on for 48 hours in case of delayed onset DHR such as 
delayed onset urticaria, SJS and TEN 22.  
The Intradermal test is one in which a small amount of the allergen is injected with a 
hypodermic needle under the dermis to determine immunogenicity of a drug to the 
patient. This has previously been used to determine allergy after anaphylactoid 
reactions to anaesthetics 23,24. 
These in vivo tests are somewhat invasive and can lead to discomfort for the patient. 
In addition to this, these cutaneous tests have relatively low specificity, which is a 
trade-off in the interest of keeping the tests as safe as possible (sensitivity is the ability 
of a test to correctly identify those with disease, specificity is the ability of a test to 
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correctly identify those without disease). Amongst the above disadvantages, all the 
cutaneous DHR in vivo tests outlined above have the advantage of the possibility 
(however small) of inducing a response in a patient which may have harmful effects. 
The development of diagnostic and predictive in vitro assays will circumvent this 
issue, and potentially allow for more accurate, safer diagnosis and prediction of drug 
induced hypersensitivity reactions.  
1.2.2.2 IN VITRO  
1.2.2.2.1 PERIPHERAL BLOOD MONONUCLEAR CELLS  
Peripheral blood mononuclear cells (PBMC) must be obtained in order to carry out 
any of the following in vitro experiments as most of them rely on the availability of T 
cells, and in some instances, antigen presenting cells such as dendritic cells or 
monocytes. When PBMCs are isolated from patient samples, the availability of drug 
specific T lymphocytes are of the utmost importance, as their activation proves the 
diagnosis, and further work can be done to classify the phenotype of the reaction. Drug 
specific T cells are invaluable for the development of useful and accurate in vitro tests, 
and importantly are detectable in the PBMC up to several years after the final 
administration of the allergenic drug 25. 
1.2.2.2.2 LYMPHOCYTE TRANSFORMATION TEST (LTT)  
The Lymphocyte transformation test (LTT) is the most used in vitro assay for the 
diagnosis of DHR 26. It makes use of PBMCs, which are cultured with the potential 
allergenic drug in various concentrations for 5 days. The readout of the assay which 
produces the result relies on the detection and quantification of T cell proliferation in 
response to the drug over the five day period, in which time the drug will have had 
time to be processed and presented by APCs such as dendritic cells, leading to T cell 
12 
activation and proliferation. Radioactive 3[H] thymidine is added on day 5 which is 
incorporated into the DNA of the T cells, which can then be detected by a beta-counter. 
The detected T cell proliferation is compared to control samples without drug addition, 
and tetanus as a positive control (as most of the population will have been sensitised 
to tetanus at some point), the quantified T cell response can then be used primarily to 
determine if a DHR has occurred in response to the drug in question, but can also be 
used to assess optimal concentrations of drug to use. Some of the positive aspects of 
the assay are that it is less invasive than the use of in vivo cutaneous tests and has no 
chance of harming the patient in any way. PBMCs are readily available from blood 
and contain drug specific T cells which can be used in a plethora of ways in order to 
further understand DHRs. The LTT can also investigate both immediate and delayed 
onset DHR reactions, therefore nothing is lost when using the LTT in place of in vivo 
methods 27. However, the use of radioactive 3[H] thymidine to enable detection of 
lymphocyte proliferation increases the cost of the assay. At 6 days, the assay is also 
more time consuming and labour intensive than some of the older in vivo methods. 
Cross-reactivity between certain antibiotics can also be observed, leading to false 
positives in the assay 28, in addition to the fact that the assay cannot provide insight 
into the mechanism of the adverse event or immune aetiology of a DHR. Despite these 
shortcomings of the assay, the LTT remains as the most widely used in vitro assay in 
DHR diagnosis at this time.  
1.2.2.2.3 ENZYME-LINKED IMMUNOSORBENT SPOT ASSAY  
An Enzyme-linked immunosorbent spot assay (ELISpot) is another useful diagnostic 
tool in drug hypersensitivity, as it gives more of an idea as to the phenotype of the 
reaction, rather than just the yes/no provided by the LTT. It works by pre-coating 
antibodies to a membrane in the well of a 96-well plate, and then culturing either 
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PBMCs or specific T cell populations with APCs and the drug in question. Upon 
activation of T cell by the drug, the cytokine to be detected may be secreted by the T 
cells which then bind to the specific antibodies on the pre-coated membranes. The 
cells are then washed off, and enzyme conjugated detection antibodies are added, 
followed by a substrate which causes the appearance of black spots on the membrane. 
Each spot is considered a site of cytokine secretion, meaning the more spots on the 
membrane, the more cytokine secretion is occurring. The ELISpot is both sensitive 
and specific; being able to quickly detect relatively low-level secretion of cytokines 
from T cells. The assay can be used to characterise the DHR by the detection of several 
cytokines secreted by activated T cells, including pro-inflammatory cytokines such as 
IFN-γ, anti-inflammatory cytokines such as IL-13, regulatory cytokines such as IL-10 
and cytotoxic mediators like Granzyme B 29. This information gives some insight into 
the type of reaction occurring, and the role of either a specific subset of T cells (if 
using T cell clones) or the type of response elicited by the total PBMC in response to 
drug challenge. For example, IFN-γ release from drug-specific T cells was detected in 
more than 90% of amoxicillin hypersensitive patients tested with ELISpot 30, and is 
able to achieve this more sensitively than the ELISA assay.  
1.2.2.2.4 T LYMPHOCYTE CLONING  
Cloning of T lymphocytes is something to be discussed briefly, as although it is not 
strictly a diagnostic assay, it is an important mechanistic tool that can then be linked 
to a variety of other diagnostic in vitro techniques. T cell cloning is established through 
the culture of PBMC with drug for 2 weeks, at which time the cells are assayed into 
96-well plates in 1 cell per well. The cells are then re-stimulated with irradiated 
heterologous PBMCs which stimulates extensive proliferation. Cells are kept alive and 
growing through repeated mitogen stimulation with IL-2 and can then be tested for 
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specificity by proliferation and ELISpot experiments. This protocol would strictly be 
classed as a mechanistic assay, as it allows for the clonal expansion of single drug-
specific T cell populations. The further characterisation of these T cell populations 
then provides some mechanistic insight into reactions occurring, as well as the ability 
to find out a great deal about some of the T cells that are involved in DHRs. The T cell 
populations can be phenotyped for CD4/CD8, proliferation data can be acquired, as 
well as being able to profile the T cells by the types of cytokines they release either 
through the use of ELISpot or intracellular staining and analysis through flow 
cytometry. The use of T cell clones has helped to establish the characteristics of some 
T cell populations involved in DHR and can even help establish whether cross 
reactivity between antigens is occurring through the detection of one or more cell 
surface antigens. The use of this technique is important for the characterisation of the 
pathomechanisms involved in DHR and the detection of rare T cell populations in 
patients presenting with negative diagnostic assays 31,32. However, T cell clones can 
be vulnerable to infections, exhaustion of loss of specificity if kept in culture for too 
long.  
1.2.2.2.5 FLOW CYTOMETRY  
Flow cytometry is one of the most widely used immunological techniques that can be 
used in an array of applications as it can be used for the detection and expression of 
cell surface markers, as well as for the detection and sorting of cell populations into 
specific subsets.  Specifically, for DHR prediction and diagnosis immune cells can 
either be PBMC or tissue derived - with markers able to identify and sort specific 
immunological cell subsets, as well as the identification and expression of tell-tale 
immunological markers; including antigen-specific T cell subsets and their activation. 
Multiple markers can be concurrently analysed through use of fluorescently 
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conjugated antibodies, with their relative expressions compared vs unstained negative 
controls.  
The CD69 upregulation assay makes use of the increased expression of the cell-surface 
CD69 marker following T cell activation. This can be detected by flow cytometry to 
determine the extent of T cell activation following antigenic stimulation 33–35.  
The fluorescent biomarker carboxyfluorescin diacetate succinimidyl ester (CFSE) can 
be used to detect proliferative responses in T cells, as CFSE is incorporated into cells 
by interaction with intracellular proteins. Fluorescent intensity is halved by subsequent 
T cell divisions; which can be quantified by flow cytometry 36.  
Flow cytometry can also be used to determine the presence of certain cell populations 
and their abundance within a culture in response to drug treatment; such as the increase 
in T regs observed during naïve T cell priming in Chapter 4 of this thesis.  
Intracellular staining can also make use of fluorescent antibodies as well as flow 
cytometry to detect expression of cytokines and other cellular factors in response to 
drug treatment. The main difference between cell surface marker analysis and 
intracellular staining is the need to fix and permeabilise cells to detect intracellular 
expression. This can be used as an alternative to the ELISA and ELISpot assays and 
can be incorporated into other panels concurrently; an advantage over the ELISA and 
ELISpot systems. 
 THE IMMUNE SYSTEM 
1.3.1 THE ROLE OF THE IMMUNE SYSTEM  
The main role of the immune system is to protect the body against foreign antigens; 
including bacteria and viruses. It does this primarily through a variety of different 
immunological mechanisms that include variations on the detection, interaction with, 
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and ultimately the destruction of said foreign antigen. The innate immune system plays 
a major role in early immune defence mechanisms, whilst the adaptive immune system 
is often involved at a later point, including recognition of the same antigen upon re-
exposure. This often concludes with the adaptive immune system being the main 
driving force of an immune mediated response to a specific antigen. However, the 
nature of the immune system means that there are milieu different immune 
mechanisms, and thus, many different ways in which the body reacts to protect itself 
upon antigenic recognition. Due to the extreme complexities involved in the 
mammalian immune system, the lines can be blurred between an innate and adaptive 
response. Immune homeostasis is critical for the healthy function of the human body, 
and any defects to the immune homeostasis can lead to the adverse events discussed 
throughout this thesis. Indeed, the innate immune system can react more generally to 
antigens in an immediate manner; however, once adaptive immunity has taken over, 
reactions are mounted against specific antigens in a more delayed manner.  
The experiments contained within this thesis focus mainly on the adaptive immune 
system, as the experiments are designed to investigate delayed (type IV) DHR through 
the determination of outcomes of antigen-specific T cells upon exposure to the 
antigen; including the priming of naïve T cells and the related immune mechanisms.  
1.3.2 LYMPHOCYTES  
Lymphocytes, especially T cells (T lymphocytes), are central to the adaptive immune 
response. Naïve T cells can be polarised through exposure and interaction with 
cytokines into different categories of effector T cells, each with their own distinct role 
and mechanism of action. These include cytotoxic T cells (CD8+), helper T cells 
(CD4+), as well as regulatory T cells (Tregs) amongst others. T cells express a large 
range of receptors on their surface, most importantly, the T cell receptor (TCR) that is 
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required for interaction with the MHC of APC to form an immune synapse (signal 1). 
The ability of the TCR to recognise antigenic peptide fragments, displayed on the 
MHC of APCs is central to the formation of the immune synapse, and ultimately, T 
cell priming, activation, and clonal expansion. The mechanisms employed by 
differentiated T lymphocytes are mainly linked to the production of either pro- or anti-
inflammatory cytokines dependent on the required outcome of action. Whilst B cells 
are generally differentiated into plasma cells that secrete antibodies in response to an 
antigen or are reserved as memory B cells.  
Below is a summary of the main lymphocyte families involved in the immune response 
to an antigen and are therefore relevant to the study of DHR within this thesis. 
1.3.2.1 CD8+ T CELLS 
Cytotoxic T cells can be primed in the secondary lymphoid organs such as the spleen 
or lymph nodes from CD8+ naïve precursors in the presence of IL-7 37. CD8+ T cells 
are cytotoxic in nature and respond in an MHC class I restricted manner, meaning that 
the interaction of the CD8+ TCR is restricted to peptides displayed on the surface of 
MHC class I on APCs or other cell types that express MHC class I 38. CD8+ T cells’ 
mechanism of action is to target and destroy previously damaged or infected cells 
through the release of several cytotoxic and cytolytic molecules; including perforin, 
fas ligand (FasL), granulysin, and granzyme B.  Granzyme B and granulysin work in 
tandem with perforin to elicit their killing effects on cells. Perforin forms pores into 
the targeted cells, enabling the entry of granzyme B and granulysin to cleave cellular 
proteins and induce cell death through caspase signalling dependent apoptosis. 
Granulysin can also cause membrane disruption to induce cell death. Both granulysin 
and granzyme B are important cytokines for their cytolytic killing effects, but are also 
important immunological cytokines that activate further downstream cytokine 
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signalling in an immune response, and the recruitment of other T cells and 
inflammatory agents 39,40. FasL is another cytotoxic molecule released from activated 
CD8+ T cells and induces the caspase signalling pathway and subsequent apoptosis 
41,42. Due to the ability of perforin, granzyme B, granulysin and FasL to induce 
apoptosis and cell death, CD8+ cytotoxic T cells have been implicated in severe DHRs 
such as SJS/TEN. Keratinocyte destruction and subsequent skin detachment occurs as 
a consequence of cytotoxic T cell secretion of the aforementioned cytolytic molecules 
43,44.  
1.3.2.2 CD4+ T CELLS 
 
Figure 1.1 – T cell plasticity; differentiation of Th0 naïve T cells to different subsets. Featuring the main 
transcription factor and cytokines influencing differentiation, as well as key cytokines secreted from 
each T cell type. Simplified and adapted from 45.  
1.3.2.2.1 T HELPER CELLS 
Naïve T Cells (Th0) can differentiate into a number of different subclasses of 
lymphocytes dependent on the activated transcription factor. An important population 
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of T cells  are T helper cells (primed from naïve CD4+ precursors), which can be 
further categorised into different subsets, identifiable by the transcription factor 
involved, the cytokines involved in the polarisation event, and the expression pattern 
of the cytokines they secrete. The main role of the T helper cell is the recruitment of 
other immune components to the site of infection/antigen detection through the 
secretion of specific cytokines dependent on the T helper subset involved. They are 
involved in the activation of cytotoxic T cells, as well as B cell class switching.  
The best-established T helper subsets are the Th1 and Th2 T cells, as they were the first 
classes to be discovered experimentally. Th1 cell development is driven by the T-bet 
transcription factor and IL-12 from the naïve T cell population, they are characterised 
by the secretion of pro-inflammatory cytokines such as IFN-γ. This secretion of IFN-
γ can help protect against intracellular antigens (e.g. viruses) through pro-
inflammatory activation of CD8+ cytotoxic T cells, macrophages and NK cells 46. Th2 
cell development is driven by the GATA3 transcription factor, as well as the anti-
inflammatory cytokine IL-4; which Th2 cells also secrete for self-promotion and 
interaction with DCs. Th2 cells were largely known as anti-inflammatory T helpers 
due to their secretion of IL-4, IL-5, IL-10 and IL-13. They promote B cell, eosinophil, 
and mast cell IgE mediated immunity against extracellular parasites and helminths 
46,47. Despite early research into T helper cells describing a Th1/Th2 balance in the 
adaptive immune system; many other cell types are also involved during a response. 
Indeed, in DHR patient studies, both IFN-γ and IL-13 have been detected, indicating 
that both Th1 and Th2 are involved in these iatrogenic responses 37. Despite this, 
traditionally Th1 cells were described as being involved in auto-immune diseases and 
Chron’s, whilst Th2 cells are involved in atopic disorders (presumably due to their IgE 
mediated action) 48.  
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More recently, the discovery of novel T helper subsets Th17 and Th22 have led to 
further implications of T helper involvement in drug allergy. Th17 cells are driven by 
the RORγt transcription factor as well as IL-6 and TGF-β, whereas Th22 cells require 
AhR transcription factor and IL-6 alone. Th17 cells are known to secrete both IL-17 
and IL-22, whilst Th22 cells secrete IL-22 and TNF-α. Th22 cells are involved in skin 
inflammation and DHR such as reactions to piperacillin treatment; IL-17 augments 
inflammation, IL-22 infers a protective role on the tissue 49,50. Furthermore, work 
within the group previously detected IL-22 secreting antigen-specific T cells during 
naïve T cell priming assays to piperacillin when PD-1 signalling was blocked 50.  
Less studied T helper subsets such as Th9 (IL-9 secreting, PU.1 transcription factor 
driven) have been implicated in both IBD and skin disorders 51,52. T follicular helper 
(Tfh) cells driven by Bcl-6 are located within temporary germinal centres and interact 
with B cells through a CD40 co-stimulatory pathway (to form IgE responses), and also 
secrete IL-21 and IL-4. They have been a target of interest for improvement of 
vaccination strategy, but have also been implicated in auto-immunity 53,54.  
1.3.2.2.2 T REGULATORY CELLS 
Tregs are characterised by an expression profile of CD4+CD25+FOXP3+ and are an 
important cell type involved in maintenance of immune homeostasis through immune 
regulation 55. They are differentiated from naïve CD4+ T cells as part of T cell 
plasticity through the forkhead box protein 3 (FOXP3) transcription factor and are 
further influenced through TGF-β signalling 56,57. They are an important immune self-
check mechanism as they can establish tolerance against self-antigens or be the 
determining factor in whether an appropriate immune response is mounted against a 
foreign antigen. Tregs are known mainly for their immuno-suppressive actions which 
can be implemented via different mechanisms. Tregs express high levels of CTLA-4 
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(discussed in section 1.5.1), leading to decreased Treg-APC interaction; causing 
lymphoproliferative suppression as a viable immune synapse cannot be formed 58,59. 
Tregs have also been implicated in IL-2 uptake – a key interleukin involved in T cell 
activation – which limits availability to, and subsequent activation of other T cells. 
This is also important as IL-2 has also been shown to induce Treg development and 
so despite its role in T cell proliferation activation of effector T cells, can also induce 
immunosuppressive events 60. The secretion of the anti-inflammatory cytokines IL-10 
and TGF-β from Tregs also form a large part of their immunosuppressive role in the 
immune system; again, through presumed disruption of APC antigen presentation to 
circulating TCR 61. The importance of Tregs on immune homeostasis is outlined by 
the fact that defective Tregs have been found to be accountable for the exacerbated 
immune responses observed in DHRs such as hypersensitivity pneumonitis 62.  
1.3.2.3 B CELLS 
B lymphocytes developed in the germinal centres and are known to express CD19 and 
are involved in antibody production in response to antigenic recognition by various 
immunoglobulins expressed on their cell surface. CD19 acts in a synergistic manner 
with cell surface immunoglobulins to induce B cell maturation after peptide 
recognition on MHC class II of T cells 63. B cells can be differentiated into antibody 
secreting effector plasma cells, or long-lived memory B cells through the cross-linking 
of their surface receptors. Plasma cells utilise complement pathway fixation and 
antibody secretion for the removal of viral fragments and can undergo class switching 
through somatic hypermutation at germinal centres which regulates the nature of the 
antibodies produced (IgM, IgE, IgG, IgA). Whilst memory B cells are long-lived and 
may remain dormant until re-exposure to an antigen, at which point polyclonal 
antibody production mediated by IgG and IgA immunoglobulins occur. Antibodies 
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produced by B cells can either become solubilised within the blood plasma (forming 
part of humoral immunity), or remain bound to B cell receptors on the cell surface 64.  
Antibodies secreted by B cells can take part in adverse events such as tissue injury; 
and are also involved in autoimmune pathogenesis through their interaction with T 
cells including antigen presentation, cytokine secretion, and co-signalling pathway 
activity 65.  
B cells were used experimentally within this thesis as an APC in chapter 6 – 
immortalised EBV transformed B cells were developed due to their ease of long-term 
culture, their antigen presenting capabilities, and their ability to be irradiated 
(preventing proliferation during antigen-specific T cell proliferation assays).  
1.3.2.4 NATURAL KILLER CELLS  
Unlike T helper cells, natural killer (NK) cells are effector T cells involved in innate 
immunity through secretion of cellular damaging molecules (similar to cytotoxic T 
cells). However, they can also form interactions with DCs, macrophages, and other T 
cells to elicit a regulatory phenotype under certain circumstances 66. They are deemed 
part of the innate immune system as they do not use TCRs to respond to specific 
antigen like members of the adaptive immune system (T cells). They respond in a more 
general manner; using Ly49 and killer Ig-like receptor (KIGR) to carry out anti-
tumour, and anti-viral responses and maintain tolerance through the distinction 
between self and non-self. NK cells use KIGR to detect down-regulation of MHC class 
I in circulating cells which acts as a targeting mechanism for NK cells, as MHC class 
I is down-regulated during cellular stress/damage. NK cells respond to a multitude of 
cytokines including pro and anti-inflammatory: IL-12, IL-18, IL-27, IL-35, IL-2, IL-
7 and IL-15 67,68. NK cells also secrete cytolytic molecules such as granulysin and 
granzyme B to induce apoptosis in targeted cells in an immediate innate manner. 
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However, activation of TLRs on NK cells can lead to IFN secretion, which in turn can 
induce T-bet transcription factor and the subsequent activation of the adaptive immune 
system through Th1 responses 66,69,70. 
1.3.3 MONOCYTES – MACROPHAGES & DENDRITIC CELLS 
Monocytes are differentiated from a precursor myeloid cell progenitor cell; they have 
a single nucleus, and overall are larger than other granulocytes. They can be 
characterised by their expression of the cell-surface marker CD14, something which 
we select for when separating monocytes from whole PBMC 71. Monocytes are then 
able to differentiate into further subpopulations of monocytic phagocytes; 
macrophages (M1 or M2) or DCs, dependent on the surrounding cytokine signalling 
microenvironment, or alternatively remain as inflammatory Ly6C+ monocytes.  
M-CSF as well as IL-6 influences the differentiation pathway towards macrophages, 
whose job is the recognition (through constitutively expressed TLRs) and 
phagocytosis and degradation of antigen through lysosome fusion and ROS/nitric 
oxide destruction. This is in addition to their role in antigen presentation to circulating 
Th1/Th2 cells and the recruitment of granulocytes such as neutrophils 72,73. 
Macrophages can be classed as either M1 macrophages which secrete pro-
inflammatory cytokines such as IFN-γ and induce a Th1 mediated response, or M2 
macrophages which are considered anti-inflammatory; resulting in a largely Th2 
response 74.  
Dendritic cells are the main APC used experimentally within this thesis and are the 
one of the main initiators of the adaptive immune response in vivo. Experimentally, 
we were able to differentiate CD14+ monocytes to DCs through a 7-day culture with 
GM-CSF and IL-4 as well as TNF-α stimulation 71. In vivo, TNF-α is a major 
differentiating factor in DC development as it limits the M-CSF pathway which would 
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usually result in macrophage development. DCs are one of the most important barriers 
to whether or not adaptive immune activation occurs due to their involvement in 
recognition of foreign antigen by TLRs, engulfment and internalisation of the antigen, 
internal processing of the antigen to antigenic peptides, before presentation to 
circulating T cells on the upregulated MHC class I or II. DCs are found in the 
peripheral blood but migrate to secondary lymphoid organs upon maturity to elicit 
their professional APC capabilities and form the backbone of adaptive immunity and 
immunological memory. During immaturity dendritic cells function better as 
phagocytes, acting to engulf and internalise foreign antigen – whereas upon maturity 
they become larger and more granular, forming their trademark dendrites (see figure 
1.2). This along with the upregulation of MHC class II allows for better antigen 
presenting capability and the formation of an immune synapse (signal 1). DCs are 
further involved in T cell mediated responses as they also up-regulate both CD80 and 
CD86 - involved in the co-stimulatory CD28 family pathway (signal 2) – as well as 
the co-stimulatory CD40. Both signal 1 and signal 2 are a pre-requisite for adaptive 
immune activation (section 1.5.1) 75,76. Maturity of dendritic cells can be induced by a 
number of factors interacting with TLRs on the cell surface, these include: activation 
by damage associated molecular patterns (DAMPS) such as HMGB1, or heat-shock 
proteins such as HSP70 77,78. Pathogen associated molecular patterns (PAMPS) such 
as lipopolysaccharide (LPS) are also used experimentally to induce DC maturation in 
vitro 71,79. DC maturation can also be directly induced by drugs or CRMs such as our 
major experimental compound SMX-NO; potentially acting through a DAMPS 
mechanism through cell toxicity 80. It is for the above reasons DCs play such a vital 
role in the adaptive immune system and is the ideal candidate to be used as the 
predominant professional APC in experiments throughout this thesis.  
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Figure 1.2 – The maturation of dendritic cells. Simplified and adapted from 81. 
 
1.3.4 OTHER IMMUNE COMPONENTS - GRANULOCYTES 
There are also a range of other cell types involved in the mediation of innate immunity. 
These are not involved in experiments contained in this thesis but are important for 
immediate DHR. They are renowned for their multi-lobed nucleus and originate from 
myeloid precursors.  
Neutrophils are the most abundant granulocyte and are involved in the primary 
immune response through chemotaxis to the site of inflammation. Once there they 
identify the target, before engulfment and phagocytosis, followed by destruction 
internally by ROS, lysozymes and cathepsins 82. Neutropenia – low concentration of 
neutrophils in the blood – can be a serious detriment to the primary immune response 
in an individual and can be caused due to systematic diseases leading to congenital 
disorders, or through self-limiting viral infection 83.  
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Basophils are the least common granulocyte. IgE mediated activation leading to 
degranulation results in the release of multiple signalling molecules such as histamines 
heparin and proteolytic enzymes, as well as DC differentiation factors GM-CSF and 
IL-4. They are also known to be involved in Th2 mediation 84.  
Eosinophils are another granulocyte that are derived from progenitor stem cells before 
circulation in the blood. Eotaxins and IL-5 signalling are involved in the recruitment 
of this cell type to inflammatory sites, where a range of pro-inflammatory cytokines, 
cytotoxic granule proteins, and ROS are released 85. Severe inflammation can occur 
when the concentration of eosinophils within the blood becomes abnormally elevated 
(450-550 cells/uL of blood) – this is known as eosinophilia 86.  
Mast cells are also involved in innate immunity – they are a subset of granulocytes 
derived from myeloid precursors. They are larger granular immune cells secreting 
many of the same inflammatory molecules as basophils. Upon activation through B 
cell secreted IgE cross-linking, de-granulation occurs with the previously mentioned 
molecular inflammatory mediators being secreted. Mast cells are involved in many  
IgE-mediated allergic reactions and participate in failure of immune tolerance which 
may lead to autoimmunity 87,88. Severe allergic responses can be observed when 
mastocytosis occurs; an excess of mast cells locating in the tissues.  
 T CELL ACTIVATION & GENETICS 
The activation of T cells in vivo is largely a function of the interaction between an 
antigen, the human leukocyte antigen expressed on antigen presenting cells (APC), 
and the T cell receptor. The interaction between these three immunological 
components can lead to the formation of an immune synapse, and thus completes at 
least one stage of the necessary interactions leading to the initiation of T cell response. 
Due to the major role inferred by the HLA on immune activation, there is a heavy 
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genetic component involved in this process. Genetic associations with disease were 
first recognized in the early 20th century, when Archibald Garrod discovered that 
alkaptonuria – a disease which prevents the processing of phenylalanine and tyrosine 
by the body – followed Mendel’s rules of inheritance and relied on a recessive 
mutation 89,90. Since then, other diseases have been revealed to have a genetic 
aetiology, leading to generational inheritance. Variations in the population’s genetics 
mean that some people are predisposed to developing illnesses such as specific 
cancers, or hereditary conditions like cystic fibrosis or Huntington’s disease. In some 
instances, the severity of the symptoms can be linked to distinct genetic mutations in 
the individual.  
1.4.1 HUMAN LEUKOCYTE ANTIGEN 
The HLA gene complex encodes a multitude of proteins that are largely responsible 
for the body’s ability to mount an adaptive immune response to an antigen. First 
identified in the 1950s, it took 30 years before the structure and function of the HLA 
was elucidated through seminal work on the HLA-A*02 allele by Bjorkman and Wiley 
91. HLA alleles are split into Class I and II, which encode HLA class I and II proteins, 
respectively. Variations in the sequence of the HLA peptide-binding groove are 
responsible for intraindividual variations in the body’s response to antigens (including 
drugs). Due to the highly polymorphic nature of the HLA gene complex, there are 
allelic variations of both classes. HLA-A, HLA-B, and HLA-C are individual loci of 
HLA class I proteins, with each locus possessing multiple alleles, whereas HLA-DR, 
HLA-DP, and HLA-DQ are HLA class II variants 92–94. There are several thousand 
allelic variants of HLA class I and II that encode proteins with differing structures that 
in theory will present different peptides on the surface of APC. Presentation allows 
for the recognition of an antigen by a T cell receptor and is necessary for the formation 
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of an immunological synapse and T cell activation. The subdivision into HLA classes 
I and II can be determined both by structure and the nature of antigen binding. HLA 
class I proteins are expressed on all nucleated cells and present peptides of intracellular 
origin to CD8+ T cells. In contrast, HLA class II expression is mainly restricted to 
APC and the HLA proteins present peptides derived from extracellular proteins to 
CD4+ T cells. HLA loci are the most polymorphic of the human genome leading to a 
broad range of genetic diversity. The nomenclature of HLA helps to distinguish and 
categorize the differences between the different proteins (Figure 1.3). Although the 
structure of HLA class I and II proteins are different, they are both are heterodimeric 
(Figure 1.3). 
 
Figure 1.3 – Nomenclature and structure of HLA class I and II molecules 95.  
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HLA class I consists of an alpha chain encoded by the HLA class I gene, which, makes 
up the peptide-binding groove that interacts with β-2 microglobulin. HLA class II 
proteins are composed of an alpha and a beta chain that are encoded by individual 
HLA class II A and B gene loci, respectively. Different ethnic populations express a 
range of common alleles and this has resulted in several forms of DHR primarily 
affecting specific geographical regions. For example: (1) carbamazepine-induced 
Stevens–Johnson syndrome is strongly associated with HLA-B*15:02; and (2) 
dapsone hypersensitivity syndrome is strongly associated with HLA-B*13:01. Both 
of these alleles are expressed at high levels in Chinese populations but are almost 
absent from Caucasians. This topic is covered in more detail below. The identification 
of HLA allele associations with DHRs has allowed researchers to focus on specific 
drug interactions with single HLA proteins. The three most studied examples being 
HLA-B*57:01 with abacavir and flucloxacillin and HLA-B*15:02 with 
carbamazepine. At the turn of the century, drugs were thought to interact with HLA 
via two basic mechanisms: either the hapten or pharmacological interaction (p-i) 
pathway. After 15 years of intense research, the importance of these pathways to 
different forms of DHR is now clearer. Furthermore, studies focusing exclusively on 
abacavir have identified a third alternative or complementary pathway coined the 
altered peptide repertoire concept. Each of these pathways are discussed below and 
then specific well-defined examples will be used to describe how our knowledge of 
each pathway has progressed. Central to the understanding of drug action is the way 
in which a drug binds to its target to elicit a wanted or unwanted response. As Paul 
Ehrlich stated over a century ago, ‘a drug will not work unless it is bound’. In terms 
of DHRs, a drug must somehow bind to HLA proteins (or an HLA binding peptide) 
and interact with specific T cells. Whether a T cell response is induced is determined 
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by the specificity of the binding interaction, the site of binding within the receptor, the 
complex nature of the bound drug, and finally the extent of binding. A plethora of 
specific receptors exist so that drugs cannot bind promiscuously, providing a self-
regulation checkpoint against continually causing unwanted adverse reactions. 
Furthermore, the interaction between drug and HLA proteins does not guarantee 
triggering activation of an immune response. For drugs that induce DHRs, two things 
must occur. First, the T cell receptor must be bound by an HLA-associated drug, and 
second, the activation threshold of the T cell receptor must be reached for the drug to 
act as an immunogen and initiate an immune response 96–98.  
1.4.2 MODELS OF DRUG HYPERSENSITIVITY – BINDING MECHANISMS OF HLA AND 
TCR 
Figure 1.4 - Different mechanisms of T cell activation by drugs. A. Haptenation occurs when a drug 
hapten binds to a protein to form an adduct. The protein adduct can then be internalized and processed 
by antigen presenting cells into peptides for loading onto the HLA, being presented to circulating T 
cells. The pro-hapten theory differs solely in the fact that the drug first must form a chemically reactive 
metabolite before binding to the protein to form the adduct. B. In the p-i pathway, the drug can interact 
directly and non-covalently with the HLA-TCR complex to induce an immune response. The nature of 
this binding interaction has not been defined. No internalization or processing by the antigen presenting 
cell is required. C. The altered peptide concept is similar to p-i in that it is a non-covalent interaction. 
However, antigen presenting cell processing is required to generate peptide sequences that bind to the 
abacavir-modified HLA. The altered repertoire of self-peptides may then induce an immune response 
99.  
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1.4.2.1 THE HAPTEN HYPOTHESIS 
The interaction between HLA located on specific antigen-presenting cells, peptide and 
the T cell receptor is a critical initiator of the T cell response. This interaction is often 
termed signal 1. The hapten hypothesis – first proposed in 1935 by Landsteiner and 
Jacobs’ working on small chemically reactive compounds – states that a chemical (or 
drug) must bind covalently to a protein to induce an immune response 100. Studies 
performed in subsequent decades have confirmed the original hypothesis and shown 
that lymphocyte reactivity with small chemicals is directly related to protein reactivity 
101–105. Work into the penicillins showed that lysine residues were covalently bound 
by beta lactam antibiotics; these modified penicillin protein haptens were later 
determined to be able to activate T cells 106,107. Soon after this synthetic peptides were 
used to explore this phenomenon, with penicillin-modified peptides being found 
responsible for T cell activation 108. Work into SMX also helped to confirm the hapten 
concept and the involvement of chemically reactive metabolites in T cell activation. 
SMX was found to form a reactive metabolite (SMX-NO) via the intermediate 
hydroxylamine (SMX-NHOH)109; the reactive metabolite was later found to drive T 
cell response in animal models 110. SMX-NO specific reactive T cells are known to be 
dependent on antigen processing, as pulsing APCs with SMX-NO (washing free drug 
away) leads to T cell activation. No response is observed when APCs are fixed to 
block antigen uptake 111.  
The term hapten refers to the chemical entity that binds covalently to protein, whereas 
an antigen is the HLA-binding peptide derived from the protein adduct after 
processing by antigen-presenting cells. We tend to assume that the drug molecule 
remains attached to the HLA-binding peptide to activate T cells; however, this 
assumption could be wrong as drug binding may alter protein processing. New peptide 
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sequences might be generated, and these could interact with HLA proteins and trigger 
T cell receptors. The reason why the study of drug hapten T cell responses is so 
intriguing and so complicated is that virtually nothing is known about the drug 
modified proteins involved in the immune response. Moreover, most drugs are inert 
on administration and undergo metabolism before they form a drug-protein complex. 
Drugs that activate T cells via a reactive metabolite are referred to as pro-haptens 112–
114. Since metabolites presumed to be involved in DHRs are intrinsically unstable, very 
few are available for functional studies. As such, our understanding of the mechanistic 
basis of drug-specific T cell activation is highly skewed. The vast majority of 
experiments conducted to date involve parent drugs that do not form relevant 
metabolites in immune cell cultures. Thus, it is highly unlikely that a drug-metabolite-
induced response will be detected in these assays. 
1.4.2.2 THE PHARMACOLOGICAL INTERACTIONS (P-I) CONCEPT 
We now know that an immunological synapse can also form through a drug interacting 
directly via noncovalent bonds with HLA peptide and the T cell receptor. This is 
referred to as the p-i concept. The concept originates from the observation that the 
lymphocyte transformation test – a diagnostic assay based on the proliferation of 
peripheral blood mononuclear cells (PBMC) from patients with DHR, but not tolerant 
controls, is positive when the cells are incubated with the parent drug 115,116. 
Furthermore, experiments using drug-specific T cell clones have shown that a hapten 
pathway for T cell activation in certain instances is not possible. First, antigen 
presenting cell fixation, which blocks antigen processing, does not inhibit the T cell 
response observed with certain drugs. A hapten pathway of T cell activation is 
dependent on protein processing; thus, T cells must be activated via a different 
mechanism 117. Second, drug antigen-presenting cell pulsing experiments, where free 
33 
drug is washed away, prior to exposure of the antigen-presenting cells to T cells yields 
negative responses 118. Thus, the T cells seem to be activated through a labile readily 
reversible (non-covalent) interaction with antigen-presenting cells. Finally, 
researchers have shown that the kinetics of T cell activation are too quick for antigen 
processing to occur 119. Several drugs including sulfamethoxazole, carbamazepine, 
lidocaine, and lamotrigine have been reported to directly activate PBMC and cloned 
T cells from patients with DHRs 119–122. Although few now doubt that T cells are 
activated with drugs bound directly to HLA molecules, several important questions 
still need to be addressed. In particular, research is needed to define the site of drug 
HLA binding (peptide binding cleft, peptide, outside the cleft), the specific amino 
acids involved in the binding interaction and whether p-i activating drugs prime naïve 
T cells. 
1.4.2.3 THE ALTERED PEPTIDE REPERTOIRE CONCEPT 
Researchers working on cloned T cells found that abacavir was able to activate certain 
cells rapidly – presumably via the p-i pathway; however, other clones were activated 
via a very different mechanism. With these clones, the response was dependent on 
protein processing. Furthermore, antigen-presenting cells pulsed with abacavir for 16 
h stimulated IFN-γ release from the clones 123,124. Antigen-presenting cell pulsing 
assays are normally used to show that drug protein adducts stimulate T cells via a 
hapten mechanism 117. Originally, these data lead researchers to propose a hapten 
mechanism for abacavir-specific T cell activation; however, time-course pulsing 
experiments yielded unexpected results. Clones were not activated with antigen-
presenting cells pulsed with the drug for shorter time periods; such as 1–4 h. What we 
now know is that abacavir needs to be present while proteins are being processed to 
liberate new HLA-binding peptides. The drug binds deep in the HLA protein binding 
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pocket altering the cleft structure and hence the peptide sequences that bind. These 
data led to evolution of the altered HLA peptide repertoire-binding concept – a second 
pathway of T cell activation occurring through noncovalent interactions between drug, 
HLA, HLA-binding peptide, and the T cell receptor. The concept evolved in 2012 
when four independent research groups identified that the pathway of HLA binding 
could not be fully rationalized in terms of the hapten or p-i concepts 123,125–127. What 
the altered peptide concept proposes is that T cells are actually activated with novel 
abacavir-dependent peptide sequences and that the drug is unlikely to participate in 
the T cell receptor binding interaction. In 2012, the data were so revolutionary because 
abacavir hypersensitivity is only detected in patients expressing one HLA allele – 
B*57:01 8,128 and hence the drug must display exquisite sensitivity for this receptor. 
However, to date, abacavir is the only that selectively activates CD8+ T cells. This is 
in stark contrast to all other drugs associated with DHRs where drug-specific CD4+ 
and CD8+ T cell responses are seen. Based on this observation alone, it is not so 
surprising that abacavir activates T cells via a unique pathway. It must be noted that 
the formation of an immunological synapse is not necessarily sufficient in order for a 
T cell reaction to occur, as a T cell can undergo apoptosis and elimination when its 
cognate T cell receptor undergoes binding in the absence of activating cytokines or 
co-stimulation (signal 2). The presence of signal 2, as well as activation of APCs 
through danger signalling from damaged host cells may be required for an immune 
response to occur upon formation of an immunological synapse between drug and 
cognate T cell receptor.  
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1.4.3 MAJOR DHR ASSOCIATIONS  
Investigation of drug interactions with HLA proteins is now heavily directed by 
pharmacogenomic studies identifying an increasing number of associations between 
HLA alleles and specific forms of DHR, and this topic is discussed below. 
1.4.3.1 ABACAVIR 
The most widely researched link between HLA risk alleles and DHRs is abacavir and 
HLA-B*57:01. Though abacavir is an effective component of combination therapy for 
patients with HIV, instances of DHRs after abacavir treatment were reported to have 
a prevalence of approximately 8% 7. Abacavir hypersensitivity presents with multiple 
symptoms, including abdominal pain, fever, headaches, nausea, respiratory problems, 
including skin rashes and gastrointestinal symptoms 128. In 2002, genetic studies 
identified that variation in the polymorphic HLA-B region played a role in the 
development of abacavir hypersensitivity; almost 50% of a group of 84 patients 
expressed the HLA-B*57:01 allele, whilst less than 5% of the control group had the 
allele 129. In the same year, a second study identified the same HLA-B allele as a 
contributing factor alongside the class II alleles HLA-DR7 and HLA-DQ3. Although 
we now believe the class II alleles are not involved in the pathogenesis of the DHR, 
these early studies suggested that abacavir withdrawal from patients who expressed 
the risk alleles would reduce the prevalence of the DHR from 9% to 2.5% 128. 
Subsequently, the Predict-1 study, which combined prospective HLA-B*57:01 
screening with patch testing to confirm diagnosis, went on to demonstrate that 
screening eliminated abacavir hypersensitivity 8. As discussed above, the altered 
peptide model has been proposed to explain how abacavir activates T cells. 
Knowledge that HLA-B*57:01 expression was critical for the development of the 
reaction allowed researchers to generate an X-ray crystal structure of the HLA 
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abacavir peptide complex and hence identify the important amino acid binding sites 
and most importantly show that the drug binds to HLA in a deep pocket under the 
peptide 126,127,130. The model proposes that drug induced changes in the chemistry and 
structure of HLA-B*57:01 alters the self-peptides that bind, allowing for the 
recognition by circulating T cells of normally harmless peptides. The structure of 
abacavir is such that the compound only binds to the protein encoded by the HLA-
B*57:01 allele; binding does not occur even with proteins encoded by closely related 
alleles such as HLA-B*58:01. Based on this data, we have recently combined 
computer modelling of the abacavir HLA-B*57:01 binding interaction with 
assessment of CD8+ T cell responses and antiviral activity using a panel of abacavir 
analogs to identify a safer abacavir derivative 130. Each compound was synthesized 
with a substitution at the 6-amino position. The study demonstrated that it was possible 
to remove the unwanted HLA-B*57:01 binding of abacavir and T cell activation, 
whilst retaining some antiviral activity. As such it may be possible to design safer 
antiviral agents that do not require a personalized approach to therapy. As research 
continues, it is critical to identify whether the altered peptide repertoire concept does 
indeed apply only to abacavir. Moreover, it is essential that the nature and origin of T 
cell stimulatory peptides are elucidated. Currently, it is not known whether ‘abacavir-
responsive’ T cells are activated by a single peptide or a multitude of peptides 
originating from different protein sources. It is intriguing to also consider whether T 
cell stimulatory peptides derive from endogenous peptides not normally seen by the 
immune system or peptides derived from microbes such as viruses. In this respect, 
White et al. 131 provided a detailed and thought-provoking insight into the concept of 
heterologous immunity, which in very simple terms suggests that patients induce a 
stepwise immune response first to virus and secondly to a drug such as abacavir in this 
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instance. The virus-specific T cells then recognize endogenous peptide presented in 
the context of HLA and drug to bring about the DHR. In theory, this concept could be 
investigated by generating virus-specific T cells from patients with and without a DHR 
and then exploring cross-reactivity with drugs. This would be of great use but may be 
made more complex due to the highly diverse nature of both the human virus, and the 
generated T cell receptors. 
 
 
 
 
 
 
 
 
1.4.3.2 SULFAMETHOXAZOLE AND DAPSONE – REACTIVE METABOLITES 
The sulfonamide antibiotic sulfamethoxazole is the drug that has been used most 
extensively to explore the role of metabolism in DHRs. This is primarily because the 
reactive nitroso metabolite of sulfamethoxazole has been synthesized 109 and can be 
used in functional assays. CD4+ and CD8+ T cells from all hypersensitive patients 
studied to date are activated with the parent drug and the nitroso metabolite 117,132,133. 
Certain clones are activated selectively with the parent drug via a p-i pathway, whereas 
others are activated with nitroso sulfamethoxazole via a hapten mechanism. The 
picture becomes more complicated than this however as other clones are cross-reactive 
HLA-B*57:01 HLA-B*58:01 
Figure 1.5. HLA-B*57:01 differs from HLA-B*58:01 in the peptide binding groove by only 1 
amino acid residue. This affects what can interact with the binding groove, inducing immune 
responses. Some drugs interact with the HLA more specifically than others, for example people 
with the HLA-B*57:01 allele are known to be pre-disposed to abacavir induced DHR. This is not 
seen in people with the HLA-B*58:01 allele, whereas flucloxacillin induced DHR has been 
observed in patients possessing either of these alleles.  Abacavir can only interact specifically with 
HLA-B*57:01, whilst flucloxacillin acts more promiscuously in nature, interacting with HLA of the 
same serological family particularly ones with very close amino acid residue sequences.  
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and activated with both the parent drug and metabolite via different pathways. 
Furthermore, nitroso sulfamethoxazole can stimulate T cells through the direct 
covalent modification of HLA molecules and/or embedded HLA binding peptides. 
Despite these data sulfamethoxazole hypersensitivity reactions are not strongly 
associated with a single HLA allele 134,135. The absence of an HLA risk allele in 
sulfamethoxazole hypersensitivity may explain why it is possible to prime naïve T 
cells to nitroso sulfamethoxazole in almost 100% of healthy donors 71,136,137. T cell 
receptors containing the Vβ20-1 have previously been implicated in hypersensitivity 
reactions to drugs. Modelling data suggest that the CDR2β domain of the Vβ20-1 T 
cell receptor docks sulfamethoxazole with high affinity, and furthermore affects T cell 
receptor sulfamethoxazole-binding affinity through its action as a ligand controlled 
switch when SMX modifies three CDR2β amino acid residues: TYRβ57, ASPβ64, 
and LYSβ65 138. However, we are yet to fully understand how this modelling data 
translate into the activation of T cells with sulfamethoxazole. In contrast to 
sulfamethoxazole, dapsone hypersensitivity among patients with leprosy is strongly 
associated with HLA-B*13:01 139. In fact, the presence of HLA-B*13:01 had a 
sensitivity of 85.5% and a specificity of 85.7% as a predictor of the DHR. HLA-
B*13:01 is present in 2–20% of Chinese people but is largely absent from Caucasians 
and Africans. Importantly, genetic screening for expression of the HLA allele has 
recently been shown to have significant utility as a genetic marker of the DHR 140. 
Modelling data have shown docking of dapsone bound to HLA-B*13:01; and has 
outlined that binding affinity of dapsone to HLA-B*13:01 should be greater than to 
HLA-B*13:02 according to free energy calculations, and difference in F pocket 
structure between the two HLA alleles 141. Dapsone is metabolized to a nitroso 
metabolite that binds covalently to cellular proteins 142,143. For this reason, dapsone 
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hypersensitivity represents the ideal model to explore drug and drug metabolite 
binding to an HLA risk allele (i.e. HLA-B*13:01) and the pathways of drug 
presentation to T cells in patients with hypersensitivity. For this reason, we have 
recently synthesized nitroso dapsone and developed cell culture methods to study the 
priming of naïve T cells with the parent drug and metabolite. As both compounds 
activated naïve T cells via different pathways, similar to sulfamethoxazole and its 
nitroso metabolite, in HLA-B*13:01 negative donors 139,144, we are now beginning to 
explore whether the parent drug or drug (metabolite) peptide adducts preferentially 
bind to HLA-B*13:01 to activate CD8+ T cells from patients with hypersensitivity. 
Sulfamethoxazole contain an aromatic amine linked to a sulfonamide group. Similarly, 
nonsteroidal anti-inflammatory drugs such as celecoxib contain an aromatic 
sulfonamide moiety. Both drugs cause a relatively high number of hypersensitivity 
reactions, but the adverse events are seemingly not linked to expression of HLA-
B*13:01. Thus, it is possible that the sulfone component and not the aromatic amine 
of dapsone in some way contributes to the selective interaction of the drug with HLA-
B*13:01. 
1.4.3.3 FLUCLOXACILLIN  
Advances in our understanding of the role HLA alleles from diverse ethnic 
backgrounds play in DHRs has led to implementation of screening of patients from 
relevant ethnicities to abrogate reactions to abacavir, carbamazepine, dapsone, and 
allopurinol. Though these examples are considered as ‘success stories’ of genetic 
screening, most other HLA associations are not strong enough to warrant the screening 
or removal of an otherwise useful drug. One such example is flucloxacillin, a β-lactam 
antibiotic. Flucloxacillin is used in the treatment of gram-positive bacterial infections, 
but its use is associated with a high incidence of liver injury 145,146 and several deaths 
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have been reported. Flucloxacillin-induced liver injury is associated with expression 
of HLA-B*57:01. Although 43 out of 51 liver injury cases in the initial cohort 
expressed the risk allele, only approximately 1 in 1000 HLA-B*57:01 carriers go on 
to develop liver injury when exposed to flucloxacillin. Therefore, to prevent 1 
incidence of flucloxacillin-related liver injury, greater than 13,000 individuals would 
need to be screened 145,147,148. For this reason, HLA-B*57:01 screening will not be 
introduced prior to flucloxacillin use unless a test for multiple HLA alleles associated 
with the development of DHRs simultaneously can be implemented, as outlined by 
Pirmohamed et al. 148. The clinical features of flucloxacillin-induced liver injury, and 
the detection of HLA-B*57:01 as a susceptibility factor suggests that predisposition 
relates to the development of an HLA-class I restricted drug-specific CD8+ T cell 
response. Wuillemin et al. 149 have demonstrated that T cells infiltrate the liver of 
susceptible patients. We isolated T cells from patients with liver injury and showed 
that flucloxacillin activates CD8+ T cells in an HLA-B*57:01-restricted manner 31. In 
contrast to the drugs discussed above, flucloxacillin binds directly to lysine residues 
on protein and activates T cells from patients via a hapten mechanism 150. Previous 
studies exploring β-lactam-specific T cell responses have shown that drug-modified 
proteins and peptides activate patient T cells confirming that the formation of a 
covalently bound drug protein adduct can lead to immune responses 108. Despite this, 
the nature of naturally occurring, drug-modified immunogenic peptides have never 
been defined. The association between flucloxacillin and HLA-B*57:01 allows for the 
use of HLA-transfected cell lines to characterize the immunopeptidome in the 
presence and absence of flucloxacillin using the methods established with abacavir. If 
drug-modified peptides are identified, they can be used in future experiments to 
explore T cell immunogenicity. Using cells from HLA-B*57:01+ drug-naïve healthy 
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donors, it was also possible to prime naïve CD4+ and CD8+ T cells to flucloxacillin 
71. Interestingly, the response to flucloxacillin in HLA-B*57:01+ healthy donors 
seems to be driven by the direct reversible binding of soluble drug to the HLA 
molecule 151. These data show the complexity of studying drug-specific T cell 
responses and highlight the importance of understanding what different models should 
and should not be used for. 
1.4.3.4 CARBAMAZEPINE 
In 2004, the second strong association between the development of a DHR and 
expression of a specific HLA allele (HLA-B*15:02) was described 152. Carbamazepine 
is an anticonvulsant drug used in the treatment of epilepsy. Administration of 
carbamazepine is associated with a high prevalence of DRHs including severe 
cutaneous reactions such as Steven– Johnsons syndrome and toxic epidermal 
necrolysis 153. These life-threatening conditions are differing severities of the same 
disease and present as an autoimmune attack on epithelial cells, leading to skin 
detachment. Both reactions are associated with a high morbidity and mortality 154,155. 
HLA-B*15:02 was first described as an allele linked to carbamazepine-induced 
Stevens–Johnson syndrome. HLA-B*15:02 is much more commonly seen in Asian 
populations than Caucasian; hence Stevens–Johnson syndrome due to carbamazepine 
treatment is more frequent in Asian populations 156,157. Europeans who develop CBZ-
induced Stevens–Johnson syndrome do not commonly express HLA-B*15:02. Those 
that do are of Asian origin/ethnicity 156,157. These data highlight an important 
difference between abacavir and carbamazepine DHRs. Reactions to abacavir are only 
seen in donors expressing HLA-B*57:01; whereas carbamazepine reactions occur in 
donors with and without HLA-B*15:02. This suggests that carbamazepine may 
interact with multiple HLA alleles to activate T cells. Early functional studies with 
42 
PBMC from patients with carbamazepine hypersensitivity confirm this. CD4+ and 
CD8+ T cells from hypersensitive patients who do not express HLA-B*15:02 are 
activated with the drug 115,134. Furthermore, the activation of CD4+ T cells was HLA-
DR and -DQ restricted indicating that the drug interacts with HLA class II molecules. 
CBZ does not need to bind covalently to protein to stimulate T cells. Instead, the drug 
interacts reversibly with HLA proteins and T cells are activated in a matter of seconds, 
much faster than the time frame observed in the hapten pathway where processing of 
protein adducts takes several hours 158,159. This shows that antigen processing is not an 
absolute requirement for T cell activation; however, the data does not exclude a hapten 
pathway in carbamazepine hypersensitivity. Carbamazepine is converted 
enzymatically to multiple metabolites and at least three of these display protein 
reactivity 160–162. The problem is that these metabolites cannot be generated in situ in 
immune assays and the metabolites are not available for functional studies or cannot 
be applied in a relevant form. For example, (1) the proteins carbamazepine modifies 
in patients and (2) the nature of the bound hapten structure have not been defined; as 
such the synthesis of immunologically relevant protein adducts is not possible. 
Interestingly, carbamazepine 10,11 epoxide, a major metabolite of carbamazepine that 
was believed to display no protein reactivity, has recently been shown to modify 
albumin in patients exposed to a therapeutic course of the drug 163. Relatively high 
concentrations of carbamazepine 10,11 epoxide selectively activates certain clones 
from carbamazepine hypersensitive patients via a p-i pathway 134. Thus, it is feasible 
that this in vitro p-i response is mimicking a hapten pathway of activation in patients 
where metabolite exposure concentrations are significantly lower. Similar to the 
implementation of abacavir genetic screening, the predictive values of the HLA-
B*15:02 association was strong enough for the FDA to recommend genetic screening 
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of epilepsy patients before commencement of CBZ treatment for individuals of 
Chinese descent. Focusing specifically on the interaction of carbamazepine with HLA, 
Wei et al. 163 and Ko et al. 164 found that HLAB*15:02 shows binding affinity with the 
5-carboxamide structure in the tricyclic ring of carbamazepine and that an arginine 
residue at position 62 of the HLA molecule was important for the direct binding of 
carbamazepine. Furthermore, an elegant series of experiments demonstrated that a 
highly restricted T cell receptor usage is observed in HLA-B*15:02+ patients that 
develop Stevens–Johnson syndrome. Patients lacking the specific receptors were 
found to tolerate carbamazepine even if they expressed the HLA risk allele. These data 
suggest that specific expression of a single HLA molecule and a T cell receptor 
determines susceptibility to this single form of DHR in Han Chinese patients. 
However, it should be noted that this restricted T cell receptor usage does not seem to 
be a major predisposing factor for other DHRs, including abacavir hypersensitivity 129. 
Since the initial discovery of an association between HLA-B*15:02 and 
carbamazepine hypersensitivity in Asian populations, HLA-A*31:01 has been 
identified as a risk factor in patients with different forms of CBZ hypersensitivity in 
Caucasian patients of European decent. The absence of the allele in the population 
decreased risk of a serious DHRs from 5% to 3.8%, but important data showed that 
the presence of the allele augmented the risk by fivefold, from 5% to 26% 154. In 
contrast to HLA-B*15:02, the interaction of carbamazepine (metabolites) with HLA-
A*31:01 has not been studied in great detail. We have focused on a single HLA-
A*31:01+ hypersensitive patient and isolated carbamazepine-responsive CD4+ and 
CD8+ T cells 165. The drug-specific CD8+ T cell response was HLA-A*31:01+ 
restricted indicating that the drug interacts with the risk allele; however, the CD4+ T 
cells were activated in a HLA-DRB1*04:04 restricted manner. Ethnicity-dependent 
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additional risk factors have been identified within the HLA-B*75 serotype for 
carbamazepine hypersensitivity. These include: HLA-B*15:02 in Indian and Han 
Chinese populations, HLA-B*15:11 in Japanese populations, and HLA-B*15:21 
found in South-East Asian populations, with members of the HLA-B75 serotype all 
displaying similar ability to bind carbamazepine, potentially leading to the induction 
of an immune-mediated adverse reaction 166–168. 
1.4.3.5 ALLOPURINOL 
Allopurinol is another of the drugs with a known HLA risk allele for DHRs. 
Allopurinol is used in the treatment of gout to decrease problematic high levels of uric 
acid in the blood. Treatment of gout with allopurinol alongside NSAIDS has been 
effective; however, serious adverse events can occur. Some of these reactions include 
the high morbidity and mortality illnesses Stevens–Johnson syndrome and toxic 
epidermal necrolysis, in addition to impaired renal function and hepatitis 169. Being of 
Han Chinese origin, female, and over the age of 60 have been shown to be risk factors 
for development of allopurinol-mediated skin eruptions 170. The risk allele HLA-
B*58:01 has also been identified as a factor in whether or not a DHR will occur in 
patients 171, whilst genotyping patients and screening out patients with the risk allele 
for allopurinol treatment has proved successful in decreasing hypersensitivity 
reactions 172. Experiments were conducted utilizing T cells from both HLA-B*58:01 
positive and negative individuals with specificity for allopurinol and its metabolite 
oxypurinol. A synergistic relationship between both the presence of the HLA-B*58:01 
allele, as well as the concentration of the drug resulted in the development of the DHR. 
Reactions involved activation of HLA-B*58:01 restricted CD8+ T cells by the 
metabolite oxypurinol. The drug metabolite-specific T cells were activated in a dose-
dependent manner via a PI pathway 169. 
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1.4.3.6 OTHER HLA ASSOCIATIONS – EXTENDED 
The proliferation of genome wide association studies has resulted in many more risk 
alleles being identified in recent years. Please see table 1.1 for an overview of some 
other purported HLA class I and II allele risk associations.  
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Table 1.1 -  HLA alleles associated with DHRs. Table in part adapted from Ghattaoraya et al., Allele 
frequency.net web archive.  
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 IMMUNE REGULATION  
The drug-MHC-TCR interaction is pivotal for the initiation of an immune response; 
the formation of this immune synapse is a determinant of immune activation. 
Following the successful formation of an immune synapse, TCR clustering and T cell 
activation occurs through the induction of a signalling cascade triggered by TCR 
phosphorylation by LCK and subsequent recruitment of ZAP70 through the LAT 
signalling pathway. MEK/ERK signalling alongside the other signalling pathways 
lead to CD69 upregulation which is a key factor of T cell activation 173. Ca2+ influx 
also leads to cellular production of interleukin-2, which is a key cytokine involved in 
T cell activation and survival; this is part of signal 3 which will be discussed later.  
However, the formation of an immune synapse alone (signal 1) is not sufficient to 
invoke an immune response. Indeed, there are a multitude of other signals that have a 
determining factor on lymphocyte activation, and the observable outcomes in vivo. 
These are termed signal 2 and 3 and can be placed under the umbrella of immune 
regulation alongside cellular immune regulation and transcriptional regulation. Some 
examples of immune regulation that are relevant to this thesis will be discussed below.   
1.5.1 SIGNAL 2 
1.5.1.1 CO-SIGNALLING 
Co-signalling is formed of a plethora of both co-stimulatory and co-inhibitory signals; 
some of which are expressed in isolation, and some that are overlapping and directly 
competitive. These pathways play a major role in the modulation and outcome of T 
cell activation, as signal 2 (especially co-signalling pathways) have a direct effect on 
whether or not signal 1 occurs and T cell activation threshold is achieved leading to 
lymphocyte activation and proliferation. If signal 1 occurs in the absence of signal 2, 
then tolerance is observed. Likewise, if signal 1 is observed alongside a co-inhibitory 
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signal 2, then tolerance and cellular anergy occur 98. However, if signal 1 accompanied 
by a co-stimulatory signal 2, then the T cell activation threshold can be achieved, 
triggering T cell activation after the processes (described in the previous section) have 
come to pass. Indeed, it has been said that in vivo there is a balancing act between 
tolerance and anergy, that is influenced by a signal 1: signal 2 axis.  
The co-signalling pathways have become an important therapeutic target over recent 
years; as scientists have discovered that these pathways may hold the key to the 
modulation of the immune system. Thus, one can develop novel therapies for diseases 
with an immune aetiology; including auto immune disorders and cancers 174,175. 
Indeed, it has been regularly reported that co-signalling plays a vital role in immune 
homeostasis, and mutations in co-signalling members such as PD-1 and CTLA-4 has 
led to Treg dysfunction and autoimmune disease in both mice and humans 176. 
Cancerous tumour cells have developed mechanisms to shield themselves from host 
immune system by relying on the effectiveness of the hosts co-signalling pathways 
and self-tolerance mechanisms; including PD-1 and CTLA4. It has also been reported 
that tumour cells can increase PD-L2 expression levels on inhabited macrophages to 
evade destruction by host immune cells 177. Thus, novel immunotherapies based on 
the blockade of co-signalling receptors may pave the way for the destruction of 
tumerous cancer cells by host immune systems 174,178.  
Despite this breakthrough in cancer immunotherapy, progress has been impaired by 
some devastating adverse events observed upon treatment with co-inhibitory 
signalling blockade in vivo 179; perhaps further indication of the influence these 
pathways have on the initiation of an immune challenge.  
There are many different receptor-ligand interactions that constitute the full range of 
co-signalling pathways. Some of the co-stimulatory members include OX40, CD137, 
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CD28 and ICOS 180,181; whilst some of the co-inhibitory signalling pathways include 
PD-1, CTLA-4 and TIM-3 137,182–184. Below will be an explanation of the co-signalling 
pathways pertaining to research in this thesis (CD28 co-signalling family, including: 
PD-1, CTLA-4, CD28) as the direct effects of these pathways on drug immunogenicity 
have been investigated in recent years 3 137,182, but their full effects upon DHR need 
to be further investigated. 
PD-1 is constitutively expressed on a wide range of immunological cell types such as 
T cells, NKT cells, NK cells and monocytes, but also throughout the body at other 
sites with a heavy immune presence such as the thymus 183. In order to exert its co-
inhibitory effects on the immune system, PD-1 must interact with one of its two known 
ligands; PD-L1 or PD-L2. PD-L1 is expressed on a range of immune cells and is 
induced by IFN signalling, whereas PD-L2 is expressed in a more focused manner on 
APCs such as DCs, activated macrophages or mast cells and is induced by IFN-γ, GM-
CSF, and IL-4 185. The interaction of PD-1 with either of its ligands has been shown 
to suppress antigen-specific T cell responses 186; whilst other studies have highlighted 
that abrogation of PD-1/PD-L1 binding can restore or increase antigen-specific T cell 
response 137,182,187. This interaction between PD-1 and either of its ligands is known to 
perturb the T cell activation cascade as described in section 1.5; as recruitment of SHP 
proteins leads to dephosphorylation of ZAP70, affecting TCR clustering, preventing 
further downstream signalling such as AKT and MEK/ERK signalling leading to T 
cell activation 188. Fife et al., also explained eloquently that PD-1 causes immune 
suppression via the prevention of signal 1 establishment, as the blockade of PD-1 
causes increased contact time between T cells and DCs 188. These immune dampening 
effects of PD-1 is also linked to decreased IL-2 expression, which is a key cytokine 
involved in T cell activation and survival 189. As previously mentioned, PD-1 is an 
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effective immunosuppressive tool that is utilised by cancerous cells to evade host 
immunity and survival of tumour cells. This thesis will further investigate its purported 
role in DHR; demonstrated by its pivotal involvement in T cell response.  
CTLA-4 is another major immune checkpoint that is involved in cancer cells. CTLA-
4 deficient mice have been shown to die within weeks of birth; often succumbing to 
lymphoproliferative disorders 190 which highlights CTLA-4 involvement in immune 
homeostasis. Like PD-1, CTLA-4 interacts with two ligands, in this case CD80 and 
CD86 to exert its effects. Unlike PD-1, CTLA-4 is in direct competition with the co-
stimulatory CD28 for binding to the CD80/CD86 ligands to determine the outcome of 
signal 2 in these instances. CD80 has been described as predominantly co-stimulatory, 
whilst CD86 is mainly co-inhibitory 191. Despite its lower expression than CD28, 
CTLA-4 has a higher affinity for the CD80/86 ligands and binds to them more readily. 
If CTLA-4 competitively inhibits CD28 binding, then co-inhibitory effects and 
tolerance are observed 58; whereas CD28 victory would determine co-stimulatory 
effects, lowering T cell activation threshold, and immune activation. CTLA-4 can also 
regulate immune responses through its effects on Treg-APC binding competition; as 
Treg binding to APCs inhibit the availability for the formation of a co-stimulatory 
immune synapse, in addition to Treg immunosuppressive effects 58,59. This action is 
mediated through CTLA-4 (which is constitutively expressed on Tregs) and CD28 
competition, as CD28 superagonist therapies such as TGN1412 were originally 
devised to modulate these interactions; reactivating Tregs in T cell deficient diseases 
such as rheumatoid arthritis and B cell leukaemia. The vital role of CD28/CTLA-4 
interplay in co-signalling and determination of immune outcomes was highlighted by 
the failure of TGN1412; as overactivation of the CD28 receptor led to overactivation 
of the immune system, concluding with cytokine storm and organ failure in 
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participants of the clinical trial 192,193. CD28 involvement in immune stimulation was 
also observed in the early nineties, as anti-CD28 antibodies were used to induce T cell 
anergy 181.  
1.5.1.2 DANGER SIGNALLING 
Whilst direct covalent binding of a drug to target cells in an organ is thought to lead 
to potential adverse events (iDILI from flucloxacillin covalent binding to 
hepatocytes), this does not always tell the whole story. Some studies have shown that 
the level of covalent binding of flucloxacillin detected is not directly related to 
incidences of iDILI 194. As signal 2 is implicated in whether or not signal 1 can be 
established, there must be some other exterior influences in this instance.  
Matzinger, in 1994 developed the first hypothesis explaining that the immune system 
can be activated in response to certain signals termed ‘danger signals’ which were 
often as result of cellular stress and damage. But the lack of these signals can lead to 
immune tolerance and anergy 195. These danger signals can be subdivided into two 
categories: DAMPS and PAMPS. DAMPS can be intracellular components, released 
during necrotic episodes in response to drug or reactive drug metabolite toxicity and 
interact with TLRs on DCs; upregulating signal 2 to induce immune response. 
HMGB1 is an established biomarker for DILI and is deemed a DAMP as it is released 
by necrotic cells, but not apoptotic cells; determining the cellular damage response 
77,196. Similarly, studies within the group on chemical sensitizers and chemically 
reactive metabolites arising from experimental drugs such as SMX-NO have been 
shown to activate DCs through TLR modulation, this would then lead to co-
stimulatory activation on DCs and T cell activation 80. Interestingly, small molecules 
and CRMs such as SMX-NO can be danger signals themselves as described 
immediately above but can also influence further downstream danger signalling such 
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as the release of DAMPs through their cytotoxic effects on cells 110,197. PAMPS, whilst 
not as directly relevant to this thesis as DAMPS, still play an important role in T cell 
activation. Lipopolysaccharide (LPS) in gram negative bacteria is a known PAMP and 
can be used in maturation of monocyte derived DCs. Other pathogens such as HIV are 
thought to be a factor in why HIV treatment so often leads to adverse events as the 
innate immune system interacts with the extracellular HIV pathogen before the 
addition of a chemical antigen leads to full immune activation 198.  
1.5.2 SIGNAL 3 – CYTOKINES  
Cytokines are small, low molecular weight signalling molecules that are released from 
a range of immune cells (including T cells, B cells, DCs, NK cells and macrophages) 
and locate to their specific receptors on target immune cells and tissues 199,200. They 
are critical for the correct function of the host immune system and are the major 
communicative pathway between leukocytes and their respective immunological 
partners. They enable the communication between immune cells, the skewing of 
phenotypes of T cells that is described by T cell plasticity (Th1/Th2), differentiation of 
immune cells (such as monocytes to DCs), the maturation of immune cells such as 
DCs which help them fulfil their function, and are also directly involved in cellular 
processes which enable immune cells to carry out their function directly; such as  
release of FasL and perforin from CD8+ cytotoxic T cells. The influence of cytokines 
on a multitude of different signalling pathways mean their function and interactions 
are endlessly complicated; they are referred to as the cytokine milieu. Therefore, they 
have a large influence on whether or not an immune mediated event occurs, as well as 
the strength of said response in its outcome. The above is also described in section 1.3.  
Examples of cytokines used experimentally in this thesis during cell culture are: GM-
CSF and Il-4. These were used during the culture of CD14+ monocytes isolated from 
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healthy volunteers and their subsequent differentiation to DCs 201. Pro-inflammatory 
cytokines such as TNF-α can be used to promote cellular maturation, and so TNF-α  
was used during DC culture to promote maturation and improve antigen presenting 
capability in naïve T cell priming cultures 202, alongside LPS (classified as a PAMP). 
As IL-2 is one of the most important cytokines related to T cell function (activation 
and proliferation) 203, we have used it for the re-stimulation and culture of antigen 
specific T cell clones in chapter 6. Like many other cytokines, once contact has been 
made between IL-2 and its receptor, a downstream JAK/STAT mediated signalling 
cascade is activated to elicit its effects; the activation and survival of T cells, especially 
Tregs are directly influenced here 203–205. Cytokines can also be detected by ELISA, 
ELISpot, or intracellular staining flow cytometry to determine the effects of cells in 
response to certain treatment conditions. Pro-inflammatory cytokines include TNF-α, 
IFN-γ, IL-1 and IL6 – whilst anti-inflammatory cytokines include IL-10 and IL-12. 
Cytokines such as IL-2, IL-4, IL-7, IL-9, IL-13 and GM-CSF interact almost 
exclusively with the adaptive immune system. The above are also described in section 
1.3.  
Cytokine production can be effectively used as part of immunomodulatory pathways 
and immune regulation. However, instances such as treatment with CD28 superagonist 
TGN1412 - leading to uncontrolled cytokine secretion (cytokine storm) - can have 
severe consequences to the treated party 192,193. This outlines the importance of 
cytokines for the proper function of the immune system in a healthy individual; any 
change to this can influence adverse events and potentially form part of the 
pathogenesis of DHR. 
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1.5.3 CELLULAR REGULATION – TREGS 
In addition to signal 2 and 3 described above, immune regulation can also take place 
at the cellular level. Tregs have an extremely important immunoregulatory function, 
and can be involved in the modulation of immune responses in either a 
immunosuppressive state, or a pro-inflammatory state. Furthermore, they become 
increasingly relevant within the context of this thesis through their immunoregulatory 
effects, as they directly interact with other members of the immunoregulatory family; 
specifically the signal 2 CD28 family 59. More detail on Tregs can be found in section 
1.3.2. 
1.5.4 MICRO RNA  
Post-transcriptional regulation of the immune system has also become an increasingly 
important focus of research in recent years. The discovery of miRNAs as biomarkers 
of biological processes have been used to predict adverse events - circulating miR-122 
in serum for the prediction of DILI 206,207 has provided a less-invasive method of rapid 
diagnosis of DILI; however, a widespread reliable diagnostic test has yet to be 
established. There has now been an explosion of research into miRNAs as regulators 
of immunological processes; including the pathogenesis of DHRs.  
MiRNAs are single stranded 22 nucleotide RNAs that regulate gene expression by 
binding to the 3′ untranslated region (UTR) of their target, promoting translational 
repression or the direct degradation of the mRNA. Upregulation of a specific miRNA 
promotes higher inhibition of the target gene which manifest in phenotypic and 
physiological changes in the cell 208. MiRNAs are involved in regulating the 
expression of 30-50% of genes; and so are involved in many key physiological and 
fundamental cellular processes 209. They can elicit regulation that alters the 
concentration of key protein components of cascading signalling pathways of immune 
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activation at the post-transcriptional level, and importantly, studies have shown that 
genetic ablation of miRNA machinery has led to auto-immunity 210. MiRNAs are 
becoming notorious as key regulators of important biological processes; such as 
proliferation, differentiation and development, as well as crucial regulators of both 
innate and adaptive immune responses 211. This occurs through a purported role in the 
induction, maintenance and function of Tregs, and regulating the differentiation of 
APCs, DCs and macrophages through TLRs 212.  
Over a hundred miRNAs have been shown to be expressed by immune cells and have 
an impact in basic immunological process 213. Despite the wide variety of miRNAs 
showing an altered expression, only a few have been studied in detail. These include 
miR-9, miR-17 ≈ 19 cluster, miR-21, miR-146a, miR-155, miR-181a, and miR-214. 
For most of these, their target genes have been validated and their function has been 
evaluated during T cell activation by functional assays 214–220. MiRNAs have also been 
implicated in the regulation, maintenance and function of Tregs, in addition to 
involvement in the co-signalling pathway; PD-L1 specifically. MiRNA binding to PD-
L1 mRNA on APCs can lead to degradation and ultimately suppression of the ligand 
and therefore overall suppression of the PD-1/PD-L1 axis, resulting in increased 
immune activation. MiR-513, miR-570, miR-34a, and miR-200 reportedly display 
inverse correlation to PD-L1 expression 221. MiRNAs have also been directly 
implicated in DHR through targeting and post-transcriptional regulation of the 
granulysin gene 222. 
 THESIS AIMS 
There is a desperate need for reliable, appropriate in vitro T cell assays for the 
prediction and diagnosis of DHR. Whilst the standard DC-naïve T cell priming assay 
can enable us to determine the likelihood of a drug to prime healthy volunteer naïve T 
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cells, there are some limitations with the assay that need to be resolved before the 
assay is ready for widespread pre-clinical use which have been discussed previously. 
Additionally, the LTT is the current gold standard for in vitro DHR diagnosis, but as 
previously mentioned also has some issues; such as the time taken to complete the 
assay. 
The aim of the thesis is to evaluate and then improve upon the current in vitro methods 
of predicting and diagnosing DHR. This leads to the development of two new assays 
to form part of a predictive screening system for the in vitro prediction of DHR. These 
assays must be able to analyse naïve T cell priming in multiple donors on a single plate 
and take into account the naïve T cell precursor frequency required for activation. 
Furthermore, we aim to investigate the role of immune regulation (at the cellular and 
transcriptional level) on the priming of naïve T cells to a drug, with a view to 
implementing our findings to improve our new in vitro assays. Finally, we aim to 
investigate whether the LTT is fir for purpose, with an aim to improve the in vitro 
diagnosis of DHR. 
 EXPERIMENTAL COMPOUNDS IN DRUG ALLERGY  
Below is a summary of the drugs used in experiments throughout this thesis.  
1.7.1 CHEMICALLY REACTIVE METABOLITE NITROSO-FORMING DRUGS 
 
Sulfamethoxazole (SMX) is a sulfonamide bacteriostatic antibiotic, often used in 
combination with trimethoprim for the treatment of opportunistic infection in both 
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HIV patients and recurring infections in CF patients. Whereas dapsone (DDS) is a 
diaminodiphenyl sulfone used in combination therapy with rifampicin and clofazimine 
for the treatment of leprosy. Despite their different classification, both have NH2 
groups attached to a benzene ring as can be seen above. SMX has been implicated in 
severe DHR reactions in up to 3-8% of the population, with DHR prevalence known 
to increase in HIV patients with an active infection 133,223. In SMX hypersensitivity 
both the hapten and p-i mechanisms of activation have been implicated. However, 
antigen specific T cells of sensitised patients were deemed reactive to both the parent 
drug SMX, and the reactive metabolite SMX-NO which is formed by liver metabolism 
via an SMX-hydroxylamine intermediate, before autooxidation to the reactive nitroso-
metabolite 111,223. Further research within the group over the years has shown SMX-
NO to be an excellent test-compound; acting as a ‘model hapten’. SMX-NO is more 
reactive than the parent drug SMX, responding in 9/10 tolerant individuals opposed to 
3/10 111.  SMX-NO has also been found to have the propensity to activate DCs through 
in a DAMPS mediated manner, and can activate co-signalling CD40 on APCs to 
induce immune responses 80. SMX-NO has been proven to consistently prime healthy 
donor naïve T cells in T cell priming assays making it an excellent candidate for use 
in this thesis 71,135,137,182. Dapsone, like SMX, also forms a nitroso reactive metabolite 
(DDS-NO), and has been implicated in DHR 224. DDS-NO involvement in DHR is 
less established than SMX-NO, but recent studies in the group have aimed to rectify 
this with research showing a HLA-B*13:01 restricted CD8+ T cell responses to DDS-
NO, but not DDS in healthy donors 144,225. For this reason, DDS-NO was also used 
experimentally in this thesis, albeit to a lesser extent than SMX-NO.  
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1.7.2 BETA-LACTAM ANTIBIOTICS 
Beta-lactams are a class of antibiotics that are identified through the presence of the 
beta-lactam ring contained within their molecular structures. Beta-lactams include 
penicillins, cephalosporins, carbapenems and monobactams which are used in the 
treatment of bacterial infection. Despite their widespread use as a treatment strategy 
for bacterial infection, beta-lactams are also renowned for their contribution to adverse 
events and DHRs. Indeed, they are the most common cause of immune mediated 
ADRs. Both beta-lactams used experimentally within this thesis have been implicated 
in such events; piperacillin has been found to cause both immediate adverse reactions, 
and also delayed type IV hypersensitivity skin reactions such as macropopular 
exanthema and uticaria 226,227. Flucloxacillin on the other hand has been implicated in 
drug induced liver injury 228. Beta-lactam’s known pathomechanisms takes place 
through covalent binding, modified drug-protein adducts have been investigated 
throughout the years as a potential cause of DHR as modified drug-protein adducts 
have been found to activate T cells directly 229. The opening of the beta-lactam ring 
has been determined to be the major antigenic pathway for this class of drugs 230, 
which under normal working conditions specifically target certain lysine residues on 
HSA to enable favourable binding conformations. At higher concentrations, or after 
long-exposure times beta-lactams can target multiple residues as opposed to the 
favoured lysine 150,230. Work within the group have functionally characterised 
piperacillin specific drug reactive T cells in vitro to understand their involvement in 
skin related DHR. Expansion of circulating and skin-resident Th22 cells that secrete 
IL-22 but not IL-17 have been implicated in such reactions. Whilst skin-homing of T 
cells occurs due to the expression of chemokines CCL17 and CCL27 50. 
Flucloxacillin-specific T cell clones were found to secrete cytolytic granzyme B and 
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FasL and perforin, as well as IFN-γ. Flucloxacillin activation was HLA-B*57:01 
restricted and processing dependent, with covalent binding to specific lysine residues 
on albumin correlating with T cell activation 31. For these reasons, the beta-lactams 
piperacillin and flucloxacillin were deemed to be worthy of further investigation and 
used as test compounds during the development of our screening assays for DHR. 
1.7.3 CONTACT SENSITIZERS 
Bandrowski’s base (BB) was also used as a test compound in the development of T 
cell assays. BB is formed as an oxidised product of p-phenylenediamine (PPD) which 
is used throughout the cosmetics industry in hair and tattoo dyes, meaning that many 
people will have become sensitised 104. PPD has been implicated in both immediate 
and non-immediate reactions, with a purported patho-mechanism of PPD-keratinocyte 
binding and interaction with Langerhans cells, whilst BB has been reported to be ten 
times more potent than PPD as a contact sensitizer 231. Due to its severe and potent 
reactivity with the skin and its ability to activate T cells, it was decided to be an 
important test compound to test the ability of in vitro naïve T cell priming. Indeed it 
has the propensity to prime naïve T cells in our standard naïve T cell priming assays 
in a strong and reproducible manner 104,232. However, data has shown that PPD only 
activates T cells in allergic patients, not healthy volunteers; whilst BB can activate T 
cells in both cohorts. Hence its inclusion in our experiments on healthy volunteer cells 
in this thesis 233.  
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 REAGENTS AND MATERIALS 
The reagents and materials used throughout this thesis and where they were obtained 
from can be found below: 
 Lymphoprep was purchased from Axis-Shield (Dundee, UK).  
 Recombinant IL-2, GM-CSF, IL-4 and TNF-α  was from Peprotech (London, 
UK).  
 Propan-2-ol was purchased from Fischer Scientific (Loughborough, UK).  
 Di-methyl sulfoxide was from Sigma-Aldrich (Dorset, UK).  
 Fetal bovine serum was from Invitrogen (Paisley, UK).  
 Human serum albumin was from Innovative Research (Michigan, USA).  
 [3H]-methyl tritiated thymidine was from Moravek (California, United States). 
 Sulfamethoxazole-nitroso was from Dalton Pharma Solutions (Toronto, 
Canada).  
 Piperacillin was from Wrockhardt Limited (Wrexham, UK).  
 Tetanus toxoid was from Statens Serum Institut (Copenhagen, Denmark).  
 Flow cytometry fluorescent antibodies were from R&D Systems (Minnesota, 
USA) or BD Bioscience (Oxford, UK). 
 All ELISpot kits were from Mabtech (Stockholm, Sweden).  
 ELISpot plates were from Millipore (Watford, UK).  
 Melt-on wax scintillator sheets, glass fibre filter mats and plastic sample 
wallets were purchased from Perkin-Elmer Life Sciences (Massachusetts, 
USA). 
 Magnetic bead separation kits were from Miltenyi Biotech (Surrey, UK). 
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 Cell culture plates, flasks, dishes and other assorted plastic-ware were 
purchased from Thermo Scientific (Hemel-Hempstead, UK). 
 TRI-reagent for RNA extraction was from Sigma-Aldrich (Dorset, UK).  
 Universal cDNA synthesis kit was from Exiqon (Copenhagen, Denmark).  
 SYBR Green master mix and primer kits were from Exiqon (Copenhagen, 
Denmark).  
 All other regents and consumables related to RNA work, PCR, or qPCR were 
obtained from Qiagen (Manchester, UK).  
 Unless otherwise stated, any other reagents or supplies were obtained from 
Sigma-Aldrich (Dorset, UK). 
 BUFFERS AND CELL CULTURE MEDIUMS 
Standard lymphocyte cell culture medium contained: 
 RPMI 
 10% HSA  
 Penicillin (100U/ml)  
 Streptomycin (0.1mg/ml) 
 Transferrin (25µg/ml)  
 L-glutamine (2mM)  
 HEPES buffer (25mM) 
Cell freeze mix contained 1:1 ratio of the above T cell culture medium, supplemented 
with: 
 80% FBS 
 20% DMSO 
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FACS Buffer (Flow cytometry medium) contained:  
 Hanks balanced salt solution (HBSS) 
 10% foetal bovine serum  
 0.03% sodium azide (NaN3) 
MACS buffer (Magnetic cell separation medium) was made to 10x stock, 
(subsequently diluted to 1x with HBSS) using: 
 2.5g BSA  
 2mL EDTA (500mM)  
 48mL HBSS  
 INSTRUMENTATION  
The following instruments were used experimentally for the generation of data in this 
thesis: 
 Cell harvester (assays using thymidine incorporation) was from TomTec 
(USA).  
 Micro Beta Trilux Counter for counting harvested T cell assays was from 
Perkin Elmer (Cambridge, UK). 
 ELISpot plates were read using AID ELISpot Reader from Cadama Medical 
(Stourbridge, UK). 
 MRX plate reader from Dynex (Lincoln, UK) was used to quantify ELISA 
assays.  
 BD FACS Canto II from BD Biosciences (Oxford, UK) was used in all flow 
cytometry experiments.  
 Flowing 2 was used for flow cytometry analysis (Turku University, Finland).  
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 All instruments related to magnetic cell subset separation were obtained from 
Miltenyi biotech (Surrey,UK).  
 Nanodrop 2000 from Thermo Scientific (USA) was used to quantify RNA.  
 Quantitative PCR was performed using a ViiA 7 Real-Time PCR System 
(Thermo Scientific, USA) 
 Qiacube from Qiagen (Manchester, UK) was used to fill the PCR plates with 
samples.  
 BLOOD SAMPLES 
Approvals for studies were obtained from the Liverpool local Research Ethics 
Committee, informed written consent was acquired from all participating blood donors 
(including healthy volunteers). Hypersensitive paediatric patient samples (Chapter 5) 
were obtained from either: Regional Cystic Fibrosis Unit at St. James’s University 
Hospital, Leeds, UK, or the Royal Manchester Children’s Hospital, Manchester, UK.  
 EXPERIMENTAL PROCEDURE 
2.5.1 PBMC ISOLATION  
Peripheral blood mononuclear cells were obtained from either healthy donor or patient 
blood samples. Blood was taken in accordance with ratified studies and ethics 
committees. Blood arrived in heparinised blood vials before being layered with 
syringe and quill in a 1:1 ratio into a 50mL falcon tube with lymphoprep. Tubes were 
centrifuged (25 minutes, 400g, room temperature, moderate acceleration, brake 
deactivated) which generated a buffy coat. Buffy coat containing PBMC was carefully 
extracted using a Pasteur pipette before being washed twice in 50mL HBSS (15-
minute centrifugation, brake on full, room temperature). Viable cells were then 
counted using trypan blue exclusion method in 1:1 ratio. Cells were frozen at 
10,000,000/mL at -80 degrees Celsius overnight before being transferred to either -
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150 degrees Celsius freezer, or liquid nitrogen for longer term storage. Cells could 
then be carefully thawed, spun down and re-counted before being used in any of the 
following experiments.  
2.5.2 SEPARATION OF CELL SUBSETS 
PBMC were re-suspended in MACS buffer at 800uL/1x108 cells before being 
incubated in the dark at 4 degrees Celsius for 15 minutes with CD14 microbeads 
(200uL/1x108 cells). Cells were washed in MACS buffer (centrifuged at 4 degrees 
Celsius, 10 minutes, 400g) before being re-suspended in MACS buffer (500uL/1x108 
cells) and passed through an LS column mounted to magnetic stand. CD14- cells 
passed through the column, whilst CD14+ cells were eluted from the column by 
plunging MACS buffer through the column. Cells were then counted, CD14- cells 
were then used for subsequent cellular isolations.  
All subsequent cell separations were performed under the same conditions, the only 
difference being the type of microbeads used, and the amount of microbeads added. 
They were used as follows: Pan-T biotinylated antibody cocktail (100µl per 1x108 
cells) was used to isolate all CD3+ cells, anti-biotin microbeads (200µl per 1x108 cells) 
were used in conjunction with the antibody cocktail for this cell isolation. Flow 
through cells were CD3+ and were used for further cell isolations. CD3- cells were 
frozen down and contained B cells which could be used for EBV transformed B cell 
generation.  
CD25 and CD45ro microbeads were used to positively select out Tregs and memory 
T cells, leaving the negatively selected cells (CD45ro-) which were naïve T cells. All 
cells were then frozen down using previously described freeze mix and stored for 
future use or could immediately be incorporated into experimental assays.  
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2.5.3 LYMPHOCYTE TRANSFORMATION TEST 
LTT was used to detect antigen-specific T memory cell responses to test compounds 
as previously described by Pichler et al. 116. PBMC were assayed into a 96-well U-
bottomed cell culture plate in triplicate at 1.5x105/well with a range of drugs in 
different concentrations (100uL each to a final volume of 200uL/well). Cell culture 
medium alone was used as a negative control, whilst tetanus toxoid (0.5µg/ ml, 100µl) 
was used as a positive control as most of the adult population will have previously 
been sensitized to this. For the paediatric LTT assays, PHA was used as the positive 
control as children may not have been sensitized to tetanus toxoid at that point. Plates 
were then incubated for 6 days (37°C, 5% CO2). Sixteen hours prior to the end of the 
experiment, 3[H] thymidine was incorporated into the assay (0.5µl/well) before being 
harvested onto a fibreglass filtermat and sealed by wax scintillation. Sealed plates were 
then counted on a beta-counter and CPM (count per minute) values were obtained.  
2.5.4 NAÏVE T CELL PRIMING ASSAY 
The ‘original’ naïve T cell priming assay was utilised as described previously by 
researchers in the Professor Dean Naisbitt research lab 71.  
 
Figure 2.1 – Standard T cell priming assay. Described below.  
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This assay was used to prime naïve T cells from healthy volunteers to drugs and 
compounds. It is the original assay developed by our lab that was the start point for 
the further development of the screening assay systems in Chapter 3. It makes use of 
naïve T cells, mature DCs (as APCs), and a drug/compound of choice.  
CD14+ monocytes were cultured in the presence of GM-CSF (800U/mL) and IL-4 
(50µg/mL) for 6 days in a 6-well plate; fed every other day with cell culture medium 
supplemented with GM-CSF and IL-4. TNF-α (50µg/mL, 3µL/mL) and LPS 
(1mg/mL, 6µL/mL) were added on day 6 for 16 hours to induce maturation of the 
monocyte derived DCs to moDCs.  
moDCs were scraped from 6 well plate and plated in a 24-well cell culture plate 
(2x104/well) with naïve T cells (2.5x106/well) along with the optimal concentration of 
drug/compound to prime the naïve T cells. Plates were incubated at 37˚C, 5% CO2.  
After 7 days T cells were removed and washed in HBSS before being plated in 
triplicate in a 96-well U-bottomed plate (1x105/well) with a fresh round of moDCs 
1x104/well along with either cell culture medium (negative control), a range of test 
drug/compound concentrations, or PHA (5µg/mL). Plates were incubated for 48 hours, 
at which point tritiated 3[H] thymidine was added to all wells for 16 hours. Plates were 
then harvested, sealed and counted as previously described. 
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2.5.5 T CELL MULTI-WELL ASSAY (T-MWA) & T CELL MULTI-DONOR ASSAY (T-
MDA) 
 
 
Figure 2.2 – T-MWA & T-MDA assays. Described below. 
The T-MWA and T-MWA assays were developed to be a higher throughput version 
of the standard naïve T cell priming assay. Thus, DCs and naïve T cells were plated in 
a 96-well plate from the start instead of the 24-well plate used previously. The whole 
experiment would take place in the same plate, and as such, no second round of 
moDCs are needed. Due to the numbers of replicates being plated in a single assay, it 
would be easier to look at the priming of naïve T cells to an antigen in more detail in 
the T-MWA. Additionally, the precursor frequency of activation of T cells would be 
taken into consideration by this assay due to the numbers being plated up and primed 
simultaneously.  
In the T-MDA it is easy to screen multiple donors simultaneously, in order to rapidly 
determine the likelihood of response across multiple, phenotypically different, naïve 
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T cell donations. This is because the cultures are set up with three wells of negative 
control (cell culture medium only), and three wells of drug treatment, enabling 16 
donors per plate to be assayed.  
Another benefit of the new screening assay system is that as a 96-well plate is used 
throughout, fewer DCs are needed to fulfil the experiment, and fewer naïve T cells are 
required per well, enabling the different plating configurations observed in the T-
MWA and T-MDA.  
CD14+ monocytes were cultured to moDCs as previously described before being 
plated directly in a 96-well U-bottomed plate (8x103/well) in co-culture with naïve T 
cells (1x105/well) and drug/compound at optimal concentration. Co-signalling 
blockers (PD-L1 and CTLA-4) could also be added at this point. In the T-MWA cells 
were cultured as 16 wells of negative control (media only), and 40 wells of test 
drug/compound treatment. In the T-MDA, multiple donors could be plated in a single 
96-well plate. For each donor, 3 wells of negative control were plated, and 3 wells of 
drug/compound treatment were assayed. Plates were incubated for 14 days at 37˚C, 
5% CO2. On day 14, plates were carefully washed three times in cell culture medium 
by centrifugation (2200rpm 4 minutes). Cells were then re-suspended in cell culture 
medium and re-challenged with drug for 48 hours, after which point 3[H] thymidine 
was added for 16 hours. In the T-MWA assays, supernatant can be removed at this 
point for analysis by ELISA assay as described in section 2.5.10. Plates were 
harvested, sealed, and counted as previously described. T-MWA data can be displayed 
as scatter plots of CPM values (with Mann-Whitney statistical test applied), or SI 
values can be calculated as previously described. SI values were categorised as 
negative, weak, good, or strong as previously described by Faulkner et al., 71,135. T-
MDA data can be displayed as SI values, or by bar graph of CPM averages.  
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2.5.6 FLOW CYTOMETRY 
Flow cytometry was used to analyse expression of cell-surface and intracellular 
proteins. Cells were washed before being re-suspended in FACS buffer and 5uL of 
fluorescently conjugated antibodies for 25 minutes in the dark. After this time, cells 
were washed and re-suspended in either 200uL FACS buffer for immediate analysis, 
or 200uL 4% para-formaldehyde for analysis at a later point. Cells were then analysed 
using a BD Bioscience FACS Canto II, FCS filed were analysed with Flowing 2 
software. For intracellular staining, cells were fixed and permeabilised before antibody 
incubation using a cell fixation and permeabilization kit from Thermo Scientific.  
2.5.7 T CELL CLONING  
T cell cloning is a method used to be able to mechanistically analyse drug-specific T 
cells. The T cells produced using this method are specific to the antigen used and are 
expanded from a single T cell clone and originate from a single precursor cell. This is 
opposed to a population of drug-specific T cells that may be phenotypically different. 
PBMCs were cultured in a 48-well plate (1x106 cells/well) with the drug of interest to 
a final volume of 1mL/well for 14 days to generate bulks. IL-2 was used to stimulate 
T cell activation and proliferation on days 6 and 9.  
On day 14 the bulks were harvested and plated into 96-well U bottomed plate as serial 
dilutions; cell concentration of either 0.3, 1, or 3 cells per well. Cells were then re-
stimulated with allogeneic irradiated PBMC (5x104/well), PHA (2µg/mL) and IL-2 
(75U/mL). Cells were fed every 2 days with standard cell culture medium with IL-2 
(75U/mL). Wells that were proliferating were picked and placed into a new 96-well 
plate before being re-stimulated as previously described. Picked cells were split as 
required and were continued to be fed every other day.  
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The T cell clones were tested for antigen specificity using a standard proliferation 
assay where an SI>2 was deemed positive. SI was calculated as CPM of drug treated 
wells divided by the CPM of the negative control wells (media). Alternatively, the 
ELISpot test was used to determine cytokine secretion of the antigen specific T cell 
clones.  
2.5.8 PROLIFERATION ASSAY 
5x104 T cell clones per well were plated in a 96-well U-bottomed cell culture plate 
with 1x104 irradiated autologous EBV transformed B cells to a volume of 100uL. 
Wells were made to a final volume of 200uL with either cell culture medium (negative 
control), drug at the optimum concentration, or PHA as a positive control (5ug/mL). 
Plates were incubated for 3 days; 16-hours prior to the end of the experiment 
0.5uCi/well tritiated 3[H] thymidine was added to all wells. Plates were then harvested, 
sealed and counted as previously described.  
2.5.9 ELISPOT 
ELIspot, like the ELISA, can measure cytokine secretion. The main difference being 
that the ELISpot measures cytokine secretion from T cells, rather than using the 
supernatant (as in the ELISA). 96-well ELISpot (high protein binding plates from 
Millipore, USA) were pre-wet with 70% ethanol and then washed with distilled water. 
Wells of the plate were then coated with 100uL of the appropriate antibody (diluted 
as per manufacturer instruction) and incubated at 4˚C overnight. Plates were washed 
5 times with HBSS before wells were blocked with cell culture medium (200uL/well) 
at room temperature for 30 minutes. After this, irradiated EBV, T cell clones, and drug 
were added in identical concentrations/conditions as the previously described 
proliferation assay. Plated were then incubated for 48 hours at 37˚C and 0.5% CO2.  
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Wells were then washed five times with PBS and 0.5% FBS before 100uL/well 
detection antibody (diluted as per manufacturer instruction) and incubated for two 
hours at room temperature. Plates were then washed five times with PBS and 0.5% 
FBS, at which point streptavidin-ALP (100uL/well, 1:1000 dilution) was added and 
incubated at room temperature for one hour. Again, plates were washed five times 
with PBS and 0.5% FBS before filtered BCIP development substrate was added to all 
wells (100uL/well) for 15 minutes in the dark. After fifteen minutes had elapsed the 
back-plate was removed, and the plate carefully rinsed under the tap to stop the 
reaction. Plates were left to dry for a minimum of 24 hours before being read on the 
ELISpot plate reader.  
2.5.10 ELISA 
ELISA kits were obtained from eBioscience and utilised in accordance with the 
manufacturer’s directions. ELISA assays were used to quantify secretion of cytokines 
into the supernatant of our T cell assays. Briefly, a capture antibody was coated (at 
manufacturer’s recommended concentration onto the wells of a 96-well flat bottomed 
cell-culture plate (along with HBSS and 0.5% FBS) and incubated overnight at 4 
degrees Celsius in the dark. Wells were washed with 5x PBS and blocked for one hour 
with assay diluent. Samples (supernatant) was added (100uL/well) before being 
incubated for 2 hours at room temperature. Plates were washed before detection 
antibody was added (diluted to manufacturer recommended concentrations in assay 
diluent) and incubated for a further hour at room temperature. Plates were washed 
again before 100uL/well, 1ug/mL streptavidin-horseradish peroxidase was added to 
wells and incubated for 30 minutes. Wells were washed and 100uL/well TMB 
substrate solution was added to wells for 15 minutes. Stop solution (1M NaOH) was 
added 50uL/well, plates were read at 450nm.  
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2.5.11 RNA ISOLATION & QUANTITATIVE REAL-TIME POLYMERASE CHAIN 
REACTION (QRT-PCR) 
Total cellular RNA was extracted using TRI-Reagent (Sigma, USA) following the 
manufacturer’s instructions. Briefly, RNA was resuspended in water and quantified 
using a NanoDrop 2000/2000c UV-Spectrophotometer (Thermo Scientific, USA). 
Using 100ng of total RNA, miRNAs were reverse transcribed using the Universal 
cDNA synthesis kit II (Exiqon, Denmark) using a thermocycler (42 degrees Celsius – 
1 hour, 95 degrees Celsius – 5 minutes, finally, 4 degrees Celsius). The cDNA was 
mixed with ExiLENT SYBR Green Master Mix (Exiqon) and with specific primer sets 
for miR-9, miR-18a, miR-19b, miR-21, miR-146, miR-155, and miR-214. 
Quantitative PCR was performed using a ViiA 7 Real-Time PCR System (Thermo 
Scientific, USA) (95 degrees Celsius – 10 minutes, 10 cycles of 95 degrees Celsius – 
10 seconds, 60 degrees Celsius – 1 minute).  
The results of the qRT-PCR were calculated as relative expression (RE) by comparing 
the expression of drug treated cells with nontreated using U6 as a reference gene (as 
seen below). All qPCRs were performed in triplicate, and values higher than 1 were 
considered as an up regulation in the expression.  
Calculation for RE values: 
ΔΔCT = ΔCT24 - ΔCT0 
ΔΔCT = (CTt(miR-155)-CTt(U6)) - (CT0(miR-155)-CT0(U6)) 
RE = 2- ΔΔCT  
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 INTRODUCTION  
In recent years, drug hypersensitivity reactions (DHRs) have become increasingly 
problematic for patients, clinicians, and the pharmaceutical industry. This has led to 
high morbidity and mortality rates for patients who suffer an adverse reaction from a 
prescribed drug. ADRs have provided an additional administrative and financial 
burden on the NHS in the UK; with projected costs being in the region of £500 million 
and 4% of the hospital bed capacity being utilised due to such reactions even 15 years 
ago 1. The financial burden of post-licensing drug withdrawal due to DHR, in-part, 
contributes to the high cost of drug development for a single drugs exceeding 
$2billion. Hence proper diagnosis and prediction of DHR is of the upmost importance 
234,235.  
The diagnosis of the culprit drug in DHR can be difficult; especially in hypersensitive 
patients on multi-drug therapy when drug-drug interactions can cause even more 
confusion. Classification of the reactions can be aided by the time of onset of the 
reaction, as immediate reactions are often innate, mast cell mediated. Whereas delayed 
type IV hypersensitivity reactions have an onset greater than one hour after drug 
administration, as the mechanism of action has APC processing, interaction with the 
T cell TCR, and priming of naïve T cells a prerequisite for a response to occur 15. The 
introduction of skin testing for the diagnosis of drug allergy has improved the ability 
to diagnose DHR. Some studies have determined that diluting the active principles in 
skin patch testing is the best way to detect delayed hypersensitivity to corticosteroids 
(rather than intradermal testing) 236. Whereas others have stated that whilst one can 
achieve 72% positive skin tests for suspected DHR, a combination of patch, prick and 
intradermal tested dependent on the drug and clinical manifestation of cutaneous ADR 
should be observed 16. In contrast to the findings of Barbaud et al, another (albeit 
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limited study) concluded that one must use a combination of skin testing, IgE 
determination, and drug challenge after observing only a 27% confirmation of reaction 
in patients with a history of beta-lactam hypersentivity; displaying none of the above 
tests to be robust enough to stand alone 237. In vitro assays for DHR diagnosis are 
preferable to drug challenge/intradermal or provocation tests as they are less invasive 
for the patient and can be done without risk of further allergy. Upregulation of CD69 
or CD203c as markers of basophil activation has also become a useful in vitro tool for 
the diagnosis of immediate DHR as it often has higher sensitivity and specificity than 
other in vitro tests, despite variance in results between different drug classes 238. 
Basophil activation, along with lymphocyte activation test can increase the sensitivity 
of in vitro diagnosis, potentially obviating the need for more invasive traditional skin 
testing 239.  
The lymphocyte transformation test (LTT) is a useful in vitro assay for the diagnosis 
of delayed-onset DHR as it can be used to detect drug triggered T lymphocyte 
proliferation in patient PBMC after 6 days exposure to the drug. Patient PBMC can be 
cultured with the suspected culprit drugs for 6 days, and then T lymphocyte 
proliferation can be measured by 3[H] thymidine incorporation. Studies have 
previously shown that skin patch testing or the LTT can be used to confirm clinical 
diagnosis of DHR; with the LTT displaying a marginally improved success rate (6/10 
vs 6/20) 240. Although the skin tests displayed the same specificity as the LTT in some 
studies (85%), the sensitivity was lower than the LTT, meaning the LTT can be 
considered a more useful tool than skin tests in the diagnosis of delayed onset DHR 
241, especially if one considers the risks to the patient and invasiveness of the respective 
techniques. Later studies have shown that flow cytometric evaluation of CD69 
upregulation on T cells may be a more useful tool than the LTT as it overcomes the 
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main weakness of the assay. The 6-day assay time can be critical if one needs to rapidly 
evaluate which drug in a multi-drug therapy is the cause of the DHR, whereas CD69 
upregulation can be observed in all of the LTT positive patients, but in a 2-day 
timeframe 242. Yet more work must be done to improve the diagnostic assay systems 
currently employed as the LTT can be inconsistent. Detection of positive LTT in 15 
SJS/TEN patients had a sensitivity of 27% in a Porebski et al., study in 2013, whereas 
detection of granulysin expression alongside ELISpots for granzyme B and IFN-γ 
provided 80% sensitivity 243.  
Despite some advancement in the development of DHR in vitro diagnostic tools, the 
prediction of DHR remains an inherent problem in the drug development process. As 
delayed onset DHR is idiosyncratic in nature, there is often no clear picture of the 
potential immunogenicity of a novel compound or drug during early development. The 
drug could be safe in the majority of patients, with only a very limited number with 
the potential of suffering DHR. Over the years there have been a plethora of 
hypotheses why some drugs cause an unwelcome immune response and DHR at 
therapeutic dose. It is thought that if the mechanisms and reasons for immune 
activation can be elucidated, then the ability to predict said events prior to drug 
approval will follow. 
Genetic susceptibility factors such as HLA alleles have been outlined as a possible 
explanation for pre-disposition of certain individuals to DHR; and why a majority of 
patients do not have adverse immune responses to drugs. Genome wide association 
studies (GWAS) have shown links between certain HLA risk alleles with a greater 
susceptibility to DHR with specific drugs 128,145,244,245. Unwanted T cell activation 
leading to iatrogenic disease arises from the drugs’ direct interaction with a protein 
encoded by the specific risk allele. Both strong and weak associations have been 
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outlined, but despite extensive work in this field, the majority of carriers of the HLA 
risk alleles do not present with clinically defined DHR to a suspect drug. In fact, only 
HLA-B*57:01 has been proven to have a strong enough association with abacavir 
hypersensitivity syndrome to be introduced into pre-approval screening programmes 
before being prescribed to HIV patients 7. Due to its NPV of 100%, incidence of 
‘probable or definite’ response to abacavir treatment has dropped from 1.2% to 0.2% 
by 2015 246. Other HLA alleles have been identified as risk factors of drug 
hypersensitivity: HLA-A*31:01 with carbamazepine in Europeans 245, HLA-B*57:01 
with flucloxacillin-induced liver injury 31,145, HLA-B*15:02 and carbamazepine in 
Han Chinese populations 244. Of the above only HLA-B*15:02 in Han Chinese 
populations has been robust enough for clinical application as part of a cost-effective 
pre-screening strategy. Sulfamethoxazole (SMX - parent drug of nitroso-metabolite 
used in development of the assay in this chapter) had been thought to cause DHR in 
some HIV patients due to minor HLA allele changes, but no strong HLA allele 
associations were detected 133. Viral infection, reactivation, or viral activated cross-
reactivity has also been thought to be a risk factor for DHR 247,248. But as many DHR 
patients do not display viral reactivation 249 there must be other factors at play. The 
elucidation of the pathomechanisms of T cell activation in response to drug treatment 
is a key determinant of whether or not we can successfully predict DHR moving 
forward. The naïve T cell priming assay allows for this 71, but some improvements 
must be made in order to create a clinically relevant, useful assay for the drug 
development process.  
The naïve T cell priming assay makes use of isolated naïve T cells from healthy 
donors, which are then primed to a specific drug-derived antigen over a 14-day period 
in the presence of dendritic cells. Upon re-challenge with the specific antigen a number 
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of different readout assays can be used to detect drug-specific T cell activation; 
including T cell proliferation by 3[H] thymidine incorporation and cytokine secretion 
in ELISpot assays 71. The assay utilised by Faulkner et al., has since been used to 
determine healthy donor naïve T cell priming when altering a number of factors. The 
assay has been used to determine the effect of immune check point inhibitors on DHR; 
including PD-1 and CTLA-4, (both of which are important signalling components and 
drug targets in cancer immunotherapy 250,251) whereby blockade of the checkpoint 
inhibitors allow for increased naïve T cell priming and T cell proliferation, and re-
introduction of T regulatory cells dampen the immune response 182. This outlines the 
need for both signal 1 and signal 2 in the T cell activation cascade and brings to light 
some of the limitations of the original naïve T cell priming assay. Another limitation 
of the original assay is that whilst healthy volunteer naïve T cells can be successfully 
primed to SMX-NO, Bandrowski’s Base, piperacillin and other class I restricted 
drugs; however, naïve T cells were unable to be primed to any drugs that display class 
II restriction 135. The assay also fails to take into account the precursor frequency and 
T cell repertoire for a specific antigen; instead assuming the same across all drugs. 
However, due to the diversity of the T cell repertoire, naïve T cells specific for a 
peptide-MHC complex are rare 252 and can vary from drug to drug. Cell numbers can 
also be problematic in instances where high volumes of blood from donors are not 
available. For the original naïve T cell priming assay, we take 108mL blood in order 
to be confident in obtaining enough PBMC, and thus, naïve T cells and CD14+ cells 
for dendritic cell generation. Finally, the assay requires a 2-3 week period for the 
detection of T cell priming and drug specific T cell proliferation from one healthy 
volunteer blood donation.  
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In order for the naïve T cell priming assay to become a useful tool for pharma and the 
drug development process, it must be further optimised and enhanced to take into 
account all of the above, whilst successfully being able to determine the potential 
immunogenicity of drugs by way of drug naïve T cell priming and T cell proliferation 
on drug re-challenge. The ability to outline other mechanisms of T cell activation by 
means of cytokine secretion is also an important factor to consider in the development 
of a new assay.  
This chapter will follow through with the first steps in the development of two new 
naïve T cell priming assays as part of a novel screening system for the potential 
immunogenicity of drugs. The first assay will be developed in order to determine the 
potential of a drug to activate the immune system using up to 16 donors on a single 
assay; the T cell multi donor priming assay (T-MDA). The T-MDA is higher 
throughput than the standard priming assay as it can screen multiple donors for 
immune responses to drugs at the same time and requires fewer cells than the standard 
priming assay. This enables the screening of multiple donors with different HLA risk 
alleles on a single assay.  The second assay – the T cell multi-well assay (T-MWA) – 
can be used to investigate drug-specific immune responses in depth. The T-MWA will 
utilise forty wells per drug treatment, as opposed to triplicates in the standard assay. 
This ensures that the precursor frequency of naïve T cells for each drug will be taken 
into consideration. The T-MWA will also provide a scaling level of immunogenicity 
as opposed to the yes/no outcome of the standard priming assay. The assay will also 
allow for in-depth mechanistic evaluation of antigen-specific T cell activation as the 
cell numbers and number of assayed wells involved will allow T cell proliferation to 
be measured by 3H thymidine incorporation assays, whilst cell supernatant can be 
taken for ELISA assays to detect multiple cytokine secretion. Together, the T-MDA 
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and T-MWA are the first steps in the optimisation of the naïve T cell priming assay. 
This is a move toward a more comprehensive screening system to detect the 
immunogenicity of novel compounds and drugs; suitable for pharma and the drug 
development process. 
 CHAPTER AIMS 
1. Develop a screening system to evaluate the intrinsic immunogenicity of a drug 
or compound.  
2. The miniaturisation of the standard naïve T cell priming assay to increase 
throughput and ease of use of the assay.  
3. The development of a medium throughput assay to screen multiple individual 
donor cells on a single plate in a single experiment.  
4. The development of an assay that enables a deeper understanding of the 
immune response to drug treatment. This must determine the number of 
responding wells to drug challenge post-T cell priming that takes into 
consideration the precursor frequency of T cells and provide a scaling level of 
immunogenicity.  
 METHODS 
All methods for techniques seen in this chapter can be found in detail in Chapter 2: 
Methods and Materials.  
 RESULTS 
3.4.1 PRIMING OF NAÏVE T CELLS FROM 4 DONORS TO SMX-NO AND 
PIPERACILLIN IN THE STANDARD DENDRITIC-T CELL ASSAY 
In order to be able to develop, optimise and improve the naïve T cell priming assay, it 
was important primarily to start this project by performing standard naïve T cell 
priming assays to drugs that would be used for the optimisation of the T-MDA and T-
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MWA. Therefore, four distinct priming assays were performed to different healthy 
donors. Naïve T cells and CD14+ cells were isolated from healthy donors (which were 
differentiated and matured to moDC) and co-cultured with SMX-NO and piperacillin 
separately. After re-stimulation with each of the drugs, some donors elicited successful 
naïve T cell priming as drug-specific T cell proliferation was observed in some 
concentrations of the drugs; however, not all donors were successfully primed to each 
drug. Priming to SMX-NO was successful in all four donors as there was statistically 
significant increase in T cell proliferation (p<0.05) in at least one concentration of 
SMX-NO in all four donors. Contrasting this, piperacillin priming was successful in 
only one out of the four donors (figure 3.1.1), when there was a significant increase in 
T cell proliferation at 1mM concentration.  
Figure 3.1.1 
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Figure 3.1.2 
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Figure 3.1.3 
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Figure 3.1.4 
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Figure 3.1.1, 3.1.2, 3.1.3, 3.1.4 Priming of naïve T cells to SMX-NO and piperacillin using the standard 
priming assay  
Naïve T cells (2.5x106 / well) obtained from healthy volunteers were co-cultured with autologous moDC 
(8x104 / well) with either SMX-NO (40µM) or piperacillin (2mM) for 14 days in a 24-well plate. T cells 
were then harvested and plated in a 96-well plate in triplicate (1x105 / well) with new autologous moDC 
(4x103 / well) to a range of SMX-NO and piperacillin concentrations and media as negative control. 
After 48-hour incubation 3H-thymidine (0.5µCi / well) was added for 16 hours before plates were 
harvested and proliferation counted on a beta-counter. Student’s T test was performed to determine 
statistical significance of T cell proliferation at different drug concentrations compared to no drug 
treatment. Statistical significance was determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001. 
Moving on from this, it was important to perform the first steps towards the 
miniaturisation of the assay, as the idea for the project was to keep all of the cells in 
the same plate from the start of the experiment until the end, as well as assaying as 
many wells as possible for each drug treatment. It was decided that SMX-NO would 
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be used primarily for the optimisation and development of the novel assay as it 
behaves as a model hapten; with positive priming of drug-naïve T cells detected in 9 
out of 10 donors tested previously (Faulkner et al., 2012). For each of the healthy 
donor cells in figure 3.2, we assayed as many wells as possible from the cell numbers 
obtained from a single donation. SMX-NO priming to donor A resulted in the majority 
of wells responding to drug re-stimulation with T cell proliferation providing a 
stimulation index (SI) at least greater than 1.5. From the plate map and stacked column 
it can be seen that most of the responsive wells could be classified as good response 
(SI 2-3.99), and some strong responses (SI>4), with only two weak responses being 
observed. Donor B naïve T cells were primed to both SMX-NO and piperacillin. Again 
for SMX-NO more than half of the wells responded to SMX-NO re-stimulation with 
antigen-specific T cell proliferation generating most SI in the ‘good’ category, with 
equal numbers of weak and strong responses. In contrast, priming to piperacillin 
yielded a majority of negative SI (SI<1.5), with only one weak, and two good SI being 
observed.  
3.4.2 INITIAL ATTEMPTS AT MINIATURISATION OF THE NAÏVE T CELL PRIMING 
ASSAY 
It was also important to compare the standard priming assay to the developing 
miniaturised version of the assay, to ensure that T cell responses to drugs were 
consistent between both formats of the assay. Figure 3.3 displays the first miniaturised 
attempt at a T-MDA styled assay[B], which is compared to the standard priming assay 
[A]. In [B], cells were again cultured in the same 96-well plate from the start of the 
assay until completion. However, in this instance the cells were plated in triplicate as 
opposed to figure 3.2. As in figure 3.1, healthy donor naïve T cells were successfully 
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primed to SMX-NO, with antigen-specific T cell proliferation being observed at 40uM 
(p<0.05) and 80uM (p<0.005) in [A], and at 40uM (p<0.005) in [B]. 
 
 
Figure 3.2 Initial attempt at miniaturisation of naïve T cell priming assay 
Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM). After 14 days plates were centrifuged, and cells were washed to dispose of free drug 
in the media. Cells were gently re-suspended and re-challenged with SMX-NO (40µM); multiple media 
treated negative control wells were also performed. After 48-hour incubation 3H-thymidine (0.5µCi / 
well) was added for 16 hours before plates were harvested and proliferation counted on a beta-counter. 
Stimulation index was calculated as cpm drug treated well / average cpm negative control wells). The 
data was then displayed in a plate-map format, as well as stacked columns to show a traffic light system 
where; white = negative (<1.5 SI), green = weak response (1.5-1.99 SI), amber = good response (2-
3.99 SI), red = strong response (>4 SI) based on scoring system in 71.  
 
3.4.3 COMPARISON OF STANDARD SMX-NO PRIMING ASSAY AGAINST INITIAL 
ATTEMPT AT MINIATURISATION OF THE ASSAY 
Upon optimisation of the T-MWA methods, as in figure 3.3, it was imperative to 
compare the assay to the standard priming assay. SMX-NO priming of naïve T cells 
was positive across all four donors (figure 3.5.1-3.5.4 [A]) to multiple concentrations 
of SMX-NO with statistically significant increases in antigen-specific T cell 
proliferation (p<0.05) compared to the control (no drug). The T-MWA [B] similar to 
the standard priming assay shows successful priming to all four donors. Box-plot 
analysis of [B] shows the spread of the data of the drug-treated wells compared to the 
SMX-NO HVN158 Piperacillin HVN-191 SMX-NO HVN-
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control as there are forty test wells of drug treated cells; potentially with different 
numbers of wells responding for each drug used and each distinct donor. Statistically 
significant increase in T cell proliferation of drug treated cells were observed 
compared to control wells in figure 3.5.1 (p<0.05), 3.5.2 (p<0.005), 3.5.3 (p<0.0001) 
and 3.5.4 (p<0.0001).  
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Figure 3.3 Using SMX-NO to compare the standard priming assay to initial attempt of assay 
miniaturisation  
[A] Naïve T cells (2.5x106 / well) obtained from healthy volunteers were co-cultured with autologous 
moDC (8x104 / well) with either SMX-NO (40µM) for 14 days in a 24-well plate. T cells were then 
harvested and plated in a 96-well plate in triplicate (1x105 / well) with new autologous moDC (4x103 / 
well) to a range of SMX-NO concentrations and media as a negative control. After 48-hour incubation 
3H-thymidine (0.5µCi / well) was added for 16 hours before plates were harvested and proliferation 
counted on a beta-counter. Student’s T test was performed to determine statistical significance of T cell 
proliferation at different drug concentrations compared to no drug treatment. Statistical significance 
was determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001. 
[B] Naïve T cells (2x105 / well) were plated in a 96-well plate in triplicate with autologous moDC (8000 
/ well) with SMX-NO (40µM). After 14 days plates were centrifuged, and cells were delicately washed 
to dispose of free drug in the media. Cells were gently re-suspended and re-challenged with SMX-NO 
(40µM) or media as a negative control. After 48-hour incubation 3H-thymidine (0.5µCi / well) was 
added for 16 hours before plates were harvested and proliferation counted on a beta-counter. Student’s 
T test was performed to determine statistical significance of T cell proliferation of drug-treated wells 
compared to no drug treatment. Statistical significance was determined as; *p ≤ 0.05; **p ≤ 0.005; 
***p < 0.001. 
 
3.4.4 T-MDA ASSAY – STILL IN DEVELOPMENT – 5 DONOR T-MDA ASSAY TO 
SMX-NO AND PIPERACILLIN 
After comparing the standard priming assay to the developing T-MDA, the next focus 
would be to recruit multiple donors to plate in a single assay. The main strength of the 
T-MDA will be to identify drug-specific T cell responses in multiple donors in a single 
A B 
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plate, so that one can rapidly screen a number of different healthy volunteer cells; or 
potentially to multiple donors expressing a range of HLA alleles. In figure 3.4.1 5 
healthy volunteer naïve T cells were primed to both SMX-NO and piperacillin in a 
single plate. Strong (donors 1,4 and 5 SI>4) or good (donors 2 and 3 SI=2-3.99) were 
observed in all five donors for SMX-NO priming, whereas for priming to piperacillin, 
only donor 2 elicited a strong response, with the others donors providing negative SI. 
In figure 3.4.2, SMX-NO priming was successful in all eight distinct donors, with four 
strong, one good, and three weak responses. Piperacillin priming was again mainly 
negative, with only two out of eight donors having positive responses to piperacillin 
re-stimulation; one strong and one weak response. Bandrowski’s Base priming was 
was positive in four out of eight donors, with one strong, one good, and two weak 
responses.  
 
Figure 3.4.1 T-MDA assay of five donors in a single plate assay 
Naïve T cells (2x105 / well) from five different healthy volunteers were plated in a 96-well plate in 
triplicate with autologous moDC (8000 / well) with SMX-NO (40µM). After 14 days plates were 
centrifuged, and cells were delicately washed to dispose of free drug in the media. Cells were gently 
re-suspended and re-challenged with SMX-NO (40µM), piperacillin (2mM) or media as a negative 
control. After 48-hour incubation 3H-thymidine (0.5µCi / well) was added for 16 hours before plates 
were harvested and proliferation counted on a beta-counter. Stimulation index was calculated as cpm 
drug treated well / average cpm negative control wells). Negative (<1.5 SI), weak response (1.5-1.99 
SI), good response (2-3.99 SI), strong response (>4 SI) based on scoring system in 71. 
88 
 
Figure 3.4.2 T-MDA of eight donors in a single assay 
Naïve T cells (2x105 / well) from eight different healthy volunteers were plated in a 96-well plate in 
triplicate with autologous moDC (8000 / well) with SMX-NO (40µM). After 14 days plates were 
centrifuged, and cells were delicately washed to dispose of free drug in the media. Cells were gently 
re-suspended and re-challenged with SMX-NO (40µM), piperacillin (2mM), Bandrowski’s Base (5µM) 
or media as a negative control. After 48-hour incubation 3H-thymidine (0.5µCi / well) was added for 
16 hours before plates were harvested and proliferation counted on a beta-counter. Stimulation index 
was calculated as cpm drug treated well / average cpm negative control wells). Negative (<1.5 SI), 
weak response (1.5-1.99 SI), good response (2-3.99 SI), strong response (>4 SI) based on scoring 
system in 71. 
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3.4.5 COMPARISON OF STANDARD PRIMING ASSAY AND T-MWA IN 4 HEALTHY 
DONORS 
Upon optimisation of the T-MWA methods, as in figure 3.3, it was imperative to 
compare the assay to the standard priming assay. SMX-NO priming of naïve T cells 
was positive across all four donors (figure 3.5.1-3.5.4 [A]) to multiple concentrations 
of SMX-NO with statistically significant increases in antigen-specific T cell 
proliferation (p<0.05) compared to the control (no drug). The T-MWA [B] similar to 
the standard priming assay shows successful priming to all four donors. Box-plot 
analysis of [B] shows the spread of the data of the drug-treated wells compared to the 
control as there are forty wells of drug treated cells; potentially with different numbers 
of wells responding for each drug used and each distinct donor. Due to much lower 
background controls, statistically significant increase in T cell proliferation of drug 
treated cells were observed compared to control wells in figure 3.5.1 (p<0.05), 3.5.2 
(p<0.005), 3.5.3 (p<0.0001) and 3.5.4 (p<0.0001). There is an observed difference in 
the background control CPM in all priming assays; this could be due to differences in 
background proliferation of T cells at different times as the immune system will be in 
different state of activation of responding slightly differently to nascent stimuli. This 
is why the calculation of SI and the use of the dot plot with statistical testing is 
important to decipher the meaning of the raw CPM values.  
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Figure 3.5.2 
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Figure 3.5.3 
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Figure 3.5.4 
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Figure 3.5.1, 3.5.2, 3.5.3, 3.5.4 Comparison of standard naïve T cell priming assay and T-MWA in 4 
healthy volunteers 
[A] Naïve T cells (2.5x106 / well) obtained from healthy volunteers were co-cultured with autologous 
moDC (8x104 / well) with either SMX-NO (40µM) for 14 days in a 24-well plate. T cells were then 
harvested and plated in a 96-well plate in triplicate (1x105 / well) with new autologous moDC (4x103 / 
well) to a range of SMX-NO concentrations and media as a negative control. After 48-hour incubation 
3H-thymidine (0.5µCi / well) was added for 16 hours before plates were harvested and proliferation 
counted on a beta-counter. Student’s T test was performed to determine statistical significance of T cell 
proliferation at different drug concentrations compared to no drug treatment. Statistical significance 
was determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001. 
A 
A 
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[B] Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM). After 14 days plates were centrifuged, and cells were delicately washed to dispose 
of free drug in the media. Cells were gently re-suspended and re-challenged with SMX-NO (40µM) or 
media as a negative control; 8 wells of negative control, 40 drug-treated wells. After 48-hour incubation 
3H-thymidine (0.5µCi / well) was added for 16 hours before plates were harvested and proliferation 
counted on a beta-counter. Mann-Whitney test was performed to determine statistical significance of T 
cell proliferation of drug-treated wells compared to no drug treatment. Statistical significance was 
determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001.  
 
3.4.6 REPRODUCIBILITY OF THE T-MWA – T-MWA ASSAYS TO SMX-NO AND 
PIPERACILLIN FROM TWO SEPARATE BLOOD DONATIONS IN TWO DIFFERENT 
DONORS TAKEN SIX MONTHS APART.  
For the T-MWA to be a viable assay for industry and the drug development process it 
is critical that the assay is reproducible in the same donor to ensure that the number of 
responsive wells remains the same or similar for the same donor from cells isolated 
from blood donations at different times. With this in mind, two separate donations 
were taken 6 months apart in two different donors and T-MWA assays were performed 
on the resulting isolated naïve T cells and cultured moDCs. In [A] SMX-NO resulted 
in mostly good response to drug re-challenge, with strong response observed the 
second most frequently in both donations. For piperacillin priming in [A], again the 
number and nature of response was similar across both donations, with mainly weak 
response seen in the positive wells. In donor [B] naïve T cells were primed to SMX-
NO, again with similar numbers and nature of response seen between both separate 
donations. As in [A], most positive responsive wells were categorised as ‘good’, with 
fewer numbers of ‘weak’ and ‘strong’ response. As can be seen from the stacked 
column analysis, the overall number and nature of responses (negative, weak, good, 
strong) are similar between the two different donations for both donors tested. 
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Figure 3.6 Reproducibility of T-MWA results from 2 separate donations from the same volunteer 
Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM) or piperacillin (2mM). After 14 days plates were centrifuged, and cells were 
delicately washed to dispose of free drug in the media. Cells were gently re-suspended and re-
challenged with SMX-NO (40µM), piperacillin or media as a negative control; 8 wells of negative 
control, 40 drug-treated wells. After 48-hour incubation 3H-thymidine (0.5µCi / well) was added for 
16 hours before plates were harvested and proliferation counted on a beta-counter. Assays were 
repeated with the same donor, with blood donations taken 6 months apart. Stimulation index was 
calculated as cpm drug treated well / average cpm negative control wells). The data was then displayed 
in a plate-map format, as well as stacked columns to show a traffic light system where; white = negative 
(<1.5 SI), green = weak response (1.5-1.99 SI), amber = good response (2-3.99 SI), red = strong 
response (>4 SI) based on scoring system in 71.  
 
3.4.7 ASSESSMENT OF THE POTENTIAL IMMUNOGENICITY OF SMX-NO AND 
PIPERACILLIN ACROSS FOUR DONORS USING THE T-MWA  
The optimised T-MWA was then utilised to determine the potential immunogenicity 
of piperacillin compared to our model hapten, SMX-NO. In figures 3.7.1 – 3.7.4, the 
plate map and stacked column traffic light system was used to determine the number 
of responsive wells and nature of the response in those wells. The scatter plot analysis 
was also performed in order to determine the spread of the total, raw proliferation data, 
and to determine if the antigen-specific T cell proliferation observed in the donors was 
deemed to be a statistically significant increase compared to the negative control (no 
drug). In figure 3.7.1 and 3.7.2 SMX-NO priming was successful in the majority of 
wells with responses mainly being categorised as good or strong, whereas piperacillin 
priming was mainly negative, with only a few weak or good responses but no strong 
responses. Overall SMX-NO priming was determined as successful with a statistically 
significant increase in T cell proliferation (p<0.0001 in 3.7.1 and p<0.005 in 3.7.2) 
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observed compared to control wells - T cell proliferation in response to piperacillin 
treatment was not statistically significant. Again, in figure 3.7.3, more positive 
responsive wells were observed after SMX-NO treatment than to piperacillin because 
of the large number of the non-responsive wells. Positive SMX-NO wells were mainly 
categorised as good or strong responses, with a smaller number of weak responses. 
Unlike in figures 3.7.1 and 3.7.2, strongly responding wells were present in the 
piperacillin treated wells, but these were fewer in number than the good and weak 
responses, with most wells being negative. SMX-NO treated wells resulted in a 
statistically significant increase in T cell proliferation, with piperacillin again being 
negative. In figure 3.7.4 supernatant was removed before addition of 3H-thymidine to 
perform ELISA assays for the detection of IFN-γ secretion with >50pg/mL IFN-γ 
classified as positive response. The number and nature of responding wells to both 
SMX-NO and piperacillin were again similar to those observed in previous 3.7 figures 
- again with SMX-NO response being determined to be statistically significant 
increase compared to control (p<0.0001) and piperacillin being negative overall. The 
ELISA did not match the proliferation plate map well for well, but the overall nature 
of response was conserved, with more responsive wells to SMX-NO than to 
piperacillin priming.  
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Figure 3.7.1 – 3.7.4 Using the T-MWA to assess the potential immunogenicity of piperacillin compared 
to the model drug-hapten SMX-NO 
Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM) or piperacillin (2mM). After 14 days plates were centrifuged, and cells were 
delicately washed to dispose of free drug in the media. Cells were gently re-suspended and re-
challenged with SMX-NO (40µM), piperacillin (2mM) or media as a negative control; 8 wells of 
negative control, 40 drug-treated wells. After 48-hour incubation 3H-thymidine (0.5µCi / well) was 
added for 16 hours before plates were harvested and proliferation counted on a beta-counter. 
Stimulation index was calculated as cpm drug treated well / average cpm negative control wells). The 
data was then displayed in a plate-map format, as well as stacked columns to show a traffic light system 
where; white = negative (<1.5 SI), green = weak response (1.5-1.99 SI), amber = good response (2-
3.99 SI), red = strong response (>4 SI) based on scoring system in 71. Data was also plotted as scatter 
plot; Mann-Whitney test performed to determine statistical significance of T cell proliferation of drug-
treated wells compared to no drug treatment. Statistical significance was determined as; *p ≤ 0.05; 
**p ≤ 0.005; ***p < 0.001. Figure 3.7.4 also had supernatant taken from the well after the 48 hour 
drug re-challenge and IFN- γ ELISA was performed according to Invitrogen assay instructions. 
Concentration of cytokine secreted in each well was determined before being plotted in plate format. 
Any red wells were deemed positive (>50pg/mL).  
 
3.4.8 ASSESSMENT OF THE COMPARATIVE POTENTIAL IMMUNOGENICITY OF SMX-
NO, BANDROWSKI’S BASE AND PIPERACILLIN ACROSS THREE DONORS USING 
THE T-MWA 
Figure 3.8.1-3.8.3 shows naïve T cell priming data to SMX-NO, piperacillin and the 
contact allergen Bandrowski’s Base in order than we could see the effect of using a 
contact allergen with a different mechanism of action to the other tested 
drugs/compounds. Priming of naïve T cells to Bandrowki’s Base resulted in 
statistically significant increase in T cell proliferation upon primed T cell re-
stimulation in all three donors (p<0.0001), with most or all wells showing positive 
response in all three donors. The nature of response seen was mainly good in figure 
3.8.1 and strong in 3.8.2 and 3.8.3. SMX-NO resulted in Statistically significant 
increase in T cell proliferation (p<0.0001) in figure 3.8.1 and 3.8.3 but was not 
significant in 3.8.2. As in figure 3.7 the nature of positive responses in SMX-NO 
treated wells were mostly good or strong. Piperacillin priming was less successful than 
either BB or SMX-NO with mainly negative response wells in all experiments. 
Nevertheless, in figure 3.8.3 increase in T cell proliferation after priming to 
piperacillin was determined to be statistically significant (p<0.05).  
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Figure 3.8.3 
Figure 3.8.1, 3.8.2, 3.8.3 Using the T-MWA to assess the potential immunogenicity of piperacillin 
compared to the model drug-hapten SMX-NO and contact allergen Bandrowski’s Base 
Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM), Bandrowski’s Base (5µM) or piperacillin (2mM). After 14 days plates were 
centrifuged, and cells were delicately washed to dispose of free drug in the media. Cells were gently 
re-suspended and re-challenged with SMX-NO (40µM), Bandrowski’s Base (5µM), piperacillin (2mM) 
or media as a negative control; 8 wells of negative control, 40 drug-treated wells. After 48-hour 
incubation 3H-thymidine (0.5µCi / well) was added for 16 hours before plates were harvested and 
proliferation counted on a beta-counter. Stimulation index was calculated as cpm drug treated well / 
average cpm negative control wells). The data was then displayed in a plate-map format, as well as 
stacked columns to show a traffic light system where; white = negative (<1.5 SI), green = weak 
response (1.5-1.99 SI), amber = good response (2-3.99 SI), red = strong response (>4 SI) based on 
scoring system in 71. Data was also plotted as scatter plot; Mann-Whitney test performed to determine 
statistical significance of T cell proliferation of drug-treated wells compared to no drug treatment. 
Statistical significance was determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001. 
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3.4.9 UTILISING THE T-MWA TO INVESTIGATE THE IMMUNOGENICITY OF THE 
REACTIVE METABOLITE NITROSO-SULFAMETHOXAZOLE, COMPARED TO ITS 
PARENT DRUG.  
Finally, for this chapter, the T-MWA was used to determine the difference in priming 
of naïve T cells to SMX or its reactive metabolite SMX-NO. These experiments can 
outline the nature of the response and whether or not SMX-NO is more inherently 
immunogenic than its parent drug SMX. Across all three healthy donors (figure 3.9.1, 
3.9.2 and 3.9.3) there are a higher number of responsive wells to SMX-NO than to 
SMX. Not only are there more overall responsive wells, but the nature of the response 
is generally stronger with higher SI seen across the plate. Many more ‘good’ responses 
are observed to SMX-NO than to SMX, whilst strong responses can be seen across all 
three donors, whereas only figure 3.9.2 displays SMX treated wells as having any 
strong responses. Box plot analysis of the SMX-NO data and subsequent statistical 
tests show that two of the three donors show a statistically significant increase in T 
cell proliferation (figure 3.9.1 p<0.05, figure 3.9.2 p<0.005). Priming naive T cells to 
SMX did not provide any statistically significant results in any of the donors tested. A 
positive response can be deemed as either a statistically significant increase in 
proliferation based on the dot plot, or a calculated SI>1.5 based on the 2012 paper 
which first developed the assay 71. 
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Figure 3.9.3 
Figure 3.9.1, 3.9.2, 3.9.3 Utilising the T-MWA to investigate the immunogenicity of the reactive 
metabolite nitroso-sulfamethoxazole, compared to its parent drug.  
Naïve T cells (2x105 / well) were plated in a 96-well plate with autologous moDC (8000 / well) with 
SMX-NO (40µM), or SMX. After 14 days plates were centrifuged, and cells were delicately washed to 
dispose of free drug in the media. Cells were gently re-suspended and re-challenged with SMX-NO 
(40µM), SMX, or media as a negative control; 8 wells of negative control, 40 drug-treated wells. After 
48-hour incubation 3H-thymidine (0.5µCi / well) was added for 16 hours before plates were harvested 
and proliferation counted on a beta-counter. Stimulation index was calculated as cpm drug treated well 
/ average cpm negative control wells). The data was then displayed in a plate-map format, as well as 
stacked columns to show a traffic light system where; white = negative (<1.5 SI), green = weak 
response (1.5-1.99 SI), amber = good response (2-3.99 SI), red = strong response (>4 SI) based on 
scoring system in 71. Data was also plotted as scatter plot; Mann-Whitney test performed to determine 
statistical significance of T cell proliferation of drug-treated wells compared to no drug treatment. 
Statistical significance was determined as; *p ≤ 0.05; **p ≤ 0.005; ***p < 0.001.   
 
 DISCUSSION 
The development of a screening system to predict the intrinsic immunogenicity of 
drugs in development is becoming increasingly important for pharma and the drug 
discovery process. Drug withdrawal post-licensing is detrimental to both the drug 
industry due to large monetary loss, as well as the patients that lose the benefit of 
useful, generally safe drugs that cause severe DHR in a minority of patients. A non-
invasive, medium/high throughput in vitro screening system will become critical for 
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detecting the potential immunogenicity of novel compounds in development, as well 
as determining the likelihood that an individual will develop a DHR to a licensed drug 
necessary for their treatment. HLA allele associations that determine predisposition to 
drug DHR have been a promising prospective tool for the prediction of DHR; 
purportedly to drugs such as carbamazepine, flucloxacillin and allopurinol 228,253. 
Abacavir is one of the most well-known HLA associations that has been robust enough 
to be implemented clinically for pre-screening of appropriate treatment methods in 
HIV patients due to its 100% NPV. Recently, the use of skin explant models of DHR 
to determine the immunogenicity of drugs via histology on in vitro cultured tissues 
with predicted culprit drugs has showed some promise when combined with T cell 
proliferation assays and cytokine (IFN-gamma) assays 254. Despite this, it would seem 
that this still does not define the mechanism of immune activation or provide any other 
mechanistic information on immune activation pathways (signal 1 / signal 2) such as 
the co-signalling pathways (PD-1, CTLA-4 etc.), as previous studies have determined 
their importance to immune activation in response to drug treatment 182. This 
information could be important in the prediction of drug immunogenicity and could 
lead to similarities being observed between drugs with closely related mechanisms of 
immunogenicity. It also does not determine the likelihood that a drug can prime drug 
naïve T lymphocytes to invoke the observed immune response or provide any 
indication of relative scale of immune activation of various genetically and 
immunologically heterogeneous donors. The method is also only relative for drugs 
that cause cutaneous reactions, and as such, other culprit DHR drugs such as 
flucloxacillin, or drugs where we don’t know what the manifestation of iatrogenic 
disease will be, cannot be tested using this system.  
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The standard naïve T cell priming assay has been used in various studies to determine 
the ability of a drug or antigen to prime drug naïve healthy donor T cells; which may 
give an indication of the potential immunogenicity of a drug. This assay can provide 
an avenue to determine the mechanistic inception of a DHR by T cell proliferation, as 
well as other phenotypic determination of the primed T cells through further T cell 
cloning investigations, cytokine secretion by ELISpot assays, and phenotypic analysis 
of T cell populations by flow cytometry. Nevertheless, the shortcomings of this assay 
mean that it is not yet ready for use by pharma to predict the intrinsic immunogenicity 
of a drug. In its current state, the assay lacks the propensity to screen multiple drugs 
or healthy donor cells on a single assay; and is not high throughput enough to be a 
viable method. The precursor frequency of the circulating antigen specific naïve T 
cells for the peptide repertoire of the expressed protein on the MHC surface is also not 
taken into consideration in the standard assay. It has been shown that the T cell 
precursor frequency in addition to antigen concentration is a determinant for whether 
an immune response will be mounted in response to drug treatment with different 
drugs. The likelihood of circulating T cells, specific to uniquely expressed peptide-
MHC complexes exhibited by each drug will vary depending on the drug used, and as 
such, the likelihood that a drug will induce T cell response will vary accordingly 255–
257. The two new assays developed during this chapter; the T-MDA and T-MWA, 
attempt to rectify some of the issues associated with the standard priming assay and 
other common methods of the prediction of DHR.  
The first figure of the chapter helps to explain the necessity of these changes, as the 
discrepancy between priming of naïve T cells to different drugs is clear. Only one of 
the four donors elicited a positive response to drug priming of both SMX-NO and 
piperacillin; whilst the other three donors were positive for SMX-NO priming, but 
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negative to piperacillin. DHR to piperacillin treatment occurs with a skin 
manifestation 258,259 and as such should be detectable in any predictive system 
employed. The assay must take into account that the precursor frequency of T cells 
varies with the drug in question, and that the likelihood of an immune response to 
DC:naïve T cell – drug culture will also vary according to the drug tested. A scaling 
level of immunogenicity could be employed in order to compare the relative 
immunogenicity of drugs against one another, compared to a model drug-hapten such 
as SMX-NO. Accompanying the above necessity is the laborious nature of the 
standard assay in which different cell types are cultured in different plates, the naïve 
T cell priming co-culture is then performed in a 24-well plate, before being moved to 
a 96-well plate for the readout stages. The miniaturisation of the T-MDA and T-MWA 
as described in the materials and methods section will aid both the ease of performing 
the assay, as well as enable the screening of multiple donors in a single 96-well plate. 
Or to have multiple wells (up to 40) per drug used which accounts for the T cell 
precursor frequency and the different levels of immunogenicity exhibited by different 
drugs.  
Figure 3.2 was proof of principle that the miniaturisation was possible by performing 
the DC: naïve T cell – drug co-culture step in a 96-well plate, and then keep the assay 
in the same plate throughout the entire experiment without the need for addition of a 
second round of freshly generated autologous DCs (another limiting step for both time 
and resources; as more blood is needed for isolation of CD14s for DC culture). 
Successful priming was observed in a higher percentage of wells to SMX-NO than to 
piperacillin, in line with the status of SMX-NO as a model hapten/positive control. 
The nature of SMX-NO priming led to a more potent response with good and strong 
responses, than in piperacillin which were weak, with one good. Nevertheless, 
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miniaturisation of the assay was achieved as priming was observed in some of the 
wells to both drugs. Moving on from this the next steps would be to compare the 
standard priming assay against the T-MWA to ensure that at a minimum, instances of 
positive priming and T cell proliferation were mirrored by the T-MWA; for this SMX-
NO was again used as the drug of choice for optimisation. The initial attempt to 
miniaturise the assay was successful as T cell proliferation was deemed significant in 
both versions of the assay (figure 3.3). Likewise figures 3.5.1-3.5.4 illustrates that the 
finalised version of the T-MWA (using 8 wells of control and 40 wells of drug 
treatments) results in positive priming of naïve T cells to SMX-NO; the idea now being 
that the T-MWA can be used to cover instances where standard priming was used 
previously, but will also be higher throughput, and more sensitive to use when testing 
other drugs or compounds.  
The nature of the immune response observed by T cell priming to certain compounds 
in an individual should remain consistent. Any assay developed should be 
reproducible in determining the nature of the immune response to a drug challenge. 
To show that the T-MWA is not simply generating differing ‘random’ data each time 
an experiment is performed on a donor. This then allows the T-MWA to generate 
meaningful data when comparing a drug or compound’s immunogenicity to a model 
allergenic hapten such as SMX-NO. For this reason, two blood donations were taken 
from two donors – with 6 months gap between each donation, ensuring that any T cell 
proliferation after drug challenge will be a consequence of the naïve T cell priming 
just taken place. Encouragingly, both the number of responding wells in the T-MWA, 
and the nature of the response (negative, weak, good, strong) remained consistent 
across both donations, in both donors, to all drugs tested.  
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The ability to screen multiple donors on a single assay for DHR is something that will 
enable quick determination of potential immunogenicity of novel compounds. This 
assay could work well in order to investigate potential changes in populations of 
people and may help elucidate why DHR occurs to drugs in some individuals, but not 
others. Donors of different ethnicities, or donors expressing differing HLA alleles 
could be screened using this method, which has previously shown to be effective in 
standard naïve T cell priming assays 32. This could rapidly validate and indicate some 
of the risk factors associated with DHR to different compounds. Figures 3.4.1 and 
3.4.2 help to outline this as multiple donors have been investigated in a single 
experiment. Ideally, up to 16 donors expressing unique HLA alleles can be assayed on 
a single plate, however, due to time constraints set by this project, as well as blood 
donation being a limiting factor, we managed to test 6 donors in the first experiment, 
and 8 in the second. As expected, different numbers of donors had positive priming 
responses to different drugs tested. SMX-NO, as expected, achieved positive SI scores 
in all patients across both experiments as it is a model drug-hapten that causes 
responses in almost all donors tested in previous work 136. Whilst piperacillin achieved 
positive SI scores in 2 out of 5 donors, and 2 out of 8 respectively. Bandrowski’s base 
achieved positive SI scores in only 4 out of 8 donors tested; something which was 
unusual in the context of our work, as previous work in the field has determined the 
contact allergen to be extremely allergenic. It is a product of auto-oxidation of para-
phenylenediamine to an allergenic hapten causing contact dermatitis 135,232,260. This 
could be due to cellular toxicity in the wells of the assay, resulting in lower 
proliferative responses, or indeed could be due to high background being observed in 
the negative control wells of the BB-primed T cells. BB produced T cell proliferation 
after priming categorised mainly as ‘strong’, which slightly contradicts data shown in 
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the T-MDA here. These differences could be due to cytotoxicity of strong sensitisers 
such as BB, which can have cytotoxic effects on dendritic cells in the culture due to 
inducible over-expression of CD86 surface marker 261.  
Once established in our lab, it was necessary to assess different drugs using the T-
MWA. As previously mentioned, SMX-NO and BB were used as model allergens, 
which should incite high levels of proliferative T cell responses after successful 
priming. Piperacillin was tested as a comparator drug. Previous studies have shown 
that PBMC stimulation with piperacillin does not result in positive LTT in healthy 
donors, but priming naïve T cells to piperacillin has resulted in positive proliferative 
response 32,135. Results from the T-MWA, again presented piperacillin as less 
immunogenic than either SMX-NO or BB across all experiments. The number of wells 
responding to piperacillin was lower than SMX-NO and BB, whilst the nature of those 
responding wells was generally classified as weak responses, with some good 
responses. SMX-NO and BB responded in most (and some instances all) wells of the 
T-MWA, whilst the nature of the responses observed resulted in mostly strong, or 
good SI. No piperacillin responses were statistically significant. ELISA analysis was 
performed on the supernatant of the culture wells to correlate proliferation data with 
cytokine secretion from responding T cells. Whilst the cytokine data did not match 
with the proliferation data on a well-to-well basis, the nature of the response to the 
respective drugs was conserved in that fewer wells responded to piperacillin than 
SMX-NO. This data confirms that the T-MWA can be used to generate various data 
which can be analysed in a variety of ways to determine: the nature of the immune 
response by SI categorisation, a scaling level of immunogenicity dependent on the 
number of responsive wells, the spread of the data, statistical significance and cytokine 
secretion. Multiple ways of analysing the data generated from these assays must be 
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considered in order to determine the relative immunogenicity and likelihood of a drug 
inciting a DHR in a patient.  
SMX hypersensitivity has been observed in antibiotic treatment options 248,262, 
however, the prediction of DHR to SMX has been difficult in previous experiments. 
Previous studies have shown that SMX induced DHR have been linked to metabolism 
of SMX; acting as a pro-hapten, firstly to a hydroxylamine, and then to its reactive 
metabolite form SMX-NO 110,263. However, sulfamethoxazole has also been shown to 
activate T-cells directly with no requirement for metabolic activation111. We finally 
assessed the ability of the T-MWA to determine the relative immunogenicity of SMX, 
when compared to its reactive metabolite SMX-NO. Less than a quarter of the wells 
4, 9, and 14 wells respectively registered as positive responses to SMX in the three 
donors, displaying a mixture of weak and good responses (and one strong), and no 
statistically significant responses. Again SMX-NO initiated statistically significant T 
cell response, with mainly good and strong SI responses. Although SMX can prime 
naïve T cells resulting in T cell proliferation in some wells of the T-MWA, this further 
confirms its reliance on metabolism to the reactive SMX-NO metabolite to cause 
strong responses in vitro. The T-MWA must improve upon this, as whilst detecting 
weak SI to parent drug could be helpful, the assay must be able to take into account 
those drugs that require metabolism to activate the immune system. SMX-NO is 
available for the study of SMX, but in instances where the reactive metabolite of a 
pro-hapten drug is not available or difficult to obtain; the addition of hepatocytes into 
a version of the T-MWA could be an effective tool in determining a drug’s reliance 
on metabolism to exert its immune effects.  
Whilst the main aims of the chapter were achieved by the miniaturisation of the 
standard naïve T cell priming assay through the successful development of two new 
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assays: T-MDA and T-MWA that provide a high-throughput system to investigate 
drugs that can potentially activate the immune system, more work is required to 
optimise these assays further before they can be considered robust enough for 
widespread use. Addition of hepatocytes to determine drug metabolism effects on 
likelihood of DHR would be a useful project. The assay in this chapter still hasn’t 
investigated the deeper effects of signal 2 on immune activation. Co-inhibitory 
signalling pathways such as PD-1 and CTLA-4 in particular have been exposed as 
important in not only immune activation, but also the strength of observed T cell 
responses 75,182 and are becoming increasingly significant in the cancer field due to 
their use as immunotherapies for immune targeting of tumours 250,264. It would be wise 
to also investigate the potential role of anti-inflammatory immune regulators in any 
assay being optimised. Differences in the number of T regulatory cells exerting anti-
inflammatory effects such as IL-10 or TGF-β secretion could have an effect on 
observed immune activation if expressed differentially dependent on the drug used 
182,265,266. These issues with the two newly developed assays will be addressed in the 
following chapter. 
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 INTRODUCTION 
Type IV drug hypersensitivity reactions are unpredictable by nature; and cannot be 
pre-determined based on the pharmacology of the treatment drug. This is one of the 
major factors that cause DHR to be such a large (and increasing) problem in both the 
clinic and drug development.  
Following GWAS studies HLA risk alleles have been considered an important 
determinant of whether or not DHR takes place 6. Indeed, certain encoded proteins 
from HLA alleles in an individual interact specifically with a drug derived antigen for 
an immune take place. Many HLA risk alleles have been described in the literature, 
e.g. : HLA-B*57:01 and HLA-B*57:03 in flucloxacillin have been described as a 
causative factor in DHR and DILI in particular, whilst HLA-B*57:03 has been 
described as a risk factor in carbamazepine induced hypersensitivity, and abacavir is 
the most established drug with an associated HLA risk allele – HLA-B*57:01 145,267. 
Despite the extensive description of HLA risk alleles and their associated drug in the 
literature, most of the associations are not strong enough for compulsory screening to 
be implemented clinically.  
Due to the relatively low PPV (positive predictive value – ability to correctly identify 
those with the ailment. Negative predictive value (NVP) is the ability to correctly 
identify those without the ailment) of many of the described HLA risk associations 
some other explanations have been put forward to describe why the majority of people 
who possess the one of the risk alleles do not develop DHR; and why DHR continues 
to be difficult to predict between different patient cohorts and individuals. Viral cross-
reactivity whereby T cells activate the virus; or the virus mediates DHR directly has 
been proposed 247,268. Comparably to the explanation of HLA risk alleles, viral cross-
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reactivity does not provide an adequate explanation to these difficult questions as the 
majority of DHR patients do not present with viral reactivation 249.  
In vivo and in vitro diagnostic and predictive tests have been developed to combat this, 
leading to correct diagnosis of the culprit drug for DHR and quick treatment, or even 
better, the prediction of a drug’s potential immunogenicity and prevention of its use 
in patients. As shown in the previous chapter assays such as the DC: T cell priming 
assay and elucidate differences in T cell priming through T cell proliferation in 
response to treatment with different drugs. The drug used in the assay has a large 
bearing on the outcome of T cell priming and proliferation, thus the T-MWA was 
developed to more closely analyse the exact differences in T cell priming activation to 
upon different drug treatments; considering T cell precursor frequency.  
In spite of the success of the different manifestations of the priming assay, the main 
question that now needs to be asked is are we recreating the correct immune 
microenvironment with all necessary immune regulation and parameters available, 
and can we modulate the immune regulation in order to truly elucidate the likelihood 
that a drug can invoke an antigen specific immune response.  
Immune reactions require not only the formation of an immune synapse (MHC-TCR 
interaction), but a variety of other immune regulation pathways; termed signal 2. To 
be able to understand what is occurring at the cellular level in our screening systems 
we must also understand what forms of signal 2 are occurring in our assays, and 
whether we modulate these in order to further investigate their role in the initiation of 
undesirable immune activation in DHR. In vivo there is a balancing act that occurs for 
the initiation of immune responses between signal 1, and signal 2 that involve co-
stimulatory and co-inhibitory signals that deviate between tolerance and activation.  
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A major component of signal 2 that has become increasingly important over the last 
few years are the co-signalling pathways that elicit their effects on T cell activation by 
modulating the threshold for activation. These comprise both co-stimulatory signals 
such as OX40, CD137, CD28 and ICOS 180, as well as the co-inhibitory pathways 
which include two of the focuses of this chapter PD-1 and CTLA-4 174. The co-
inhibitory pathways PD-1 and CTLA-4 have become an important drug target for a 
variety of diseases; but their targeting and blockade by drugs in cancer treatment is of 
particular interest 174,178,269, whilst their role in drug-derived antigen-specific T cell 
activation and its associated complications needs to be investigated in more detail. The 
understanding of these pathways could be key to the success of the continued 
development of the T-MWA. 
Tumour cells use the PD-1 pathway to evade host immune system; studies have shown 
there is a greater chance of death in cancer patients whose tumours express high levels 
of PD-1 270. Furthermore,  differential expression of PD-1 on immune cells has been 
implicated in mediation of autoimmunity and whether or not an immune response 
proceeds; this gives credence to the idea that investigation into this pathway may help 
to mechanistically evaluate how T cells are primed, and immune responses are 
mounted both in patients that develop DHR, as well as in our in vitro systems. PD-1 
is expressed on T cells, as well as a variety of other immune cells and interacts with 
its two ligands; PD-L1 which is similarly expressed across many immune cells types, 
and PD-L2, which has expression limited to DCs, activated macrophages, and some 
mast cells. Interaction between PD-1 and it’s ligands can cause suppression of antigen-
specific T cell response 186, whilst abrogation of the PD-1:PD-L1 axis can restore, or 
increase T cell response 137,182 through TCR coupling and dephosphorylation of TCR 
signalling; disrupting the MHC-TCR interaction.  
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CTLA-4 has also been characterised as an important immunoregulatory factor and 
another component of co-inhibitory signalling alongside PD-1. CTLA-4 is defined as 
a specific regulator of T cell activation, indeed CTLA-4 deficient (knockdown) mice 
often die within weeks of birth due to widespread lymphoproliferative disorders. As a 
component of co-signalling, CTLA-4 competes with the co-stimulatory CD28 for 
CD80 and 86 (its two ligands). As CTLA-4 expression is lower than CD28, its affinity 
for the two ligands is greater than CD28. Competition with CD28 for the two ligands 
can determine the likelihood of the development of an immune response, especially as 
CD86 has been characterised as co-inhibitory, whereas CD80 has been described as 
predominantly co-stimulatory 191. CTLA-4 can also regulate immune responses 
through its effects on Treg-APC binding competition; as Treg binding to APCs inhibit 
the formation of a co-stimulatory immune synapse, in addition to Treg 
immunosuppressive effects 58,59.  
Expression of the co-inhibitory components PD-1 and CTLA-4 may have a dramatic 
effect on naïve T cell priming and the outcome of our assays due to their immune-
suppressive effects; and may help explain differences in naïve T cell priming and 
proliferative outcomes between different drugs used. Its is firstly important to 
determine the expression of PD-1 and CTLA-4 during the course of our priming 
cultures and determine if there are observable differences dependent on the drug used 
– we will use flow cytometry to determine cellular expression as well as overall 
expression in our priming culture of DCs, naïve T cells, and drug. Once we have 
observed the modulation of these pathways in our experiments, we can then 
functionally understand their importance through blockade of the pathways in our T-
MWA assay (utilised in chapter 3). When comparing T cell priming without block to 
with co-inhibitory blocks, we can observe differences in priming and the functional 
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effects of co-signalling in our systems. This in turn can help in the further investigation 
of co-signalling relevance in DHR.  
When discussing immune regulation alongside signal 2 in the context of DHR in vivo 
as well as in our predictive systems it is important to note the importance of Tregs. As 
we need to determine the viability of the immunoregulatory microenvironment we are 
creating in our assay, the presence of Tregs is important due to their 
immunosuppressive effects on T cell activation and proliferation which takes multiple 
forms. Tregs become increasingly relevant to DHR and our predictive in vitro systems 
when considering their aforementioned relationship with CTLA-4, as CTLA-4 
expression can lead to increased Treg-APC interaction; causing lymphoproliferative 
suppression as a viable immune synapse cannot be formed. Tregs have also been 
implicated in IL-2 uptake – a key interleukin involved in T cell activation – which 
limits availability to, and subsequent activation of other T cells. This is also important 
as IL-2 has also been shown to induce Treg development and so despite its role in T 
cell proliferation activation of effector T cells, can also induce immunosuppressive 
events 60. The secretion of the anti-inflammatory cytokines IL-10 and TGF-β from 
Tregs also form a large part of their immunosuppressive role in the immune system; 
again, through presumed disruption of APC antigen presentation to circulating TCR.  
Induced Tregs (iTregs) may be generated from the naïve T cell population during 
priming, proliferating further and eliciting suppressive effects in our assay. iTregs are 
induced from a naïve CD4+ precursor and are usually supplemental to natural Tregs 
(nTregs). iTregs can elicit immune-suppressive effects and limit T cell activation, in 
this instance, TGF-β could be secreted from the DCs in our assay which can induce 
production of iTregs; something described in the literature 271,272. We will investigate 
whether Tregs are generated in our priming cultures differentially dependent on the 
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treatment drug; as this may explain differences and difficulties observed in naïve T 
cell priming between different assayed drugs.  
The knowledge gained from the investigation into immunoregulatory effects of co-
signalling/signal 2 (specifically PD-1, CTLA-4 and Tregs) can help us understand the 
role and importance of immune regulation in cases of DHR, and can further help in 
the optimisation of predictive screening systems implemented in our research.  
 CHAPTER AIMS 
1. Determine the Treg abundance in naïve T cell priming cultures, and determine 
any differences observed dependent on the antigen used for stimulation of the 
culture.  
2. Determine the expression levels of co-inhibitory PD-1 and CTLA-4 in naïve T 
cell priming cultures, and determine any differences observed dependent on 
the antigen used for stimulation of the culture.  
3. Determine the functional effects of PD-1 and CTLA-4 in our naïve T cell 
priming assays through blockade, and determine any differences observed 
dependent on the antigen used for stimulation of the culture.  
 METHODS  
All methods for techniques seen in this chapter can be found in detail in Chapter 2: 
Methods and Materials. 
 RESULTS 
4.4.1 GENERATION OF INDUCED TREGS (ITREGS) IN A NAÏVE T CELL PRIMING CO-
CULTURE 
In order to investigate the role of signal 2 and other determining factors in the 
regulation of the micro environment of T cell activation – such as the action of T regs 
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and co-signalling pathways (PD-1, CTLA-4) – it would be imperative to detect their 
presence in our naïve T cell priming cultures.   
As our priming cultures in the T cell priming assay, T-MWA and T-MDA contain a 
cocktail of solely moDCs, naïve T cells, and drug, we needed to determine the 
presence of T regs as they were potentially generated from the naïve population. It 
was decided the best way to achieve this would be to take aliquot of cells from the 
priming culture at four different time points, with Tregs then being quantified by flow 
cytometry (Tregs determined as CD4+, CD25hi, CD127lo, FOXP3+).  
Figure 4.1 shows three priming cultures from different healthy volunteers established 
through co-culture of moDCs, naïve T cells (isolated from PBMC) and drug (either 
SMX-NO or piperacillin). In all three instances the number of Tregs (as a percentage 
of CD4 cells) increased overall from day 0 to day 14 in response to treatment with 
either drug. In Treg 1 the peak number of Tregs occurred at day 14 to both drugs, with 
Tregs increasing from <0.5% at day 0, to 3% in response to SMX-NO treatment, and 
2% in response to piperacillin treatment at day 14. In Treg 2 there was again an overall 
increase in Tregs from day 0-14 to both drugs. Piperacillin increase throughout the 
time points from 0.1 to 1.5% by day 14; whilst SMX-NO generated Tregs peaked at 
day 7 (0.1 to 2.4%), before decreasing to under 2% on day 14.  
Treg 3 showed a similar story to Treg 2 in that there was an overall increase in Tregs 
in response to both treatments; piperacillin increased steadily throughout the time 
course to peak at day 14 (0.2 to 2.2%); whilst again Tregs to SMX-NO treatment 
peaked at day 7 (0.2 to 2%), before declining to day 14 1.5%. In two out of the three 
cases; SMX-NO treatment yielded a greater increase in Treg population than 
piperacillin.  
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4.4.2 SKEWING OF NAÏVE T CELLS TO A CD4/8 PHENOTYPE DURING PRIMING  
After determining the generation of Tregs in the previous experiment; it was decided 
to check the skewing of T cells during the course of priming and whether the naïve T 
cells move towards a CD4/CD8 phenotype during priming (figure 4.2). Three healthy 
donor priming cultures were set up and analysed as in the previous Treg experiments, 
but cells were stained and analysed for only CD4 and CD8. In all three instances, there 
were more CD8 cells than CD4 for both drug treatments – in all three instances the 
number of CD8 cells either decreased or remained constant in response to both drug 
treatments. In TC2 and TC3 the number of CD4 cells remained steady throughout the 
14-day time course; with a slight decrease observed in response to piperacillin 
treatment in TC3. Whilst TC1 was interesting in that the number of CD4+ T cells 
increased overall by 15% by day 14.  
 
 
 
 
 
 
 
119 
 
120 
 
121 
4.4.3 EXPRESSION OF THE CO-INHIBITORY CHECKPOINTS DURING NAÏVE T CELL 
PRIMING TO SMX-NO AND PIPERACILLIN  
Following analysis of the CD4/CD8 expression on T cells during T cell priming 
culture we decided to analyse the expression of PD-1 and CTLA-4.  
PD-1 and CTLA-4 expression was measured by flow cytometry in a similar 
experimental design and time course as the Treg and skewing experiments; only this 
time cells were stained for CD4, CD8, and then PD-1 or CTLA-4.  
It was imperative to determine the overall expression of PD-1/CTLA-4 in the cultures 
throughout priming as there could be differential expression of different receptors; 
therefore, MFI would give an idea of overall intensity of expression of the co-
inhibitory markers. In both donor 1 and 2 (figure 4.3) there were marginal increases 
in overall expression of both PD-1 and CTLA-4 on CD4 cells in response to both drug 
treatments; particularly from day 0-7. PD-1 expression of the CD8 population 
decreased in donor 1 but increased in donor 2 during the time course to both drugs, 
but CTLA-4 expression in CD8 cells marginally increased in response to SMX-NO 
treatment and decreased in response to piperacillin treatment in donor 1. In donor 2, 
CD8 cell PD-1 and CTLA-4 expression increased to a similar level in response to both 
SMX-NO and piperacillin treatment.  
In donor 3, increases were seen across the board in both CD4 and CD8 cell expression 
of PD-1 and CTLA-4 in response to either drug treatment; with the greatest increases 
seen in response to SMX-NO treatment. Overall the greatest increase in PD-1 and 
CTLA-4 expression in both CD4 and CD8 T cells was observed in cells treated with 
SMX-NO.  
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4.4.4 ASSESSMENT OF THE EFFECTS OF BLOCKING PD-1 AND CTLA-4 IN THE 
NAÏVE T CELL MULTI-WELL PRIMING ASSAY (T-MWA) 
After analysing the fluctuations in expression of PD-1 and CTLA-4 in response to 
different drug treatments, we investigated the direct effect of co-signalling on drug-
specific T cell priming with proliferation as a readout. For this, the T-MWA was 
performed on different healthy donors as in chapter 3, but instead used blocking 
antibodies to abrogate co-signalling and its effects on priming. This meant 
proliferative responses to: drug alone, drug + PD-L1 block (used to block PD-1 ligand 
on APCs and abrogate effects of PD-1), and drug + CTLA-4 block.  
It must be stated that whilst overall success of priming was determined based on 
statistical evaluation (significant – p<0.05 – increase in proliferation) of many 
individual wells treated under identical conditions, positive priming can be observed 
sporadically in some individual wells. Therefore, this could also be taken into 
consideration (albeit lesser than overall statistical significance of T-MWA) when 
evaluating the potential immunogenicity of a drug.    
Figure 4.5 shows the first experiment in which T-MWA was performed with SMX-
NO and piperacillin treatment. For SMX-NO treatment; significant proliferation 
responses (p<0.05) were observed with SMX-NO alone, and with either block applied. 
A larger increase in proliferation was observed compared to its own control in the 
presence of the co-inhibitory blocks, but there was no significant increase when 
compared directly against the proliferative readouts of drug alone. Piperacillin priming 
failed across the board for this donor; however, 3 individual wells displayed an 
increased proliferative response when re-stimulated with piperacillin (2 with PD-L1 
block, and one with CTLA-4 block).   
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Figure 4.6 again shows positive priming to SMX-NO with significant increases in 
proliferation observed in drug alone, and each block. However, this time, there was a 
significant increase in proliferation when comparing drug alone, to drug + CTLA-4 
block, which induced the greatest proliferative response. Piperacillin priming failed to 
drug alone, whereas there were significant increases in proliferation upon addition of 
either of the co-inhibitory blocks (with PD-L1 block eliciting the greatest effect on 
proliferation. Priming to flucloxacillin and DDS-NO failed across the board, 
irrespective of the use of co-inhibitory block.  
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 DISCUSSION  
The advent of numerous in vitro diagnostic and predictive test systems such as the 
LTT and naïve T cell priming assay have furthered our understanding of DHR. 
However, these current systems are not perfect, and are not yet fully fit for purpose. 
For diagnostic testing the LTT remains one of the more popular assays; whilst it is 
easy to perform and has become increasingly useful in patient cohorts where in vivo 
testing is more difficult, there is still a problem with sensitivity (~50%) despite its high 
specificity (upto 95%) 273. Prediction of DHR and the potential immunogenicity of a 
drug or compound is what is truly needed in the field. Indeed, the naïve T cell priming 
assay as well are T cell cloning are used extensively by our lab with this question in 
mind. Whilst these assays are currently the best on offer, and can be used to study 
mechanisms when a problem has been identified by the clinic, there are a few 
questions that need to be answered. For example, we still currently struggle to prime 
naïve T cells to drugs with MHC class II restriction; whilst we regularly prime to those 
with MHC class I restriction. Additionally, we sometimes struggle to prime to a parent 
drug, and instead must prime to its reactive metabolite (i.e. SMX-NO instead of SMX).  
HLA risk alleles have been implicated in the onset of DHR with specifically 
interacting drugs; as certain proteins encoded by HLA alleles are able to interact 
specifically with a drug derived antigen, causing immune response and subsequent 
DHR. Perhaps the best example of this is HLA-B*57:01 association with Abacavir 
induced hypersensitivity which has been demonstrated to be the only association 
robust enough to be implemented widespread in the clinic; whilst other associations 
such as HLA-B*57:01 have been demonstrated through GWAS and experimental 
studies, but have not yet been implemented clinically as they are not as consistently 
trustworthy 274. Indeed, the majority of people who possess a supposed HLA risk allele 
128 
do not actually develop DHR when exposed to the drug/antigen, therefore, there must 
be some other factors to be considered when trying to predict whether a DHR will 
occur.  
In addition to this, in the previous chapter we optimised the traditional naïve T cell 
priming assay 71 to develop a two new assays: T-MWA and T-MDA. The T-MWA 
allows us to more closely analyse the immune response and naïve T cell priming and 
takes into consideration the precursor frequency of T cells necessary to reach the 
activation threshold. This allows for analysis of the strength of the induced response 
as well as the number of wells stimulated by a drug. As the T-MWA still consists of 
only moDCs, naïve T cells, and drug we do not know if we are fully replicating the 
optimal immune microenvironment for priming T cells. The assay does not consider 
the full repertoire of immune regulation that participates in immune activation and 
responses; as immune activation is dependent not only on signal 1 (the formation of a 
APC-TCR immune synapse), but is heavily reliant on the balance of signal 2 axis of 
co-stimulatory and inhibitory factors, such as PD-1 and CTLA-4, in addition to the 
action of other immunosuppressive cell types such as Tregs.  
In this chapter, the presence of, and importance of signal 2 (co-inhibitory factors and 
Tregs) during naïve T cell priming was investigated in response to the use of different 
drugs/antigens. We also investigated the functional outcome of blockade of the co-
inhibitory factors PD-1 and CTLA-4. This information can help us further understand 
the immunological pathomechanisms of DHR in response to different drug treatments; 
explaining why different drugs have different effects, and may also help elucidate why 
HLA risk alleles are not always an accurate measure of predisposition to DHR upon 
specific antigen exposure. This additional information may also help us further 
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optimise our in vitro predictive assay conditions; providing a more comprehensive, 
accurate representation of the considered immune microenvironment and signal 2. 
In our Treg expression analyses we compared the presence of Tregs, proliferating from 
the naïve population at days 0, 1, 7, and 14 of our priming cultures, in response to 
treatment with either SMX-NO or piperacillin. Across all three donors there was an 
overall increase in Tregs from day 0-14 with both drugs used; similar responses have 
been described in response to anti-convulsant drug therapy, whereby cytotoxic T cells 
have been shown to switch to Tregs during DHR immune responses 275. Furthermore, 
the ratio of FOXP3 Tregs increases in patients with DHR/DRESS 276. These findings 
indicate that the immune system attempts to protect the host at very early stages of an 
effector T cell response. This also confirms the transient changes of T cell phenotype 
from CD4 to CD8 in two of three donors, and the vast increase in CD4:CD8 ratio 
observed in the first donor in figure 4.2 as the T cells undergo priming they can 
fluctuate between a state of CD8 cytotoxicity, and Treg/CD4+ memory cells. Other 
studies have shown similar expansion of Tregs in acute stages of DHR such as TEN; 
coupled with massively impaired functionality of the immunosuppressive cell type 
which can help to explain the immune systems inability to regulate immune responses 
in such severe circumstances 277. Now that we have shown there to be an increase in 
Tregs during T cell priming, it would be important to determine their functional effects 
in the constructs of our in vitro screening systems. Of particular importance would be 
the assessment of whether these Tregs are drug responsive, and if so, what is their 
method of immune-suppression. Following priming, we attempted to remove the 
generated Tregs using MACS CD25+ beads and cell separation columns, before re-
stimulating cells with drug to compare with ‘standard’ priming culture. Unfortunately, 
in preliminary attempts this yielded a complete failure of the assay – presumably as 
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the harsher treatment (37 down to 4 degrees Celsius, then back to 37 during the 
separations), washes and passage through the cell separation column caused a loss of 
function in the remaining T cell populations. Interestingly Gibson et al., discovered 
that introduction of autologous Tregs into a priming culture can significantly dampen 
antigen specific T cell priming 182. If more time were available to us, we would have 
spent time to optimise this experiment, as the implication of Tregs in DHR are clear, 
particularly when considering the connection to other signal 2 components such as 
CTLA-4 which we will move on to next. 
Upon analysis of the mean expression of co-inhibitory markers PD-1 and CTLA-4 
upon drug treatment during the course of our priming cultures, we observed 
fluctuations in expression of each of the two co-inhibitory regulators. This worked 
aimed to determine any observable differences in PD-1 and CTLA-4 expression upon 
different drug treatments. Across the three donors there were transient increases in 
PD-1 expression in the CD4+ T cell populations, which was mirrored by CTLA-4 
expression. The same trend can be observed under the same conditions when 
considering only the CD8+ T cell subset in 2 out of 3 donors; whilst in the third donor 
there were marginal decreases observed in both PD-1 and CTLA-4 expression to each 
of the two drug treatments. Interestingly, there was a decrease in expression observed 
between days 7 and 14 in the SMX-NO treated CD4+ T cells in 2 out of 3 donors, and 
in the piperacillin CD4+ treated T cells in 1 out of 3 patients; mirroring the decreased 
Treg abundance between days 7 and 14 from our previous work. This fluctuation in 
expression of the co-inhibitory markers may serve to highlight its potential importance 
of these two receptors in immune activation and downstream DHR. On balance, SMX-
NO induces a greater expression of PD-1, whereas piperacillin induces a greater 
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increase in CTLA-4. However, the observed differences between drug treatments are 
marginal.  
There is an overall increase of the both PD-1 and CTLA-4 during our priming cultures, 
perhaps increased to maintain tolerance during the priming of naïve T cells. Similar 
studies have also observed such increases, for example, antigen specific T cells 
isolated from multi-drug hypersensitivity patients had augmented PD-1 expression 278. 
Previous studies within the group have described similarly increased expression 
profiles of PD-1, CTLA-4 and another co-inhibitory contributor TIM3 182.   Now that 
we had observed increases in expression profiles of PD-1 and CTLA-4 in our priming 
cultures, it was important to then highlight whether this is translated functionally in 
our T-MWA; as PD-1 and CTLA-4 expression increases during priming, does their 
blockade translate to a functional decrease in antigen-specific T cell priming and 
proliferation? The literature has certainly observed a greater increase in risk of allergy 
when PD-1 expression is low 279, whilst there is a hugely increased risk of adverse 
events when PD-1 and CTLA-4 are blocked in cancer immunotherapy treatments 
280,281. This gives credence to the idea that blockade of PD-1 and CTLA-4 should be 
able to increase the degree of proliferation observed in our T-MWA, as achieved in 
the previous traditional priming assays 137,182, and may even be able to restore positive 
naïve T cell priming in instances of failed priming to certain drugs. 
An increase in the intensity of proliferation amongst the SMX-NO treated wells was 
observed with all donors tested using the T-MWA to look at the effects of PD-1 and 
CTLA-4 blockade. The individual number of wells that responded to SMX-NO on the 
scatter plot, and in terms of statistical significance of overall proliferation were both 
increased when compared to its own control. It must be stated that not only does the 
intensity of the drug treated wells increase upon co-inhibitory blockade, but the control 
132 
well proliferative intensity also increases upon use of PD-L1/CTLA-4 block. This 
could be explained due to the lack of regulation after co-inhibitory block, leading to 
decreased activation threshold of T cells that can now respond to nascent stimuli in 
the wells, causing increased basal proliferation. In all tested donors, piperacillin, 
flucloxacillin and DDS-NO treatment yielded statistically non-significant priming, 
despite individual wells in the scatter plot showing increased proliferative intensity. 
The increase in background influenced by co-inhibitory blockade meant that no 
statistical significance in overall proliferation was observed. However, it was noted 
that there was statistically significant increase in proliferation observed when 
comparing drug treated wells to drug + block treated wells, opposed to their own 
control in piperacillin treated wells.  
Although blocking the co-inhibitory pathways increased the intensity of the immune 
response, negative priming in wells treated with drug alone was generally not reversed 
upon blockade of the checkpoints - as observed previously using the standard priming 
assay 137,182. This is perhaps unsurprising given that treatments using immune 
checkpoint inhibitors can cause lowered immune activation threshold which can lead 
to severe adverse events 174,178,221,250. Whilst we weren’t able to achieve a reversal from 
negative to positive priming in instances where priming had failed with drug alone, 
we did see increases in proliferation in individual wells. Although antigen-specific 
proliferation was not significant in some instances, there was an overall increase in T 
cell proliferation upon checkpoint inhibition, presumably due to the decreased 
activation threshold leading to non-antigen specific T cell proliferation that could still 
participate in an immune attack in DHR in vivo.  
If additional time were available, we would have liked to perform mechanistic 
evaluation of the depletion of Tregs by removing the generated population post-
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priming to investigate the difference they make to the readout proliferative response. 
Co-signalling is a vast network of co-inhibitory and co-stimulatory factors. Whilst 
other co-inhibitory checkpoints such as TIM-3 have been shown to be of lesser 
importance than PD-1 and CTLA-4 137,182, it would be interesting to investigate the 
role that co-stimulation can play in our assays such as CD28 that competes for its 
ligands with CTLA-4 and has been therapeutically modulated to prevent immune 
eruptions and autoimmunity through organ rejection following transplantation 282. 
We achieved the aims set out in this chapter as we were able to ascertain the 
involvement of immune regulation in our in vitro assays: Tregs were generated from 
the naïve T cell populations during priming, there were increases in expression of both 
PD-1 and CTLA-4 during the course of priming, and blockade of the co-inhibitory 
checkpoints led to an increased lymphoproliferative response. This clearly shows the 
importance of immune regulation in DHR and in our assays. Further investigation 
must take place to understand the importance of immune regulation to the fullest 
extent. We can then use this information to further improve the T-MWA in particular 
and may be able to use this knowledge to improve patient outcomes in diagnostic 
assays for DHR. 
  
134 
5 APPLICATION OF THE LYMPHOCYTE 
TRANSFORMATION TEST FOR USE AS A CAUSALITY 
TOOL FOR THE DIAGNOSIS OF PAEDIATRIC DHR. 
 Introduction ............................................................................................. 135 
 Chapter Aims ........................................................................................... 141 
 Methods .................................................................................................... 141 
 Results ....................................................................................................... 141 
5.4.1 LTT on paediatric patient PBMC treated with both flucloxacillin and benzylpenicillin
 142 
5.4.2 LTT on paediatric patient PBMC treated with both flucloxacillin and rifampicin ....... 142 
5.4.3 LTT on paediatric patient PBMC treated with flucloxacillin or meropenem ............... 143 
5.4.4 LTT on paediatric patient PBMC treated with both flucloxacillin and meropenem..... 143 
5.4.5 LTT on paediatric patient PBMC treated with: temicillin, trimethoprim, ciprofloxacin, 
teicoplanin, tazocin and meropenem ......................................................................................... 143 
5.4.6 LTTs on paediatric patient PBMC treated with either meropenem and ceftriaxone or 
tazocin, amphotericin B and vancomycin .................................................................................. 144 
5.4.7 LTTs on paediatric patients PBMC treated with both meropenem and tazocin ........... 150 
5.4.8 LTT on paediatric patient PBMC treated with both flucloxacillin and ciprofloxacin .. 150 
5.4.9 LTT on paediatric patient PBMC treated with: amoxicillin, co-amoxicillin, teicoplanin 
and tazocin ................................................................................................................................. 156 
5.4.10 LTT on paediatric patient PBMC treated with both tazocin and aztreonam ............ 156 
 Discussion ................................................................................................. 159 
  
135 
 INTRODUCTION  
Drug hypersensitivity reactions are becoming an increasing issue in the medical field, 
causing high morbidity iatrogenic illness that costs the healthcare system millions of 
pounds per year. This in main is due to the filling of hospital beds by this potentially 
preventable illness, the cessation of treatment of otherwise useful drugs causing 
wastage, and the removal of useful drugs from market, in addition to the treatment of 
patients suffering from DHR with alleviating drugs.  
One group of patients that are at an increased risk to DHR are patients being treated 
for cystic fibrosis (CF). This life limiting autosomal recessive disease affects in the 
region of 70,000 people worldwide; mainly Caucasians. If left untreated prognosis can 
be expected to be less than ten years, whilst current treatment strategies have led to 
the median age of mortality in CF sufferers to rise to 37 years old. The majority of 
deaths (>80%) associated with the disease are due to airway infection and longer term 
obstructive disease of the lungs 283. The disorder is caused by dysfunction of the 
chloride channels of the endocrine glands, specifically, the cystic fibrosis 
transmembrane conductance regulator (CFTR). This occurs due to gene mutation and 
affects multiple internal organs; mainly the lungs and respiratory systems. But can also 
negatively affect the pancreas, liver and respiratory organs to varying degrees 284. The 
discovery of the CFTR gene 30 years ago 285 has vastly increased the scope of 
prospective therapies available to sufferers, as research into the development of 
personalised gene therapies have become increasingly popular. These include both 
viral and non-viral gene therapies, as well specific molecule therapies aimed one of 
the 1900 identified CFTR causative mutations 286. The addition of a fully-functioning 
CFTR gene into defective airway cells has also been put forward as the purported best 
way to treat CF for pan-CFTR mutations 287. Despite these genetic advancements in 
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an effort to cure CF, the main mechanism of improving the prognosis for those 
diagnosed with the disease, is to target end-point airway destruction through the 
administration of single or combination therapy of antibiotics against bacteria such as 
pseudomonas aeruginosa 288. This has led to this particular group of patients becoming 
particularly reliant on long-term treatment regimens of parenterally administered 
antibiotics; penicillin(s), cephalosporins, and aminoglycosides, and as such, have 
increased risk of DHR when compared to other patient groups 289. Whilst relatively 
low morbidity skin-based reactions such as rash and pruritis are the most common, 
these patients can also suffer more severe skin reactions, causing high morbidity, and 
in even more extreme cases, mortality. In some instances of antibiotic induced DHR 
there are immediate IgE mediated anaphylaxis, however, the majority are late-onset 
type IV DHRs that manifest in the aforementioned skin rash as well as fever 290. The 
increased lifespan of CF patients due to advances in antibiotic therapy has become a 
double-edged sword, as the longevity of this treatment plan can be brought into 
question as DHR increases due to the long-term nature of high dose antibiotic 
administration. These reactions are not currently predictable based on the 
pharmacology of the drug, and are especially difficult to diagnose, owing to the fact 
that there is no current global consensus on whether single antibiotic or combination 
antibiotic administration is the most effective treatment plan 288. It is imperative to be 
able to accurately ‘look through the noise’ of these multiple drug regimens and 
diagnose actual DHR; with the correct culprit drug elucidated so that there is not 
cessation of treatment for other correctly functioning beneficial drugs. Despite long-
term drug administration being a major cause of DHR, paediatric CF patients are also 
at risk of adverse events and can be even more difficult to diagnose due to the invasive 
nature of current diagnostic tools that are not fit for purpose.  
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Misdiagnosis of DHR is a common problem in children, and can lead to cessation of 
treatment, causing risk to the child as treatment options become increasingly limited 
and the risk of infection heightens. This is evidenced by the fact that despite 10% of 
parents reporting suspected drug allergies in their children, only a few are positively 
confirmed following current diagnostic evaluation 291. The use of other drugs due to 
misdiagnosis also leads to increase antibiotic resistance and increased costs for the 
healthcare system 292. Misdiagnosis and under-diagnosis are both a major issue, as 
misdiagnosis can prevent the child from receiving potentially life-lengthening 
treatment, whilst under diagnosis can cause to increased risk of high-morbidity or 
mortality DHR. In order to properly manage drug allergy in children, it is important 
to be able to accurately diagnose true DHR 293, this is especially true of paediatric CF 
patients where the culprit drug must be identified in multiple-drug therapy to maintain 
effective treatment of airway disease. Of course, as the number of drugs involved in 
the treatment increase, the likelihood of the current diagnostic tests being able to 
accurately detect the true culprit drug decreases.  
Current in vivo diagnostic techniques to identify drug allergy have already been 
discussed in Chapter 3. It can be said that the issues elucidated for tests such as the 
skin prick, skin patch, and drug challenge tests, can be amplified in this instance as in 
vivo tests in children can be complicated and difficult to use effectively due to their 
invasive and risky nature in patients suffering severe cutaneous adverse reactions 
(SCARs) in particular. There is a need for a non-invasive, specific and sensitive test 
for this group of vulnerable patients, as the importance of correct diagnosis of DHR 
in paediatric patients is of even greater importance than that of adult patients when 
attempting to improve prognosis through long-term administration of antibiotics. This 
treatment is a ‘necessary evil’ until an effective, safe, gene therapy is developed, which 
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can cure CF through reinstation of a functioning CFTR gene in the airway cells of 
those suffering from the disorder. It is for this reason that this chapter will focus mainly 
on the use of the lymphocyte transformation test (LTT) in the diagnosis of drug allergy 
in patient samples. The utility of the assay will be discussed which will include the 
positive attributes of the assay, as well as the drawbacks. Whether or not the assay is 
fit for purpose in this instance will also be decided, and a list of potential 
improvements to the assay will also be put forward.  
For the LTT to be correctly discussed, it must first be recognised that it is one of 
multiple in vitro tests developed with the intention of accurate DHR diagnosis – others 
including the CD69 leukocyte activation test, and the ELISpot assay (which our lab in 
particular uses to characterise expression and cytokine secretion from different T cell 
subsets including clones.  
Upregulation of lymphocyte activation marker CD69 can be detected by flow 
cytometry in order to determine activation of T cells in response to drug treatment 
within 48 hours. Studies have shown that when compared to the LTT which takes 6 
days to complete, 15 out of 15 positive LTT samples also showed CD69 upregulation 
within two days. It was argued that this can be a preferable alternative to the LTT in 
situations of severe DHR such as SJS/TEN where rapid diagnosis is vitally important 
242. Other studies have compared CD69 upregulation to in vivo patch tests, concluding 
that four out of six patients that were skin patch positive, were also positive for CD69 
upregulation 294, which although limited, does not show this method to be equivalent 
to the more established in vivo tests. That said, CD69 upregulation remains an 
important consideration in drug allergy, especially owing to its involvement in 
immune regulation through control of Treg differentiation and secretion of IFN-γ, IL-
17 and IL-22 295. The detection of secreted cytokines such as IFN-γ is important for 
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the profiling of T cell responses and has been used regularly to diagnose cutaneous 
DHR. ELISA, electrochemiluminescence and flow cytometry can all be used to 
achieve this, but the ELISpot in particular has been used by groups such as ours to 
great effect over the years and is a mainstay of immune profiling of T cells 50,225,296,297. 
Whilst its use in immune profiling has been useful, some studies have shown that the 
sensitivity of the ELISpot is 100%, but only achieved sensitivity of 47%, lower than 
that of the ELISA and flow cytometry (50% and 57% respectively) 298.  Another issue 
with current in vitro testing is the inability to conclude that one of the tests is suited to 
diagnosing all types of observed manifestations of DHR. There is currently no 
comprehensive test for DHR diagnosis as the utility of each of the in vitro methods 
depend on the mechanism involved 299,300. One of the main concerns surrounding in 
vitro tests is that whilst generally displaying excellent specificity (approx. 100%); the 
sensitivity of these tests leaves much to be desired, and so the risk of false positives is 
relatively high. This is particularly problematic for this vulnerable population of 
paediatric CF patients as misdiagnosis and drug withdrawal is one of the major 
concerns surrounding their treatment plan and is already the main reason for the need 
for better diagnostic testing. A major theme concerning in vitro testing is that there is 
an inherent need to develop one particular improved diagnostic test for DHR that can 
work in all situations, spanning different treatment strategies, drugs used, and immune 
mechanisms involved 301.  
The LTT has been used to test for drug allergy for over forty years – Warrington et 
al., utilised the LTT to a suspected DHR causing drug in 1979; the assay was accurate 
in diagnosing immediate reaction, but only detected positive responses in 3 out of 11 
patients with delayed-type reactions to penicillin. Nine out of eleven patients showed 
positive LTTs for isoniazid induced DHR, whereas only eight out of thirty-one 
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displayed positive LTT responses when the suspected drug was penicillin 302. PBMC 
are isolated from blood donation and then cultured for 6 days with the suspected culprit 
drug before proliferation is measured through addition of tritiated thymidine and 
counting on beta-counter. Proliferation of drug challenged cells is compared to 
negative control cells, with stimulation index being calculated by CPM stimulated 
cells/CPM medium only treated cells; tetanus or PHA can also be used as a positive 
control to ensure cells have the propensity to proliferate. Further studies confirmed the 
application of the LTT in detecting T cell responses in patients presenting with liver 
dysfunction attributed to isoniazid, once again with a high specificity (83-90%) but 
only 50% sensitivity 303. Due to its versatility in being able to diagnose DHR in 
different classes of antibiotics, the LTT is deemed superior to the competing in vitro 
tests, as the need for a single solution in becoming increasingly important. 
Additionally, despite the sensitivity of the assay being relatively low (60-70%) for 
detection of DHR to beta-lactam antibiotics, this is still higher than competing assays 
26.  
Clearly, there is an inherent need for a one size fits all in vitro diagnostic test to 
specifically, and sensitively detect the culprit drug responsible for DHR in a patient. 
The test must work well across a range of drugs with different immune mechanisms 
at play. It can be argued that currently, the closest assay available to fit the above 
criteria is the LTT. Despite this, there are issues with the current version of the assay 
such as: number of PBMC required makes it difficult to test a range of drugs and 
concentrations in paediatric samples, the assay has relatively low sensitivity causing 
false negatives and drug withdrawal which is another major issue for paediatric CF 
patients, and cross-reactivity between different antibiotics/classes of antibiotic 
coupled with low sensitivity makes it difficult to discern the culprit drug in multi-drug 
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treatment strategies. This chapter will utilise the LTT to diagnose DHR, detecting the 
culprit drug in multiple-drug therapy in paediatric patients with CF. These data will 
help to assess whether the current assay is fit for purpose. The main aim is to elucidate 
both the strengths and weaknesses of the current assay, highlighting areas in which we 
can improve this for both adult and paediatric patients.  
 CHAPTER AIMS 
1. Assess the utility of the LTT as a tool for the diagnosis of DHR in paediatric 
patients undergoing multiple antibiotic treatment from different classes.  
2. Establish whether or not the LTT is for purpose.  
3. Formulate new ideas how we can improve in vitro diagnostic testing for DHR 
– especially for vulnerable patients such as CF paediatrics.  
 METHODS 
All methods for techniques seen in this chapter can be found in detail in Chapter 2: 
Methods and Materials.  
 RESULTS 
During the course of this chapter the utility of the LTT for the diagnosis of DHR in 
paediatric CF patients’ blood samples is assessed. All samples analysed by LTT in this 
chapter were received through ongoing collaborations with the Royal Manchester 
Children’s Hospital, and St James’ Hospital in Leeds cystic fibrosis wards. Informed 
consent was obtained from all parents for the blood donations. Due to the extremely 
sensitive nature of paediatric patient data, the only information provided alongside the 
samples was: anonymised patient code, antibiotics currently being used in treatment, 
the fact that they had a suspected DHR (generally skin reaction), and the fact that they 
were under 16 years of age. As in vivo diagnostic tests were not suitable for use in 
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patients of this age, we were providing a service to attempt to diagnose the culprit 
causative drug through use of the LTT; this was not confirmed through in vivo tests 
such as skin patch or drug challenge. All PBMC were isolation on arrival of the blood 
sample, and all LTTs were performed on freshly isolated PBMC (not frozen) for 
consistency and to maintain the integrity of the immune cells for the function of the 
assay. The proliferative propensity of the PBMC were confirmed through stimulation 
with either tetanus toxoid (TT) or the mitogen phytohaemaglutinnin (PHA).  
5.4.1 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH BOTH 
FLUCLOXACILLIN AND BENZYLPENICILLIN 
As can be seen in figure 5.1 the first sample received (LANC001) had a suspected 
DHR during the course of treatment with the beta-lactam antibiotic flucloxacillin and 
benzylpenicillin (penicillin G). Proliferation was observed only when PBMC had been 
stimulated with PHA, however, treatment to a range of concentrations of both 
flucloxacillin and benzylpenicillin did not cause significant increase in proliferation 
when compared to base level negative control (no drug).  
5.4.2 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH BOTH 
FLUCLOXACILLIN AND RIFAMPICIN 
Figure 5.2 displays the data achieved from the second patient sample received. The 
patient was again being treated with flucloxacillin, but instead of benzylpenicillin was 
receiving rifampicin when they suffered a suspected adverse event. Again, 
proliferative viability of the cells was displayed after stimulation with PHA, but no 
significant increase in proliferation was observed in response to flucloxacillin 
treatment at any concentration tested when compared to negative control. However, 
rifampicin treatment did result in a significant increase in proliferation (p<0.05) at a 
concentration of 12.5µM.  
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5.4.3 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH FLUCLOXACILLIN OR 
MEROPENEM 
The next two patient samples received (MAN001 & MAN003) are displayed in figure 
5.3 as each of them were only receiving treatment of a single antibiotic at the time of 
suspected DHR occurrence. Note: MAN002 sample was destroyed due to incorrect 
tube being used when sample was collected resulting in coagulation of the blood 
during transit. MAN001 was being treated with flucloxacillin when suspected DHR 
was observed. Marginal increase in proliferation compared to baseline was seen across 
multiple concentrations of flucloxacillin testing; with significant increase (p<0.05) 
observed upon treatment with 0.5mM flucloxacillin. MAN003 was being treated with 
meropenem, but no increase in proliferation was observed across any of the range of 
concentrations tested (0.25-4mM). The proliferative nature of the cells was confirmed 
through stimulation with TT to ensure lack of proliferation upon drug treatment was 
not due to natively unresponsive or damaged cells.  
 
5.4.4 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH BOTH 
FLUCLOXACILLIN AND MEROPENEM 
MAN004 seen in figure 5.4 was being treated with both flucloxacillin and meropenem. 
In this instance, we were not able to detect the suspected culprit drug. Despite being 
tested at a range of concentrations (0.25-4mM) a significant immune response in the 
patients’ PBMC was not detected. 
5.4.5 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH: TEMICILLIN, 
TRIMETHOPRIM, CIPROFLOXACIN, TEICOPLANIN, TAZOCIN AND MEROPENEM 
Next a sample was received (MAN005 – figure 5.5) where the patient had been 
receiving multi-drug antibiotic therapy for CF induced airway infection to six different 
144 
antibiotics: temicillin, trimethoprim, ciprofloxacin, teicoplanin, tazocin and 
meropenem. In this instance LTTs were performed to all six drugs to a range of 
concentrations (5 different concentrations to tazocin and meropenem, 4 different 
concentrations to each of the other drugs), with a view to elucidating the culprit drug(s) 
that induced the suspected DHR in the patient. Significant proliferative responses were 
observed with the following drugs: temicillin (25 and 50µg/mL), trimethoprim 
(12.5µg/mL), tazocin (1, 2 and 4mM) and meropenem (4mM). No significant 
proliferative responses were observed for ciprofloxacin and teicoplanin, whilst TT 
successfully stimulated cells in all instances. 
5.4.6 LTTS ON PAEDIATRIC PATIENT PBMC TREATED WITH EITHER MEROPENEM 
AND CEFTRIAXONE OR TAZOCIN, AMPHOTERICIN B AND VANCOMYCIN 
The culprit drug(s) responsible for the suspected DHR were not outlined by the LTT 
in either of the next two patients (MAN006 – figure 5.6, MAN007 – figure 5.7). 
MAN006 was being treated with meropenem and ceftriaxone and was negative across 
the range of concentrations tested, whereas MAN007 was tested for immune response 
against tazocin, amphotericin B and vancomycin in multiple concentrations; no 
significant responses were observed to any of the drugs at any concentration. Again, 
proper immune function was observed through PHA stimulation.  
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Figure 5.1 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. Under sterile 
conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was removed through by 
pipetting before being washed and counted. Cells were then diluted in R9 media before being assayed in a 96-well 
plate at 150,000 cells per well in triplicate in 100uL volume R9. Patients’ treatment drugs were then made up at a 
range of concentrations in R9 at a final volume of 100uL before being assayed in triplicate with the PBMC. 
Triplicates of no drug treatment (R9 only) or antigen and mitogen stimulation (TT or PHA) were also added. Plates 
were then incubated at 37˚c (0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated 
thymidine was added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and significant 
increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.2 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.3 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.4 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.5 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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5.4.7 LTTS ON PAEDIATRIC PATIENTS PBMC TREATED WITH BOTH MEROPENEM 
AND TAZOCIN 
Upon completion of the MAN cohort samples, we received CF paediatric blood 
samples from a new cohort RMCH. Both of the first two samples received from this 
new cohort (RMCH001 and RMCH002) were treated with both tazocin and 
meropenem. In each of these patient samples, a cellular proliferative response was 
confirmed by mitogen stimulation, but both tazocin and meropenem did not induce a 
significant immune response (measurable by LTT assay) at any concentration tested 
in either of the two patients. Tazocin did show a marginal increase in proliferation at 
0.5, 1 and 2mM concentration in RMCH001, but replicates leading to large SD meant 
these were not deemed significant by statistical test (T test). However, stimulation 
index (SI) was calculated by: average of drug treated wells/average of negative control 
wells, showed a reasonably strong response (SI=3).  
5.4.8 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH BOTH 
FLUCLOXACILLIN AND CIPROFLOXACIN  
RMCH003 was another patient being treated with more than one antibiotic, this time 
flucloxacillin and ciprofloxacin were used. Mitogen stimulation again confirmed 
correct immune function of the cells, and 0.5mM flucloxacillin treatment led to the 
LTT detection of a significant increase in proliferation whilst ciprofloxacin treatment 
did not register and significant change.  
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Figure 5.6 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.7 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.8 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.9 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.10 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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5.4.9 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH: AMOXICILLIN, CO-
AMOXICILLIN, TEICOPLANIN AND TAZOCIN 
Patient RMCH004 in figure 5.11 was being treated with four different antibiotics: 
amoxicillin, co-amoxicillin, teicoplanin and tazocin. Despite attempts to outline the 
suspected culprit drug responsible for the purported adverse event, none of the drugs 
at any of the concentrations assayed resulted in an observed significant increase in 
proliferation. It must be noted that small (but not statistically significant) increases in 
CPM were observed at 1mM tazocin, and 50µg/mL teicoplanin treatments.  
5.4.10 LTT ON PAEDIATRIC PATIENT PBMC TREATED WITH BOTH TAZOCIN AND 
AZTREONAM 
The last patient sample received was RMCH005 (figure 5.12). In this final sample the 
patient was being treated concurrently with tazocin and aztreonam for CF induced 
lung and airway infection. Aztreonam did not invoke a significant immune response 
at any of the tested concentrations, whilst the LTT assay displayed a large significant 
increase in proliferation at both 1 and 2mM. Indeed, proliferative response to tazocin 
almost matched mitogen stimulation of the cells in this instance.  
Overall, 13 different patient samples were obtained during the course of this study and 
were analysed by LTT in order to attempt to diagnose the culprit drug involved in 
suspected DHR. Of the 13 patients involved, only two of them (MAN001 and 
MAN003) were receiving single antibiotic treatment, whilst the others were receiving 
concurrent treatment of two or more antibiotics. MAN005, MAN007 and RMCH004 
were treated with 6, 3 and 4 antibiotics respectively. Over half (8) of the 13 patient 
samples involved in the study did not lead to the detection of the culprit drug as they 
were negative for all drugs tested by LTT at all concentrations assayed. At least one 
potential culprit drug was outlined in the other five patient samples tested as a 
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significant increase in proliferation was observed after drug treatment when compared 
to the negative control (no drug). MAN005 was the only sample in which significant 
proliferation was detected in more than one drug tested as 4 out of 6 assayed drugs led 
to a significant increase in proliferation (temicillin, trimethoprim, tazocin and 
meropenem). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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Figure 5.12 Diagnosis of culprit drug involved in DHR in patient LANC001 through use of LTT assay.  
Paediatric patient blood sample was obtained to diagnose suspected DHR and detect culprit drug. 
Under sterile conditions blood was layered onto lymphoprep (1:1) and centrifuged, PBMC layer was 
removed through by pipetting before being washed and counted. Cells were then diluted in R9 media 
before being assayed in a 96-well plate at 150,000 cells per well in triplicate in 100uL volume R9. 
Patients’ treatment drugs were then made up at a range of concentrations in R9 at a final volume of 
100uL before being assayed in triplicate with the PBMC. Triplicates of no drug treatment (R9 only) or 
antigen and mitogen stimulation (TT or PHA) were also added. Plates were then incubated at 37˚c 
(0.5% CO2) for five days. Sixteen hours before harvesting the plates 0.5µCi tritiated thymidine was 
added to all wells. Plates were then harvested and sealed by wax scintillation before CPM was 
calculated through counting of the plates on a beta-counter. Standard deviation was calculated and 
significant increase in proliferation was determined through paired T test when p<0.05. 
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 DISCUSSION 
Despite the prediction of DHR before occurrence being the ideal end goal through 
determination of the immunogenicity of a compound or drug in an individual, the 
problem of reliable diagnosis of DHR in patients who are already afflicted remains 
unsolved. In vivo testing can work effectively through skin patch and challenge testing 
to diagnose alleged DHR. Well trained clinicians can provide these tests in a semi-
controlled environment to provide a more direct proof of the clinical relevance of the 
adverse manifestation of the treatment 304. However, these in vivo tests can be both 
invasive, and risky depending on the severity of the DHR that individual suffers in 
response to drug challenge; this is exacerbated in children. Nevertheless, drug 
provocation testing has remained the gold standard even in paediatric testing 305, and 
for this reason, we believe that although adult work-ups of diagnostic testing can also 
be clinically relevant when dealing with a paediatric cohort of patients, this is not 
sufficiently reliable enough in adult testing, and even more so in children. A 
dependable in vitro test with both high sensitivity and specificity that works across a 
range of drugs (in this instance classes of antibiotics) should be the new gold standard, 
particularly when dealing with a group of patients that are so vulnerable to severe 
DHR due to long-term treatment regiments of multiple high dose antibiotics. The data 
obtained in this set of experiments will be used to assess the utility of the LTT both in 
the context of this set of patients, and in general use. It has already been made clear 
that there is an inherent need for an assay such as the LTT; it will be decided whether 
or not the current version of this assay is fit for purpose, before potential improvements 
to the assay will be suggested for future studies upon receipt of further patient samples.  
As can be seen from the results section, over half of the patient samples analysed did 
not elicit a significant proliferative response to any of the drugs tested at any 
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concentration. In each of these instances different drugs were used from different 
classes of antibiotics. LANC001 was being treated for DHR in response to 
flucloxacillin and benzylpenicillin treatment, whereas MAN003 was treated solely 
with rifampicin. MAN004 was tested against flucloxacillin and meropenem like 
LANC001, and MAN006 was the first LTT negative patient not receiving 
flucloxacillin as they were being administered meropenem and ceftriaxone. MAN007 
was actually negative to all three tested drugs (tazocin, amphotericin B and 
vancomycin). RMCH001 and 002 were negative in treatment to tazocin and 
meropenem whilst testing against amoxicillin, co-amoxicillin, teicoplanin and tazocin 
all yielded negative results in RMCH004. Previous studies have shown that whilst the 
sensitivity of the LTT is not usually high (up to 70%), the specificity of the assay is 
usually good (>80% up to 100% dependent on drug tested) 241,306. It could be said that 
the negative results of the LTT indicates that the patients were not actually suffering 
DHR in response to any of the tested antibiotics used in the treatment of their disease. 
Indeed, misdiagnosis and self-diagnosis in response to an observable rash is still a 
major problem in the treatment of children. Many rashes seen in children that can be 
incorrectly diagnosed as DHR could actually be due to viral infections, which are 
common in children 293, or excipients 307. Other infections and complications caused 
by the aetiology of CF such as lung or airway complications such as protein-energy 
malnutrition leading to dermatitis and other skin conditions 308,309. It is likely that the 
LTT in this instance has correctly established that the skin reactions observed in the 
children are not DHR due to treatment with the tested antibiotics. However, it must be 
stated that this cannot be comprehensively proven by LTT alone, as there is still a 
chance that due to the specificity of the LTT 26,297, there is still a 1 in 5 chance that 
these data could be false negatives. With patient safety being of the upmost 
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importance, we could say that it is likely that these drugs tested by LTT are not causing 
DHR, but proceed with caution, as high morbidity manifestations of DHR can still 
occur if false negatives are present in the test.  
Pleasingly, in this study the LTT did detect a statistically significant increase in 
proliferation to a single suspected culprit drug (out of two or more drugs tested) in 
four of the patients tested (LANC002, MAN001, RMCH003 and RMCH005). It is 
imperative that any in vitro test can elucidate the culprit drug in a multi-drug treatment 
strategy in order to know which drug must be removed from the treatment plan, whilst 
keeping the other drugs included. In the four patients listed above this was able to be 
achieved by the standard LTT assay used, and clinicians were informed which drug 
was the likely culprit in the suspected DHR observed.  
For MAN005, four out of six drugs tested by the LTT resulted in a significant positive 
proliferative response. Multi-drug hypersensitivity (MDH) has been described in the 
literature; with some of the drugs featured in this experiment such as tazocin and 
trimethoprim being implicated regularly. It is stated that the effects of the second DHR 
can overlap with the remnants of the first drug stimulation 310.  Despite this, it is 
unlikely that all four out of these six drugs would raise a DHR in the patient if tested 
in confinement. This is an issue when the true culprit drugs for the DHR must be 
detected. MAN005 was being treated with drugs from the beta-lactam, penicillin, beta-
lactamase resistant penicillin, carbapenem and semisynthetic glycopeptide classes of 
antibiotics. During multi-drug therapies such as this one, it can be difficult to single 
out or accurately detect one or possibly two drugs out of six due to the different 
immune mechanisms amongst different classes of antibiotics. Incidences of cross-
reactivity between the different classes of antibiotics have been observed in DHR(up 
to 50% between penicillins and carbapenems for example), usually due to similarities 
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in side-chain determinants 311,312. This may somewhat excuse the result of this LTT as 
potential cross-reactivity between these drugs has meant that more than one are 
responsible for the DHR, or that cross-reactivity has led to false positives in this 
particular LTT. The issue is that if the results of this LTT are false-positives, it is a 
dangerous precedent to set if four out of the six tested drugs are removed from the 
treatment plan for MAN005. It is clear that further understanding of drug reactions 
and cross-reactivity will both improve treatment plans for patients, lowering the risk 
of DHR, but also may help optimise the assay in order to circumvent the issue of false 
positives arising from antibiotic cross-reactivity 313.  
Instances such as those above illustrate why although the LTT has its uses, and is the 
best in vitro test currently available for diagnosis, it is not truly fit for purpose and 
must be optimised further if we are to improve patient outcomes when dealing with 
groups of people at risk of severe DHR. This is a sentiment that has been echoed 
preciously 26. Paediatric CF cohorts are heavily reliant on accurate diagnosis of DHR, 
as false positives leading to incorrect withdrawal of a drug can have dire consequences 
as treatment options become increasingly limited, resulting in the patient succumbing 
to lung and airway infections. It is for this reason that it is imperative that any assay 
in use can accurately pick out the culprit drug(s) from a multi-drug treatment – 
something that is not currently readily available. Similarly important is the ability to 
correctly diagnose DHR so that the use of problem drugs inducing DHR is not 
continued as severe DHR can occur in these patients leading to high morbidity and 
even mortality. Below are some suggested improvements to current in vitro strategies, 
as well as improvements to the LTT itself.  
The ELISpot is an important in vitro tool to assess the cytokine secretion profile of 
immune cells following drug stimulation. It has been incorporated into diagnostic 
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testing as whilst LTT provides information on proliferation of the immune cell 
populations, 3[H] thymidine incorporation does not show drug-specific reactive T cell 
proliferation explicitly, as proliferating bystander cells are also registered on the beta 
counter. The use of a negative control (no drug) aids in determining drug-specific 
proliferation; but the ELISpot can detect drug specific cytokine secretion in response 
to treatment and can also provide information on the nature of the immune response 
through knowledge of the predominantly secreted cytokine (TH1 – IL-2, IFN-γ / TH2 
– IL-4, IL-13) 314,315. The LTT generally has displayed higher specificity than the 
ELIspot, whereas the ELISpot can be more sensitive depending on the cytokine being 
detected; lower for IFN-γ, higher for IL-4 300. It would be useful to have both 
proliferation data, and antigen-specific cytokine secretion when determining a drugs 
immunogenicity and likely involvement in DHR. This is something than could be 
utilised in adult patient samples. For the diagnosis of DHR in children this is not 
currently viable due to the small volume of blood able to be obtained from children 
and the low PBMC numbers isolated subsequently, coupled with the high numbers of 
cells needed for an ELISpot (minimum 300,000 per well). We attempted to overcome 
this issue in the lab so that we could perform LTT and ELISpot concurrently by 
titrating the number of PBMC used per well. When attempting to use fewer than 
150,000 cells per well in the LTT, significant increases in proliferation disappeared, 
meaning it was not possible to lower cell numbers used in the assays. Instead of 
lowering cell numbers needed for the LTT and ELISpot, supernatant could be taken 
from the wells of the LTT and cytokine secretion detected by ELISA. The main issue 
with this method being that this only shows overall cytokine secretion on a well-by-
well basis, whereas the ELISpot can determine antigen-specific cytokine secretion on 
a cell-by-cell basis, determining the approximate number of cells secreting cytokines.  
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The improvement of the LTT lies in the question: ‘are we replicating the current 
immune micro-environment in the wells of the LTT’. Can we learn anything from the 
mechanistic evaluation of naïve T cell priming from the previous experimental 
chapters, including immune regulation (signal 1: signal 2 axis) in order to more 
accurately replicate the correct immune micro-environment in the LTT. And by doing 
so, could we potentially improve the sensitivity and specificity of the assay for both 
adult patient diagnosis, but more importantly paediatric patients where problems 
surrounding low cell numbers from blood donations are apparent.  
T regulatory cells (Tregs) can be involved in both pro- and anti-inflammatory 
responses to antigens 316, but are more frequently associated with immune suppression 
to maintain self-tolerance 317,318. If regulatory T cells could be safely removed from 
PBMC population before and during drug incubation time (as we know from chapter 
4 that numbers of Tregs increase during T cell priming) to discover immune responses 
that were previously suppressed by Tregs. However, preliminary experiments in 
chapter 4 showed that removing Tregs during drug treatment of immune cells in assay 
(by MACS separation) destroyed any proliferative response observed and the end 
point of the experiment; needs optimising further. In a similar way to the removal of 
T cells, the modulation of the co-signalling factors PD-1/PD-L1 and CTLA-4 can be 
used in order to more accurately replicate the correct immune microenvironment. 
Previously published studies from within the group 137,182 as well as data from chapter 
4 of this thesis have shown that the co-signalling pathway plays an important role in 
both naïve and memory responses to drug challenge, and have already developed an 
easy method to modulate these pathways through blocking antibodies. The utility of 
PD-1/PD-L1 and CTLA-4 blocks should be explored in the LTT to determine if the 
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modulation of signal 2 in this way could (similar to Treg removal) uncover immune 
responses suppressed by negative regulation of signal 2.  
The involvement of dendritic cells (DCs) in the immune response (both naïve and 
memory) is well-established. DC from hypersensitive patients can be driven by 
antibiotics such as amoxicillin to shift toward a semimature phenotype 319. This 
information could be useful as we could isolate DCs from patients with suspected 
hypersensitivity and culture them with the different suspected drugs and then analyse 
the DCs for shift towards maturity (upregulation of MHCII) in order to determine 
which is the likely culprit drug prior to addition to the LTT as a source of antigen.  
Implementing the above ideas into the LTT may improve the proliferative readout of 
the diagnostic assay, but another approach would be to use a different readout 
altogether. Upregulation of miR in response to adverse events such as liver injury has 
become an important research area for biomarker discovery 320. Upregulation of miR 
and their role as regulators in immune response have also been observed 321,322. Using 
this knowledge, the final experimental chapter of this thesis (chapter 6) will explore 
the relevance of this information through the alteration of an LTT-like diagnostic assay 
where the readout is miR expression. The modified assay will calculate upregulation 
of certain immunologically relevant miRs and its use as a potential novel diagnostic 
platform to improve on the LTT will be evaluated.  
The main limitations of this study were the fact that the samples were anonymised so 
that we did not have any information on the genotype of the patients (who may express 
risk alleles for DHR to some of the drugs tested). It also meant that there were no in 
vivo confirmatory tests to compare the LTT results with, and we did not know the 
outcome of the patient treatment (whether drugs were removed from treatment and if 
this prevented further DHR. Despite this, the main aims of the chapter were achieved 
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in that we were successfully able to use these important paediatric samples in order to 
assess the utility of the LTT in instances such as this one. Whilst there were some 
positives, the data in this chapter suggests that the LTT test alone is not sufficient for 
use as a gold standard assay. The data in this chapter would have also been aided by 
some clinical data and observations. However, due to the nature of paediatric samples, 
we were not able to obtain this information. The data then gave rise to ideas on how 
we can improve the LTT (or develop new techniques) to develop desperately needed 
reliable in vitro diagnostic assays for DHR in both adults; and especially, children.  
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 INTRODUCTION   
Adverse drug reactions (ADR) account for almost 6% of all hospital admissions 
causing approximatively 42,000 deaths every year in the European Union with an 
estimated economic loss of around 79 billion euros 323,324. Drug hypersensitivity 
reactions, although rare, are one of the most serious forms of ADRs. Recent analysis 
of computational integrative data has estimated that a single drug could directly 
modify 25 transition immune states. We hypothesise that some of these changes may 
lead to human iatrogenic diseases that cannot currently be predicted during drug 
development 325.  
The presence of drug-specific T cells in the peripheral blood and inflamed tissue of 
hypersensitive patients has been widely documented 111,326,327. Several factors 
including genetic background, co-morbidities at the time of the reaction, metabolism 
and reactivity of the drug, individually or together, contribute to the generation of the 
drug-specific T cell response. Despite the complexity of the major histocompatibility 
complex (MHC), drug−T cell receptor (TCR) interaction, it has been possible to 
elucidate three basic mechanisms of drug-specific T cell activation through in vitro 
experiments using PBMCs from hypersensitive patients: (1) the hapten/pro-hapten 
pathway; (2) the pharmacological interaction or P−I theory; and (3) the altered self-
repertoire pathway (as described in chapter 1) 274,328. Furthermore, the ability of drug 
specific T cells to damage target tissue such as liver and skin has been described 149,155. 
In the previous chapter, we showed that current in vitro diagnostic tests such as the 
LTT, whilst being the best available choice for diagnosis of DHR patients exposed to 
multiple possible culprit drugs, are not truly fit for purpose amongst all patient groups. 
The data acquired from the analysis of paediatric CF patient samples did not 
consistently enable us to diagnose DHR or pick out a single drug from multiple drug 
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treatments. This is problematic as incorrect drug withdrawal is potentially as big an 
issue as continued use of a drug causing an adverse event, especially for paediatric 
cystic fibrosis patients. That said, the LTT is the most consistent assay for the 
diagnosis of DHR across a range of drugs from different classes, especially when 
compared to alternatives such as the ELISpot and CD69 up-regulation assays. Assays 
such as the LTT and ELISpot are adequate assessors of immunological responses by 
through measurement of proliferation of cells and cytokine secretion respectively. As 
suggested at the conclusion of the previous chapter, whilst these current readouts for 
assessing immune response to drug challenge have their uses, it is important to 
understand the what is happening at the transcription and post-transcription level, as 
immune regulation occurs at this stage, leading to suppression and activation of 
immune responses. Another aspect of the LTT that can be improved upon is the length 
of time taken to perform the assay (6 days) – in such a time sensitive situation where 
the DHR must be rapidly diagnosed in order to prevent potential death of the patient. 
In this chapter, one of the initial aims was to investigate the role of transcription and 
post-transcriptional factors in the development of DHR, as well as improve the time 
taken to perform any novel in vitro diagnostic test, developed through the knowledge 
gained in this set of experiments.  
Little is known about the role of post-transcriptional regulators, particularly miRNAs, 
in the pathogenesis of drug hypersensitivity. MiRNAs are single stranded 22 
nucleotides RNAs that regulate gene expression by binding to the 3′ untranslated 
region (UTR) of their target promoting translational repression or the direct 
degradation of the mRNA. Up-regulation of a specific miRNA promotes higher 
inhibition of the target gene which manifest in phenotypic and physiological changes 
in the cell 208. MiRNAs are involved in regulating the expression of 30-50% of genes; 
170 
and so are involved in many key physiological and fundamental cellular processes 209. 
They can elicit regulation that alters the concentration of key protein components of 
cascading signalling pathways of immune activation at the post-transcriptional level 
and importantly, studies have shown that genetic ablation of miRNA machinery has 
led to auto-immunity 210. MiRNAs are becoming increasingly notorious as key 
regulators of key biological processes; proliferation, differentiation and development, 
as well as crucial regulators of both innate and adaptive immune responses 211 through 
a purported role in the induction, maintenance and function of Tregs, and regulating 
the differentiation of APCs dendritic cells and macrophages through TLRs 212. 
Over a hundred miRNAs have been shown to be expressed by immune cells and have 
an impact in basic immunological process. Despite the wide variety of miRNAs 
showing an altered expression, only a few have been studied in detail. These include 
miR-9, miR-17 ≈ 19 cluster, miR-21, miR-146a, miR-155, miR-181a, and miR-214. 
For most of these, their target genes have been validated and their function has been 
evaluated during T cell activation by functional assays 214–220.  
Interestingly, the role of miRNA in immune function regarding the development of 
DHR can also tie in well to the data obtained in chapter 4 – as miRNA can act as post-
transcriptional regulators of other immune regulatory pathways that are discussed 
through the course of this thesis. This includes the aforementioned regulation 
maintenance and function of Tregs, in addition to involvement in the co-signalling 
pathway; PD-L1 specifically. miRNA binding to PD-L1 mRNA on APC can lead to 
degradation and ultimately suppression of the ligand and therefore overall suppression 
of the PD-1/PD-L1 axis leading to increased immune activation; with  miR-513, miR-
570, miR-34a, and miR-200 reportedly displaying inverse correlation to PD-L1 
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expression 221. MiRNAs have also been directly implicated in DHR through targeting 
and post-transcriptional regulation of the granulysin gene 222.  
Regarding drug hypersensitivity reactions, microarray analysis has been made using 
biopsies of patients with mild and severe cutaneous reactions, and some of the 
miRNAs, selected for this study showed an altered expression. In particular, a direct 
correlation between miR-18a expression and the severity of the reaction was observed. 
Moreover, bioinformatics and functional analysis demonstrated that miR-18a targets 
the BCL2L10 gene, a negative regulator of apoptosis. Interestingly, the same miRNA 
is up-regulated during CD4+ T cell activation and has a similar effect on CD4+ T cells, 
but only when it is overexpressed alone 217,329.  
The main challenge associated with this chapter was developing an assay that would 
also overcome the main pitfalls associated with current in vitro assays such as the LTT 
and ELIspot. Whilst we were not able to obtain further paediatric samples in order to 
carry out these studies, it was apparent throughout the project that any assay developed 
during the course of these set of experiments must improve upon the aforementioned 
LTT, not only for adult patient populations, but for vulnerable paediatric patients as 
well. The assay utilised in this chapter improved upon the time taken to perform 
analysis from six days to three; speeding up time taken for diagnosis. We were also 
able to ensure that the miRNA assay did not use more cells than the LTT, and used 
fewer cells than needed for the ELISpot.  
The aim of this study was to determine the changes in the expression of miRNAs 
previously shown to be involved in CD4+ T cell activation (miR-9, miR-18a, miR-
19b, miR-21, miR-155 and miR-214) using drug-specific CD4 + T cell clones and 
PBMCs obtained from drug hypersensitive patients. Should we discover up-regulation 
of immunologically relevant miRNA listed above in response to specific drug 
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challenge, the most important question to be answered if we wish to further develop 
this knowledge into a viable in vitro DHR diagnostic assay is: are we correlating drug 
specifically induced, increased expression of targeted immunologically relevant 
miRNA for DHR with proliferative responses observed in functional T cell assays?  
 CHAPTER AIMS 
1. Assess the drug-specific up-regulation of DHR immunologically relevant 
miRNA in hypersensitive patients in response to drug challenge.  
2. Determine if up-regulation of miRNA observed correlates to a proliferative T 
cell response.  
3. Assess whether or not miRNA upregulation assays used in this chapter are a 
feasible improvement to the classical in vitro diagnostic assays such as the LTT 
and ELISpot. 
 METHODS 
All methods for techniques seen in this chapter can be found in detail in Chapter 2: 
Methods and Materials.  
 RESULTS 
6.4.1 ACTIVATION OF CD4+ T CELLS WITH PIPERACILLIN AND CARBAMAZEPINE 
A total of 11 CD4+ T cell clones from carbamazepine and piperacillin patients were 
used. IFN-γ/IL-22 and IFN-γ/granzyme-B were selected as relevant ELISpot readouts 
for piperacillin and carbamazepine respectively, based on recent investigations 50. All 
clones were stimulated to proliferate and secrete cytokines/cytolytic molecules after 
drug-treatment (Table 6.1 and Figure 6.1). All TCC secreted IFN-γ following drug 
treatment. Four out of five piperacillin-specific TCC secreted IL-22, while all of the 
carbamazepine-specific TCC secreted granzyme-B.  
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6.4.2 DRUG-SPECIfiC CD4+ T CELL CLONES UP-REGULATE PARTICULAR SETS OF 
MIRNAS  
Expression of miRNAs in activated TCC was measured by qRT-PCR at 24h when 
incubated with antigen presenting cells (APC) in the presence or absence of the 
relevant drugs. A drug-specific increase in miR-155 expression was observed with all 
clones. MiR-18, miR-21, and miR-9 showed up-regulation in 10, 7, and 6 of the 
piperacillin and carbamazepine clones (Figure 6.2. A, B). Only two carbamazepine 
TCC showed up-regulation of miR-19b and miR-146, whereas piperacillin TCC did 
not up-regulate these miRNA. Increased expression of miR-214 was not detected. A 
strong positive correlation was observed between the extent of proliferation and miR-
155 (R2 = 0.85) and miR-18a (R2 = 0.74) expression in carbamazepine clones (Table 
6.1).  
Table 6.1. Proliferation, IFN-γ secretion, and miRNAs expression by drug-specific CD4+ T cell 
clones obtained from piperacillin and carbamazepine hypersensitive patients 
 
A similar relationship was not observed with the piperacillin clones with the same 
miRNAs; however, a moderate but positive correlation between the extent of 
piperacillin-specific proliferation and miR-9 expression (R2 = 0.51) was determined. 
To confirm that miRNAs were expressed by CD4+ T cells during drug challenge, we 
incubated APC and TCC in the absence of drug, and the expression of the miRNAs 
was measured a different time points. As expected, the RE values were below one in 
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most cases, though some TCC showed a slightly higher value, but when the same TCC 
was incubated in the presence of the drug, a positive 3 to 10-fold change was seen 
(Table 6.1, Figure 6.2 A, B). Moreover, to rule out any change in miRNA expression 
because of a non-specific interaction of the drugs and other immune cell receptors, 
TCC and APC were incubated alone in the presence of the drug, and no change of 
miRNAs expression was observed (Figure 6.2 D). Finally, to demonstrate that 
miRNAs up-regulation was the result of the initial signals provided by the drug to the 
TCR, we incubated the best drug responding TCC (clones that expressed all miRNAs 
with drug-treatment) with a non-toxic concentration of cyclosporine-A. A significant 
decrease in expression of all the miRNAs, below the reference value, was observed 
with cyclosporine-A. Figure 6.2 C compares the response of clones to drug in the 
presence and absence of cyclosporine-A. Thus, our results demonstrate that miRNA 
up-regulation is the result of a drug-specific CD4+ T cell activation. 
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Figure 6.1 Cytokine secretion from
 activated drug-specific C
D
4+
 T cells. (A) IFN-γ secretion from
 piperacillin-specific C
D
4+
 T cell clones and 
(B) carbam
azepine-specific CD
4+
 T cell clones incubated for 48 h with 2 m
m
ol/L and 50 μg/m
L of piperacillin and carbam
azepine, respectively. 
(C) IL-22 secretion from
 piperacillin-specific C
D
4+
 T cell clones incubated for 48 h w
ith 2 m
m
ol/L piperacillin. (D
) G
ranzym
e B secretion from
 
carbam
azepine-specific CD
4+
 T cell clones incubated 48 h with 50 μg/m
L of carbam
azepine. The num
ber in the im
ages correspond to the num
ber 
of spot form
ing units (SFU
) where a value above 30 SFU
 is considered positive. 
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Figure 6.2 Up-regulation of miR-9, miR-18a, miR-21, and miR-155 is the result of the 
interaction between APC, drugs, and CD4+ drug-specific T cells. (A) MiRNAs expression in 
piperacillin-specific TCC and (B) carbamazepine TCC in the presence or absent of the culprit 
drug. (C) Cyclosporine (1μg/mL)blocks the up-regulation of miR-9, miR-18a, miR-21, and 
miR-155 in two carbamazepine-specific TCC incubated with APC and the drug for 24h. (D) 
The presence of APCs, the drugs and TCCs are necessary for miRNAs up-regulation. Values 
are shown as relative expression and are the mean of a triplicate ± standard deviation. 
Statistical analysis was performed between relative expression of TCC cultured with medium 
alone and TCC cultured with drug. **P ≤ 0.05l n.s., Not significant. 
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Table 6.2. Patient’s clinical inform
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 results 
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6.4.3 TIME-DEPENDENT UP-REGULATION MIRNA IN DRUG STIMULATED PBMC 
FROM HYPERSENSITIVE PATIENTS 
To investigate if the miRNAs up-regulated in TCC are also up-regulated in PBMC of 
hypersensitive patients, we focused on miR-18a, miR-21, and miR-155. 
Sulfamethoxazole, lamotrigine, piperacillin, and carbamazepine hypersensitive 
patients presenting with a range of cutaneous manifestations, varying in severity from 
maculopapular exanthema to toxic epidermal necrolysis, were included in the study 
(Table 6.2). PBMC from all patients, but one, were stimulated to proliferate in the 
presence of the culprit drug (stimulation index of 2 or higher; Table 6.2). Because of 
the variety of skin manifestations, which might affect the number of blood circulating 
drug-specific T cells and their phenotype/function 330, miRNA expression was 
assessed at two time points, 24 and 48h. PBMCs from all patients, including the one 
with negative lymphocyte transformation test showed up-regulation of miRNAs after 
drug treatment (Figure 6.3).  
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Figure 6.3 Time-dependent expression of miRNAs in PBMCs of drug hypersensitive patients. 
Relative expression of miR-18a, miR-21, and miR-155 from eight hypersensitive patients to 
sulfamethoxazole (SMX1-2), lamotrigine (LMTG1-2), piperacillin (PIP1-3) or 
carbamazepine (CBZ1) with different clinical manifestations. PBMCs were incubated in the 
presence of culprit drug for 24 and 48h prior to analysis. Values are shown as relative 
expression and are the mean of a triplicate ± standard deviation. 
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Figure 6.4 M
axim
al m
iRNAs up-regulation can be correlated w
ith the degree of proliferation in the presence of the culprits’ drugs. Relative 
expression of (A)m
iR-18a, (B)m
iR-21, and (C)m
iR-155, in dictated with the bars, in drug-treated PBM
C
s, shows that a positive expression 
of m
iRN
As correlates with a positive proliferation (SI), indicated with sym
bols, in hypersensitive patients to sulfam
ethoxazole (SM
X1-2), 
lam
otrigine (LM
TG
1-2), piperacillin (PIP1-3), or carbam
azepine (CBZ1) with different clinical cutaneous m
anifestations. Im
portantly, 
drug treatm
ent of PBM
C
s obtained from
 tolerant patients (Tol) or hypersensitivity patients in the absence of the drug (*) did not up-
regulate m
iRNAs or stim
ulate proliferation. 
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As seen with the TCC, no increase in PBMCs miRNA was observed over the duration 
of the assay in the absence of the drug in the PBMCS (Figure 6.4). The times in which 
the different miRNAs were expressed with drug treatment differed. A higher level of 
miR-18a was detected in most patients after 48 h, while miR-21 was expressed earlier, 
at 24 h. In contrast, miR-155 was detected at a similar level at both time-points, 
irrespectively of the severity of the skin reaction. Drug-stimulated PBMCs from the 
SJS/TEN patients showed high levels of all the miRNAs analysed. Figure 6.4 
compares the lymphocyte transformation test results of individual hypersensitive and 
tolerant patients with the up-regulation of miR-18a, miR-21, and miR-155. All patients 
showed a positive expression of at least 1, in most cases 2, miRNAs. In some cases, 
drug-treated samples displayed 5−20 times higher miRNAs expression than basal 
levels. Up-regulation of miRNAs was seen with drug-treated PBMCs from piperacillin 
hypersensitive patients; however, a direct correlation between miRNAs upregulation 
and proliferation was not always observed. When the expression of miRNAs was 
assessed in piperacillin tolerant or other tolerant controls, the presence of the culprit 
drugs did not up-regulate the expression of any of the miRNAs tested (Figure 6.4). 
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 DISCUSSION 
Until recently, the main method of prediction, diagnosis, and analysis of DHR has 
been heavily reliant on functional T cell assays; with the end readout being either 
proliferation (LTT & T cell priming) or cytokine secretion (ELISpot/ELISA). It was 
decided that opposed to looking purely at proliferation or cytokine secretion, it would 
be important to have an understanding at what is happening at the transcription and 
post-transcription regulatory levels in the initiation of DHR.  A great deal of attention 
has focused on the changes in gene expression, particularly miRNAs dysregulated 
during T cell activation, since they play an important role in the phenotype of the 
activated cells and neighbouring cells. T cell activation is paramount for the initiation 
of drug hypersensitivity reactions; however, until now, the regulation of miRNA 
expression following drug-specific T cell activation has not been addressed. Here, we 
have shown an up-regulation in the expression of several miRNAs, previously studied 
during T cell activation, in drug-specific CD4+ T cell clones and PBMCs from patients 
with different forms of cutaneous hypersensitivity.  
Two sets of TCC were analysed to explore the different patterns of miRNAs expressed 
during drug-specific CD4+ T cell activation. Piperacillin-specific and carbamazepine-
specific TCC were used because, at least in vitro, the drugs activate T cell receptors 
via hapten and PI pathways, respectively. With carbamazepine, the kinetics of T cell 
activation are too rapid for antigen processing to be a prerequisite 158,159. Furthermore, 
inhibition of antigen processing does not alter the strength of the carbamazepine 
specific T cell response. After drug-specific CD4 + T cell activation, most of the 
selected miRNAs were up-regulated, and in certain circumstances their expression 
directly correlated with the strength of the drug-specific CD4+ T cell proliferative 
response. Thus, by directly comparing miRNA up-regulation and CD4+ T cell 
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proliferation, it was possible to establish the polarized pattern of miRNAs. Strongly 
proliferating carbamazepine-specific TCC showed the highest levels of miR-18a and 
miR-155 up-regulation, while miR-9 up-regulation was seen with the TCC 
proliferating strongly to piperacillin. MiR-19b and miR-146 up-regulation was not 
consistently expressed, only two of the CBZ clones showed positive values, whereas 
miR-214 was not up-regulated with any of the TCC. It is important to emphasize that 
although this pattern of miRNAs expression seems to be characteristic for the CD4+ 
T cells, further investigation is needed to explore the miRNAs pattern in drug-specific 
CD8+ T cell clones and in clones activated by other drugs.  
Previous microarray studies have found a significant change in the expression of 
several miRNAs in biopsies and plasma of patients with SJS/TEN, where miR-18a, a 
member of the miR-17≈ 92 cluster family, showed the highest up-regulation 329. 
Mechanistic studies using a miR-18a mimic transfected into keratinocytes revealed 
that the miRNA was involved in the induction of apoptosis in vitro. Interestingly, the 
same effect was seen in CD4+ T cells when the miRNA was artificially and 
individually transduced during CD4+ T cell activation. Therefore, it is possible that 
the apoptotic effect seen in drug activated CD4+ T cells is not evident because of the 
expression of other members of the cluster or the expression of miR-9, miR-21, and 
miR-155, which collectively promote proliferation. Therefore, if the effects of miR-
18a are not seen directly in the drug activated CD4+ T cells, it is possible that the 
miRNA could target a different cell type. Nonetheless, our results showed that under 
certain circumstances drug-specific activation might contribute to the overexpression 
of miR-18a.  
MiRNA communication between different cell types has been demonstrated in 
cutaneous contact hypersensitivity reactions where exosomes containing miR-150 
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travel in plasma delivering a suppressive effect on the inflammatory response 331. Thus, 
it is necessary to determine the expression levels of miR-18a in micro vesicles secreted 
during drug challenge of different T cells repertoires, at different time points. 
Furthermore, it will be important to evaluate their effect on keratinocytes. 
Interestingly, carbamazepine CD4+ T cells showed the highest expression of miR-18a, 
and carbamazepine is associated with a high incidence of SJS/TEN 134. Thus, it is 
possible that the activation of TCC with carbamazepine is related to the 
overexpression of miR-18a and together with other factors, such as genetic 
background, is a predisposing element for the development of severe bullous 
reactions.  
MiR-155 was also highly expressed in TCCs, and besides its effect on proliferation, it 
plays an important role in the inflammatory response. Functional studies using miR-
155−/− mice show a tendency to generate lower numbers of Th1 and Th17 cells during 
autoimmune diseases, and in vitro studies with CD4+ T cells from miR-155−/− mice 
secreted lower levels of IFN-γ when compared with the same cells from the WT 
animals 332. Thus, we compared the selective expression of miR-155 with the secretion 
of IFN-γ after drug treatment. The level of expression with carbamazepine-specific 
TCC correlated with the level of IFN-γ secretion, although not in a linear manner, in 
four of the six clones tested, but this pattern was only seen in two of the five 
piperacillin TCC.  
IL-2 is necessary for TCC survival, and its presence does not affect the expression of 
miR-21 and miR-155. In contrast, it might affect the expression of miR-9 which targets 
genes related to IL-2 expression 218. Thus, to avoid any interference of IL-2 in our 
studies, the TCC were deprived of the growth factor 48h before stimulating the clones 
with either piperacillin or carbamazepine. To demonstrate that miRNA up-regulation 
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was the result of drug-specific CD4+ T cell activation and downstream signalling, an 
extra experiment was conducted where cyclosporine-A was added to the assay. The 
drugs did not increase miRNA expression in CD4+ T cell clones in the absence of 
drug or in the presence of cyclosporine-A.  
In the next component of the study, we evaluated miRNA expression in activated 
PBMCs from patients with different forms of cutaneous hypersensitivity associated 
with the different antibiotics; sulfamethoxazole and piperacillin and the 
anticonvulsants lamotrigine and carbamazepine. MiR-18a, miR-21, and miR-155 were 
studied, because they showed the higher levels of expression in the experiments among 
different TCC. Given the low frequencies of drug specific T cells in peripheral blood 
and the heterogeneity of their patient cohort, we decided to analyse the expression of 
miRNAs at two time points 24 and 48 h. PBMCs from patients were stimulated to 
proliferate in vitro in the presence of the culprit drug. Similarly, up-regulation of all 
three miRNA was detected. MiR-21 expression was up-regulated to the greatest extent 
in most patients at 24 h, while miR-18a showed higher expression after 48 h. MiR-
155 expression was elevated at both time points. The expression of this miRNA was 
drug - and time – dependent supporting again that this miRNA is expressed after drug 
challenge. Thus, it might be possible to use miR-155 as an early diagnostic biomarker 
of drug hypersensitivity reactions.  
This work is important in several ways in the context of this thesis, and the 
investigation into the mechanistic evaluation of DHR in prediction and diagnosis. Two 
issues with the LTT as a diagnostic tool of DHR are the time taken for the assay to be 
completed (6 days), as well as the number of cells required to perform the assay. The 
time taken is important as the accurate diagnosis of the culprit drug in a DHR is 
extremely time-sensitive in order to know the correct course of action for treatment of 
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the patient, and in order to ensure that their regular treatment schedule is not 
interrupted as manifestations of their original disease can become harmful during 
extended period of treatment cessation. As explained by chapter 5, the number of cells 
needed for an assay (particularly for paediatrics) is often a limiting factor in both the 
amount and quality of data obtained. The assay developed for the work carried out in 
this chapter has taken both facts into account in that it takes only three days from the 
sample being taken, to the results being obtained (as opposed to six). The miRNA up-
regulation assay uses the same number of cells as the current form of the LTT; whilst 
this is not an improvement on the current LTT, fewer cells are needed than in other 
diagnostic assays such as the ELISpot. An important future experiment would be to 
assess the exact number of cells necessary for extraction of the minimum amount of 
usable RNA for assessment of miRNA up-regulation in response to drug challenge. 
We can now use the knowledge obtained from this chapter (as well as all other thesis 
chapters on T cell priming, immune regulation, and the assessment of the LTT) to aid 
in the development and optimisation of the assays utilised for the experiments carried 
out in the process of this thesis. The use of miRNA and detection of immune regulation 
at the transcription level is an important development in the understanding of immune 
activation and the initiation of a DHR; and can play an important role in their 
diagnosis. However, further studies to understand the complexity of correlation 
between T cell proliferation and miRNA up-regulation and how this may affect DHR 
patient diagnosis must be performed before any miRNA up-regulation assay can be 
used widespread. It is also important to note that we must be able to assess the quality 
of the assay in as many different classes of drugs as possible, as current in vitro tests' 
major pitfall is their lack of versatility amongst different drugs used and patient 
populations. Another interesting experiment that could be performed to understand the 
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regulatory effects miRNAs elicit on immune activation would be to isolate miRNAs 
as we have done in this chapter, and then add them into the T cell priming assay such 
as the T-MWA to see their effects on T cell priming. This could then be used in 
conjunction with flow cytometry to see the effects of the miRNAs on other immune 
regulation mechanisms such as Treg function, and the immune checkpoints PD-1 and 
CTLA-4. One potential drawback of the miRNA up-regulation assay is the difference 
in optimal incubation time of cells with drug for the up-regulation of different 
miRNAs. This means that we would need to perform further experiments to 
understand whether 24 or 48 h are better incubation times for each individual drug to 
be tested, and for each miRNA to be studied.  
To conclude, our results clearly show a change in the levels of expression of miRNAs 
in activated CD4+ T cells from hypersensitive patients after drug challenge. These 
results contribute to the current understanding of the role of miRNAs in cutaneous 
reactions by demonstrating that they could originate from drug-specific T cells during 
activation. However, how these miRNAs expressed in drug-specific T cells end up in 
the plasma or skin altering cellular and tissue physiology in drug hypersensitive 
patients’ needs to be further investigated. Importantly, this research opens a new field 
to investigate the use of miRNAs as biomarkers for in vitro diagnosis of drug 
hypersensitivity reactions. Whilst the use of the in vitro miRNA up-regulation assays 
for the assessment of DHR has been shown in this chapter to be a promising tool; 
further investigations must be done before we can say it is a marked improvement over 
the currently established methods such as the LTT and ELISpot. 
  
188 
7 FINAL DISCUSSION  
Firstly, it is important to understand the aims of the experimental chapters, and 
evaluate whether or not they were accomplished in this thesis. The main aims of 
chapter 3 were to develop a predictive screening system that can detect the number of 
donors responding to a drug, as well as the number of cells in each donor. This was 
mostly achieved in that the T-MWA is able to determine the number of responsive 
cells in multiple donors on the same plate. However, the T-MDA still needs some 
work to be able to accurately predict the number of responsive donors out of a panel. 
Chapter 4 had the aims of determining T reg abundance, PD-1 and CTLA-4 expression 
and their functional effects on naïve T cell priming in response to different drug 
treatments. These aims were all achieved expect that we were not able to successfully 
determine the functional effects of Treg generation upon different drug treatment. In 
chapter 5, the LTT was to be evaluated as a tool for the prediction of DHR in paediatric 
patients to determine if it was fir for purpose. This aim was achieved; the LTT was 
found as not fit for purpose. I was able to use this data in order to formulate new ideas 
to improve the current LTT assay. Finally, the main aims of chapter 6 were to correlate 
the upregulation of T cell activation linked miRNA and T cell proliferation to 
determine if this is a viable alternative to the LTT. Again, the aims of this chapter were 
met as four different miRNAs (especially miR-155) were found to correlate with T 
cell proliferation in response to drug treatment. This new assay could be a viable 
alternative to the LTT as it can show similar results, but in a 3-day shorter timescale.  
In recent years adverse drug reactions are having an increasing burden on the 
healthcare system; with close to 7% of hospital admissions (over 100,000) being due 
to adverse drug reactions and drug hypersensitivity reactions 1,2. Indeed, many of these 
reactions can be attributed to the sheer number of novel treatment strategies being 
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developed to a multitude of illnesses 1. Type A ADRs can be more easily prevented as 
they are on-target adverse events usually influenced by dosage and regimen. However, 
type B reactions are an increasing problem for both the healthcare systems, and for 
drug development as they are off-site adverse events that are not predictable from the 
pharmacology of the treatment drug; type B has also been referred to as ‘bizarre’ 5. 
This makes them difficult to predict and prevent. These types of reactions can include 
severe reactions with high morbidity and mortality rates such as SJS/TEN 156,274,333. In 
addition to the exorbitant cost burden to the healthcare systems, ADRs have a large 
effect on the drug development process, as ADRs are one of the major contributors to 
the well-known high rate of late-stage attrition in the R&D process after millions of 
pounds have already been spent 334,335. This often occurs frustratingly late in the 
development process, where withdrawn drugs would otherwise have been useful (and 
in some instances life-saving) treatment strategies for a large cohort of patients. As 
these reactions are unpredictable in nature and only occur in some individuals and not 
others, drugs often pass through the clinical trial stage, only to be found to cause ADRs 
in individuals post-release 336.  
The main focus of this thesis was to further the understanding of immune mediated 
adverse events; drug hypersensitivity reactions (DHRs). As well as to develop and 
improve current predictive and diagnostic research tools for the study of DHR. There 
have been numerous investigations into the pathomechanisms of DHR since Gell and 
Coombes first attempted this in 1963 337. It wasn’t until a few decades later that the 
now infamous categorisation of DHR into type I-IV was set out. Whilst many studies 
have focused on immediate reactions involving IgE and innate cell activation (such as 
mast cells); the pathomechanisms of delayed type IV DHR have yet to be fully 
elucidated.  The Gell and Coombes classification has been re-interpreted by numerous 
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scientists over the years due to the discovery of new types of DHR, and new subsets 
of detectable antibodies and antigen-specific T cells that that do not fit within the 
confines of the system set out by Gell and Coombes’ initial interpretation. This 
includes the expansion of type IV DHR by Pichler in 2003 to include subsets a-d 338,339. 
Such is the complexity and fast-moving nature of the research into immunology and 
DHR specifically, even these expanded classifications are now outdated by the 
discoveries of novel immune cells implicated in the pathomechanisms of DHR such 
as T helper subsets Th9/17/22 50.  
Other investigative work into the reasons for DHR have led to the discovery of HLA 
risk allele associations. This implicates proteins expressed on the surface of the HLA-
allele that interact specifically with a drug of interest to activate T cells. Whilst GWAS 
studies have uncovered many associations between certain risk alleles and a number 
of drugs 340, further investigations have discovered that most of these associations are 
loose at best, and indeed the majority of people who possess the risk allele do not 
actually present with DHR. Due to poor PPV and NPV of HLA-risk alleles as 
predictors of DHRs, most associations have not been clinically implemented as pre-
screening prior to drug treatment. Abacavir’s association with HLA*B-57:01 has been 
robust enough to be implemented clinically. Further experiments into this association 
have further defined this association as an important one 125–127, and even led to the 
discovery of a new mechanism of T cell activation (altered peptide repertoire). Whilst 
HLA risk allele associations may play a role in the pathomechanisms of DHR; it is 
clear that it is not the only defining feature, and certainly cannot be used in isolation 
to predict DHR. For this reason, studies in this thesis aims to better interpret the 
likelihood of immune activation by a compound/drug at the cellular level.  
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The in vitro assessment of the likelihood of DHR, as well as diagnosis of DHR, has 
been attempted in numerous formats. The CD69 upregulation flow cytometry assay 
aimed to detect the activation of basophils and T cells by their cell surface marker for 
activation. This is less invasive than traditional in vivo tests such as intradermal testing, 
and can provide increased sensitivity over tests against immediate type DHR through 
IgE detection. However, the utility of this test can vary wildly dependent on the class 
of drug being investigated 238,239.  
The naïve T cell priming assay developed by Faulkner et al., in 2012 is currently the 
method used most frequently within our lab to attempt to understand the likelihood 
that a drug or compound will induce T cell activation 71. Sulfamethoxazole-nitroso 
(our model hapten – induces responses in 9/10 individuals), Bandrowski’s base, 
piperacillin, flucloxacillin, dapsone/nitroso-dapsone and more recently ticlopidine 
have been used successfully in the T cell priming assay, with antigen-specific positive 
proliferative responses detected 28,135,137,144,225,232,296,341. As recently as 2019, nickel (a 
contact allergen) has been investigated using a naïve T cell priming assay, with both 
CD4+ and CD8+ T cell responses involved in the observed antigen specific 
proliferative responses 342.  
Despite the many successes of the naïve T cell priming assay, there are some 
limitations that needed to be addressed. There are many different steps involved in the 
priming assay; from PBMC isolation, cell subset magnetic separation, CD14+ 
monocyte to moDC culture, co-culture of moDCs, naïve T cells and antigen, and 
readout proliferation assay. Each of these up to now were performed in separate plates, 
with cells being moved from one plate to another between each individual step, 
making the priming assay more labour intensive, susceptible to mistake and cellular 
damage or contamination. Another problem that could be stated for the original 
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priming assay set out by Faulkner et al., was that thus far, the drugs that provided the 
best responses in the assay were HLA class I restricted; with HLA class II restricted 
drugs often resulting in negative priming. One reason for this could be a low precursor 
frequency of circulating antigen-specific naïve T cells to certain drugs 256,257. In a 
priming assay with readouts only performed in triplicate, the precursor frequency of 
primed T cells was not reached, leading to negative priming. Another limitation was 
that due to the numbers of cells needed for a single assay, only one donor per plate 
could be assayed at any one time. The assays developed in this thesis – the T-MWA 
and T-MDA – have served to mitigate these issues. Both the T-MWA and T-MDA are 
performed in a single 96-well plate after moDC culture and remain as such throughout 
the experiment, making them medium-throughput, and easier to manage than the 
previous T cell priming assay. The T-MWA was developed to take into consideration 
the naïve T cell precursor frequency, as 16 wells of negative control and 40 wells of 
drug treatment per donor are assayed. Finally, the T-MDA was developed to enable 
the screening of multiple donors in a single assay. This was achieved as cells were 
plated up in two lots of triplicate, with only the optimal concentration of drug being 
used for the drug treated wells. The above can be seen in section 2.5.5.  
The use of the T-MDA with multiple donors was able to outline potential immune 
activation in the different donors on a single plate. The idea being that any donors 
flagging up a potential reaction could then be investigated further using the T-MWA. 
Although we weren’t able to perform as many of these assays as we would have liked, 
the premise of the assay (cell ratios) remains similar to the T-MWA and thus any 
improvements that can be made for the T-MWA can also be considered applicable for 
the T-MDA. In the T-MWA we were able to successfully prime to SMX-NO, parent 
SMX, piperacillin and Bandrowski’s base to different levels. We were also able to 
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show that the assay is repeatable, with similar levels of weak, good, and strong 
responses observed in the same donor with blood donations taken >6 months apart.  
The traffic light system enabled us to determine the different levels of response (weak, 
good, strong) and so determine the likelihood that an immune event may occur, as well 
as the severity of the response. The scatter plots allowed for statistical evaluation of 
the antigen-specific response, as well as look at the overall distribution of responses, 
well to well. As expected, the greatest proliferative responses were observed against 
SMX-NO and BB. Whilst reduced responses were observed against the other test 
compounds; this allows us to use SMX-NO and BB as positive controls as model 
antigens, measuring other antigen specific responses against them to investigate the 
potential for a novel compound to prime and activate naïve T cells. Whilst these results 
are promising, advances in the field explained in recent literature have provided some 
evidence that our assay can be improved upon. The characterisation of antigen-drug-
peptides eluted from the MHC in instances such as HLA*B-57:01 126 have provided 
evidence for the mechanism of activation of T cells. Unpublished data within our lab 
show that the characterisation and elution of other drug-modified peptides is possible. 
We hypothesise that priming with these peptides may help to elucidate immune 
activation in our T-MWA assays against difficult to prime to drugs. Traditionally, 
SMX-NO has been easier to prime to than the parent drug SMX. SMX-NO is formed 
from the metabolism of SMX to a hydroxylamine intermediate before nitroso 
metabolite is formed 111. For this reason, it would be interested to create an assay in 
which we can culture naïve T cells, parent drug, and APCs along with hepatocytes. If 
cultured in the same well, T cell activation as well as drug toxicity will cause 
hepatocyte death. However, the use of a membrane plate system such as the IdMOC 
plate system (Sigma-Aldrich product code: Z687936) enables the culture of all of the 
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above, without the need for them to be in physical contact. The membrane allows for 
the free passage of drug and CRM post-metabolism. It would be interesting to use such 
a system to evaluate priming to parent drugs in the T-MWA that have metabolism as 
a prerequisite for immune activation. This could also be important as metabolic 
differences are observed between naïve and memory CD8+ T cells 343. Another aspect 
of the priming of naïve T cells in our systems, are the ability of the moDCs to present 
the antigen to the naïve T cells in co-culture. In our assay, DCs are matured before co-
culture is established. This does not take into account that the DC ability of antigen 
engulfment is better in immature DCs whereas antigen presentation ability is improved 
upon maturation 344. Additionally, monocyte derived DCs have increased lysosomal 
degradation of antigen compared to human derived or mouse derived DCs 345. For this 
reason, we could try to pulse the immature DCs with drug, and then mature the DCs 
after pulsing, to better take into account the different capabilities of DCs in different 
states of maturation. Recent studies have also uncovered that LKB1 is critical for DC 
activation of T cells through AMPK activation. Loss of LBK1 function can also enable 
Treg dampening of responses 346. The role of LBK1 expression should be investigated 
in our T-MWA assays. Another potential point of interest in our priming assay is the 
use of ‘naïve T cells’, which are actually CD45ra+ lymphocytes. A new subset of T 
cells described as exhausted senescent T cells could be in our ‘naïve’ population, and 
thus be causing reduced response, or failed assays as they are functionally inactive. 
These cells are known as TEMRA (T effector memory reactivated cells) and are 
phenotypically different from ‘true naïve’ cells due to their lack of CCR7 347. It could 
be important to investigate the difference in results in the T-MWA when true naïve 
cells (CD45ra+CCR7+) are primed vs our traditional naïve population (CD45ra+) and 
the TEMRA subset (CD45ra+CCR7-).  
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Whilst the T-MWA was successful in terms of increasing the throughput and ease of 
use of the traditional priming assay, it was always clear that we must investigate 
whether or not we are replicating the correct immune microenvironment for priming 
to occur. Immune regulation such as the immune checkpoints, as well as the presence 
and function of Tregs needed to be investigated, especially due to their increasing 
involvement in cancer therapies (that sometimes lead to severe adverse events). Our 
experiments in chapter 4 showed that Tregs were being generated from the naïve 
population in 3 out of 3 tested donors during priming. Due to time constraints we were 
not able to complete mechanistic evaluation of the function of these Tregs within our 
priming cultures. If further time were available it would have been useful to remove 
the Tregs post-priming (before readout stage) to understand their immune-suppressive 
role in our priming assays. The role of co-inhibitory checkpoints are an important part 
of immune activation, with disrupted PD-1 implicated in autoimmunity 184, and the 
CD28 family interaction (including CTLA-4) being considered a prerequisite for 
immune response 348. One explanation for why we observed different levels of priming 
dependent on the drug used was that the drug used may directly influence the 
expression of co-inhibitory receptors differentially. Therefore, we investigated the 
expression levels of PD-1 and CTLA-4 over the course of the priming co-culture with 
either SMX-NO or piperacillin. We were able to establish that under certain 
circumstances PD-1 expression and CTLA-4 expression were fluctuating at different 
rates dependent on the test drug used. Additionally, experiments in the chapter showed 
that blocking either of the co-inhibitory checkpoints could increase the intensity of 
proliferation observed (as well as background proliferation of T cells). It would be 
useful to continue research into the co-inhibitory checkpoints when priming against a 
larger range of drugs to uncover any patterns in expression and the direct effects this 
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has on our priming outcomes in the T-MWA. It could also be interesting to investigate 
the role of a wider variety of co-signalling molecules such as TIM-3, LAG3, and co-
stimulation such as CD28. This knowledge could be applied not only to our T-MWA 
priming assays, but to diagnostic assays such as the LTT which was used in chapter 5.  
Not only is the in vitro prediction of DHR an issue, but the diagnosis of such events 
can also prove problematic, especially for vulnerable patient populations such as 
children exposed to multiple drug regimen. Often, it is difficult to correctly pin-point 
the culprit drug causing DHR when more than one drug is prescribed concurrently. 
Indeed, in our own investigations in this thesis, there were cases where multiple 
potential drugs were flagged as positively activating T cells in paediatric patient 
samples, whilst in others, no drugs were considered to significantly activate T cells. 
Despite this, the LTT remains the gold standard for in vitro DHR diagnosis and is a 
marked improvement on some of the in vivo alternatives. Recent studies have shown 
that oral provocation tests resulted in more accurate outcomes than skin tests in 
children. Despite this, some adverse events occurred as a result of the testing 349. Other 
studies have shown intradermal tests to perform well in the diagnosis of immediate 
adverse events to ceftriaxone, they performed poorly at detecting delayed responses 
350, again outlining the importance for a safe, robust in vitro diagnostic test.  
Some issues with the LTT include the time taken for the assay to be completed (6 
days), as well as the blood volume needed to perform the assay being high for 
paediatric patients in particular. Most studies in this thesis were performed to 
investigate DHR at the cellular level, but relatively little is known about immune 
activation at the transcriptional level. miRNAs have become increasingly implicated 
as regulators of a range of biological processes; namely, the innate and adaptive 
immune system, and are known to be involved in auto-immunity 211. For this reason, 
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an assay was devised whereby an LTT -like assay was set up on day 1, and after only 
48 hours, cells were lysed and RNA was extracted before miRNAs known to be 
involved in immune regulation were detected by real-time qPCR. We were able to 
detect differential expression of miR-9, 18, 21, and 155 in T cell clones and 
hypersensitive patient PBMC, all of which had provided positive antigen-specific 
proliferation or ELISpot data. miR 155 was notable in our work, and has also been 
implicated in chronic inflammation in other studies that describe a miR-155 induced 
exhausted resident CD8 T cell population 351. This provided credence to the theory 
that miR upregulation could be used to rapidly diagnose DHR in vitro. Further studies 
in the literature have shown miR expression to be involved in the regulation of T helper 
cells and Tregs, influencing immune activation. miR investigated in chapter 7 were 
detected in this study, in addition to other miR such as miR 214, 386 and others which 
should be investigated by further study within the lab 352. Another potential target of 
interest is miR 210 which has been implicated in psoriasis-like inflammation through 
the induction of Th1 and Th17 T cell subsets 353. Work should continue to fully-
investigate the utility of the miR upregulation assay as an alternative to the gold 
standard LTT, especially for paediatric cohorts where rapid diagnosis is of extreme 
importance. This work, along with continuous developments implicating miR induced 
gene regulation on the function of macrophages, dendritic cells, T cells and B cells 354 
mean we can also investigate the role of miR as immunological regulators in our T-
MWA priming assays. A useful experiment would be to amplify the miR of interest, 
and then pulse APCs with the amplified miR, as well as adding them directly into the 
priming culture to investigate their immunoregulatory roles in vitro.  
Throughout this thesis, we were able to improve in vitro assays for the prediction and 
diagnosis of DHR. The two newly developed assays; adapted from the original naïve 
198 
T cell priming assay, fulfilled their role, as we are now able to prime naïve T cells 
from multiple donors in a single plate in the T-MDA. Following on from that, we can 
then look more deeply into the antigen-specific mechanistic activation of T cells. The 
T-MWA enables us to look at the intensity of proliferation, as well as providing a 
scaling level of immunogenicity, all the while taking into account the naïve T cell 
precursor frequency for a drug. However, it must be stated that immune regulation 
plays a vital role in the activation of T cells, and thus, our studies in chapter 5 
elucidated the generation of Tregs, as well modulation of co-inhibitory checkpoints 
PD-1 and CTLA-4 as potentially important factors in whether or not immune 
activation occurs.  
We were also able to perform LTT as a diagnostic tool on paediatric DHR patient 
samples, and uncovered some of its limitations, namely, the time taken to perform the 
assay in such a time-sensitive environment. For this reason, we were able to devise the 
miR upregulation assay and establish connections between the upregulation of DHR-
linked miR and T cell activation. This assay enabled us to decrease the time taken to 
perform the diagnostic assay from 6 days to 3. Additionally, this work uncovered 
another layer of immune regulation that is important in trying to understand naïve T 
cell priming at the transcriptional level. This work ties in nicely to one of the 
overarching important themes of this thesis – in trying to predict the likelihood that a 
drug or compound can activate T naïve T cells leading to DHR, are we replicating the 
correct immune microenvironment including immune regulation?  
Whilst we were able to successfully bring about improvements to the in vitro assays 
available to us for the diagnosis and prediction of DHR, we believe that more detailed 
studies into immune regulation (studies carried out in this thesis and future ideas 
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generated above) could hold the key to our ability to accurately and consistently 
predict and diagnose these reactions in vitro – something that is desperately needed.  
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